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vABSTRACT
Serotonin is a neurotransmitter involved in a variety of neurological and behavioural
functions. Since its discovery in 1948, the identification of serotonin receptors and their
functions is an area of research that is moving towards clinical application. Serotonin is
involved in the control of numerous central nervous system functions including mood,
emotions, aggression, pain, anxiety, sleep, memory, eating behaviour, addictive behaviour
(alcohol and substance abuse), temperature control, endocrine regulation, and motor
behaviour. Low levels of serotonin are associated with alcoholism, depression, suicide,
migraine, aggressive behaviour, sleep problems, eating disorders (anorexia, bulimia, and
obesity) and some neurological diseases. High levels have been linked to autism, tourette's
syndrome, carcinoid syndrome, and serotonin syndrome. Much remains unknown, however,
new techniques in molecular biology has resulted in more detailed examination of
serotonergic properties.
The wide ranging symptomatology of serotonin associated disorders, proposes many
challenges for rehabilitation of some of these disorders in the community which are of major
public health concern in the 20th century. Treatment with Tryptophan, drugs or diet
modification has been used to assist in the rehabilitation of such illnesses but problems occur
in all these treatment modalities. Various drugs are already being used on a non-selective
basis for treatment of serotonin deficiency diseases. There has been little work done in linking
the various roles of serotonin from biochemical to physiological, clinical and treatment
aspects. In a novel approach, the aim of this project is to review these roles of serotonin in
humans and to provide such links via an epidemiological approach and produce
recommendations for future research which will contribute to potential areas for clinical
application in the treatment and rehabilitation of serotonin deficiency diseases.
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CHAPTER 1
PART I
1. Introduction
1.1. Definition
, ,
1
.!
Serotonin (5-hydrox.ytryptamine. or 5-HT) is a neural hormone, central
neurotransmitter, and a neuromodulator similar to norepinephrine, dopamine, and
acetylcholine. A. neurotransmitter is a substance released from the axon terminal of a
presynaptic neuron on excitation, which diffuses across the synaptic cleft to either excite or
/
inhibit the target cell (Dorland's Pocket Medical Dictionary, 1982). Serotonin is involved in
many physiological functions and pathological disorders. Serotonin is found in the brain,
intestinal tissue, blood platelet and mast cells (Figure 1) and is synthesised from dietary
Tryptophan (Try)., Ninety percent of serotonin in the body is synthesised and stored in the
argentaffm or enterochromaffm cells of the mucosa of the gastrointestinal tract (GIT).
Synthesis occurs at all the storage sites except platelets (Ganong, 1969; Meyers et aI, 1968;
Montgomery, 1990).
1.2 History
In 1868, a substance was identified in clotted blood, which caused vasoconstriction
and in 1947 it was identified as serotonin ("serum tonic") (Leonard, 1994; Roth, 1994).
Seroton.in was studied in the salivary glands of octopus; mammalian intestines; human serum
during clotting; and the venom of scorpion and wasps. Prior to 1947, serotonin was known as
enteramine, vasotonin, or vasoconstrictine (Sicuteri et aI, 1976). The structure of serotonin
was elucidated at the Cleveland Clinic in 1948 by Irving Page and colleagues. At the same
time, Italian investigators identified a substance termed "enteramine" from the intestine.
Figure 1 -
Sources and effects of serotonin
Sources
Brain cells -------jf.U-
Platelets -------::::o~=----::>'%;..~
Lining of gut ----f--+I8----.;~
Effects
1rC\+ Alters mood; reduced levels
may cause headache
-----''0--- May affect respiration
L.J!1l4~\
~f----'--r-_May Influence blood
pressure, heart rate
-.-+-IHf-----Can trigger emesis
lIIus/rations for MooERN MEDICINE by Nett 0 Hardy
Taken from :Overmyer, Nov 1990 : 120
3Chemically, serotonin or enteramine was found to be. identical and it was subsequently
synthesised as indoleamine 5-hydroxytryptamine (5-HT) in 1951 (Leonard, 1994; Roth,
1994).
Following the isolation and synthesis of 5-HT in the early 1950s, there has been an
increasing interest in the physiological function of this amine. Initially it was assumed that its
main function was that of a peripheral hormone because of the relatively high concentrations
that were found in the GIT and blood. However, it was also shown to be present in the
mammalian brain, thereby suggesting that it may have a neurotransmitter role. Since this time
interest in the physiological role of serotonin in the central nervous system (CNS) has
preoccupied neurobiologists (Leonard, 1994). Serotonin was recognised to have a wide range
of biological effects and physiological functions. Further investigation of its therapeutic
potential and additional experimental analysis was required to establish its functions and
effects on the human body (Meyers et aI, 1968). Overmyer in 1990 hypothesised serotonin as
a key that fits a number of different biological "ignition switches". The identification of these
switches and their functions is an area of future clinical research (Overmyer, 1990).
1:.2.1 Clinical Implication
Serotonin is associated with a number of neurological and behavioural functions. It is
involved in the control of numerous eNS functions including mood, emotions, aggression,
pain, anxiety, sleep, memory, eating behaviour, addictive behaviour (alcoholism and
substance abuse), temperature control, endocrine regulation and motor behaviour. Low levels
of serotonin are associated with alcoholism (Gorelick, 1993), depression (Mitchell, 1994),
suicide (De Cuyper, 1987), migraine (Overmeyer, 1990; Plosker et aI, 1994), aggressive
behaviour (Murdoch et aI, 1994), sleep disorders (Holsboer, 1992), eating disorders (Wise,
1992), and some neurological diseases (Sandyk, 1992). High levels have been linked to
autism (Gorden et aI, 1993), Tourette's syndrome (Cohen et aI, 1992), and carcinoid syndrome
(Meyers et aI, 1968),
41.2.2 Therapeutic Implication
Serotonin by itself is not used therapeutically because phannaceutical preparation of
5-HT causes vascular and tissue necrosis, which is no longer, used. Therapeutic use of
Tryptophan is also severely restricted in Australia because of the eosinophilia-myalgia
syndrome. The GIT side effects of high dose of 5-HT can be severe including GIT bleeding,
vomiting and diarrhoea. 5-HT is however useful in supplying increased 5-HT and unlike
Tryptophan does not increase intermediates of the kyneurenine pathway, which may be
associated with eosinophilia-myalgia syndrome. The understanding of how serotonin and its
precursors are delivered to the eNS may have long-term benefit for the treatment of serotonin
deficiency disorders (Meyers et aI, 1968; Moulignier, 1994; Ovenneyer, 1990).
1.2.3 Rehabilitation
The wide ranging symptomatology of serotonin associated disorders, proposes many
challenges for rehabilitation which are primary, secondary and tertiary. Serotonin deficiency
and related symptoms have been treated with drugs and diet modification to assist in
rehabilitation of serotonin associated disorders. Very little work has been done in linking the
various roles of serotonin from biochemical, physiological, clinical and treatment aspects of
Serotonin deficiency diseases. The biochemical, pathophysiological and sociological
consequences of these and many other serotonin-associated disorders require better
understanding. Such understanding of the serotonergic system is the first step towards
implementing prevention and rehabilitation of serotonin deficiency diseases (Ganong, 1969;
Meyers et aI, 1968; Overmyer, 1990).
----------------------------------------
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PART 11
1.3 Biochemistry of Serotonin
1.3.1 Biosynthesis of Serotonin
Serotonin is synthesised in the body from an essential aminoacid, dietary Tryptophan
(Try) by hydroxylation and decarboxylation (Figure 2). Tryptophan is converted to 5-
hydfoxytryptophan (5-HTP), catalysed by the enzyme tryptophan hydroxylase and the
pteridine tetrahydrobiopterin (BH4), an essential cofactor for this process. 5-HTP is then
decarboxylated by aromatic L-amino decarboxylase, which is also essential in biosynthesis of
catecholamines (Figure 3) to form 5-hydroxytryptamine (S-HT) or serotonin. The synthesis
occurs at all the storage sites except platelets which take up preformed serotonin from plasma
and transport it throughout the body (Ganong, 1969; Myers et aI, 1968). Serotonin is widely
distributed in the nervous system and its highest concentration is in the pineal gland
(Weissbluth et aI, 1992). Circulating serotonin is present at birth and whole blood 5-HT
gradually decreases to reach adult levels by 9 years of age (Cook, 1990; Weissbluth et aI,
1992).
The biosynthesis of serotonin is tightly controlled by the activity of its rate-limiting
enzyme, Tryptophan Hydroxylase. Increases or decreases in its substrate, Tryptophan, trigger
increases or decreases in serotonin synthesis and metabolism. Tryptophan and the large
neutral aminoaeids (LNAA), including the branched chain amino acids (BCAAS), valine,
leucine, and isoleucine use the same carrier to enter the brain. Thus BCAAS are competitors
for transport over the blood-brain barrier. The blood level of free Tryptophan or the ratio of
free Tryptophan to other LNAA is an important parameter for this competition.
Figtn 2 - Biosynthesis ofserotooin
Tryptophan
hydroxylase
( \
DPN DPNH
+H,O +H+
Tryptophan 5- Hydroxytryptophan
PyPh
PyPh
and H,O
Aromatic ... -amino acid
decarboxylase
Tryptamine
PyPh • Pyridoxal phosphate
Taken ftom. :Ganoog, 1969 : 202
Figtn 3 - Biosynthesis ofcatechoJaminee
NH,
I
nc-coon
I
Cll,
o
Phenylalani.ne
Phel1ylalanine
hydroxylase
NH,
I
HC-CoolI
I
CII,
o,
OH
p-Tyrosine
Tyrosine
hydroxylase
1'1'11,
I
IIC-Cooll
I
CH,
I
O~ 1>01"(Dihydroxyphenylalanine)HO- ",-::::.,
OH
AromaUc \.. amino add
decarboxylase
HN-CH,
I
CH,
I
15
OH
Eplnephrlne
Phenylethanolamine-N -
methyltranaterase
5 - Adenoaylmethlonine
NH,
I
CH,
I
HC-OH
"~OOH
Norepinephrine
NH,
I
CH,
I
CH,
I
Dopamine-a-oxidase o~
_.---HO- #
OH
Dopamine
(Dlhydroxyphenyl-
ethylamlne)
Taken from : Ganong : 166
Biosynthesis of catecholamines.
7The blood levels and ratios of total and free Tryptophan to other large neutral amino acids
depends on several factors, for example:
(1) the rate of lipolysis;
(2) the activity ofhepatic Tryptophan Pyrrolase; and
(3) the uptake into the peripheral and central tissues.
Since brain serotonin synthesis depends o~ the plasma level of Tryptophan, treatment that
elevate plasma Tryptophan will promote accelerated serotonin synthesis and metabolism
(Meeusen et aI, 1995; Miller et aI, 1992; Yogman et aI, 1985).
1.3.2 Catabolism of Serotonin
Serotonin is oxidatively deaminated and inactivated by monoamine oxidase to 5 -
hydroxyindoleacetic acid (S-HIAA), the urinary and cerebrospinal fluid (CSF) metabolite of
serotonin (Figure 4). Urinary output of 5-lllAA is used as an index of the rate of serotonin
metabolism in the body. In the pineal gland, serotonin is converted to melatonin (Figure 5)
(Ganong, 1969; Meyers et aI, 1968). Serotonin concentrations in the pineal gland are highest
during daylight, but circulating serotonin concentrations are highest during the night
(Weissbluth et aI, 1992).
Figure 4 - Catabolism ofserotonin
Mo-emlne
oxidue
S-H.7c1rox)'indole""etlc ""Id
(SH1AA)
HOWlCH,COOU~ I
N
H
\
2DPNH +
2W + NH,
7
2DPN +2H,O
NH,~woJH'
N
Serotonin H "'"
(5-h)'droxytryptamlne) ~
SulCate and gluc:uroa.lcle
conjugates and other metahoUtes
+ Acet,l-Co A + Gl,cine
N-Acetyl-S-hydroxytryptamine
t
S-Hydroxyindoleauturtc acid
Melatonln
Catabolism of serotonin. In the oxidative deamination catalyzed by mono8.mtne oxidase,
an aldehyde is formed first and then oxidized to the corresponding acid. Some of the aldehyde is
also reduced to the corresponding alcohol. The heavy arrow indicates the major metabolic path-
way.
Taken from : Ganong, 1969 : 203
Figure S - Synthesis and metabolism ofserotonin
N-ACETYL-5-HT
~YO-R.o-x-y-,N-O-O-L-E-'0-·METHYLTR.ANSFERASEH C-O
3 WCH-CH-NH-OC-:I I 1. 2-
~
MELATONIN
(N-ACETYL -S-METHOXYTRYPTAMINE,
~ CW1-crH-NH.1~.l.pJJ COOH
N
H
TRYPTOPHAN!ITRvOTo""AN OX-OASE]
S- HYDROXYTRYPTOPHAN
1[oeCARBOXYLA.el
HOWCH;-CH;- NH.
N
H
SEROTONIN
(S- HYDROXYTRYPTAMINE.. S-HT)
HO~."'" 11 CH, COOH~VV
S- HYDROXYINDOLEACETIC
ACID (S-HIAA)
Synthesis and metabolism of serotonin.
. Taken from : Meyers et a1, 1968 : 200
------ --------------------------------------------,
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1.3.3 Distribution of Serotonin
5-HT is present in the brain, blood platelets and the largest amount in the intestine.
Ninety percent of serotonin in the body is synthesised and stored in the argentaffm or
enterochromaffm cells of the mucosa of the GIT. It is also stored in the platelets and released
by platelet disintegration into serum and spleen. Rates of uptake and the levels of 5-HT in
platelets show close parallels with brainstem 5-HT in many diseases (Risch et aI, 1992; Wirz,
1988). There is evidence that some brainstem neurons which contain 5-HT but lack the
apparatus for its biosynthesis obtain 5-HT from platelets. Consequently some or all brain
serotoninergic neurons may be able to make use of peripheral 5-HT via platelet transport.
Blood platelets take up 5-HT from plasma and transport it throughout the body (Ganong,
./
1969; Myers, et aI, 1968).
In tile eNS, whicll is of current interest, concentration of serotonin is greater in
the hypothalamus and, mesencephalon. Concentration of serotonin in different sites are:
CNS <lug/gm; GIT 2-15ug/gm; Blood' 0.1-0.2ug/ml of blood; carcinoid tissue 2mg/gm
(Myers et ai, 1968)~ Tryptophan, 5-HIAA, 5-HTP and other neurotransmitters can be
measured, in CSF (Earl~ 1978). There is evidence suggesting that peripheral sources
contribute little to 5-HIAA concentration in CSF and a substantial portion of brain 5-
mAA never. enter.s CSF and is removed via blood - but it has been demonstrated by a
variety of techniques that changes' in. amine metabolism in brain are reliably reflected in
par.allel changes in CSF metabolites (Jime:rson et ai, 1976). However, it must be noted
that study, measure of CSF metabolites to monitor eNS function is difficult, as
serotonin does not cr.oss the blood-brain barrier. Serotonin found in body fluids outside
the CNS originates outside the CNS. While 85-90 % of the body serotonin originates in
the GIT, about 12 % originates in the CNS (Piggott, 1979).
11
It has been demonstrated by experiments that serotorun as well as norepinephrine and
dopamine are all localised in nerve endings. Serotonin is found in relatively high
concentrations in the lateral gray horns of the spinal cord, the raphe nuclei of the brain stem,
the suprachiasmatic nuclei of the hypothalamus, and the olfactory tubercles (Ganong, 1969).
5-HT is localised in the raphe nuclei of the brain stem which lie directly along the midline of
the brainstem from the midbrain to the medulla (Figure 6 A&B). The nuclei in the medulla
project into the spinal cord and modulate transmission in spinal cord pathways involved in
pain perception. Raphe nuclei in the pons and mid brain innervate essentially the entire brain
and together with projections from the locus coerules form part of the ascending reticular
activating systems (MontgomeliY, 1990; Moulignier, 1994).
Figures 6 A&B - Location ofneurotransmitte (CNS)
Hypothalam....:======\==?~~~Amygdola_
OlIKto<y and
mtorhinal cortices
Hippocampus
{
Midbrain
Brainstem rons
Medulla
A NEURONS CONTAININC NOREPINEPHRINE, DOPAMINE, HISTAMINE,
- AND S-HT au clustf'tf'd in tht' brainltt'm ..nd hn'f' diffuse proJfdJOM to wid~
,pread .rUt of the nntul nervou, system.
To 'Pinal cord
Hippocamp...
Rostral raphe nuclei
Amygdala
I Caudal raphe nuclci
l -----'
B NEURONS CONTAININC 5-HT lorm a chain 01 raph. nud•• IrinS alons th.
midline of the br.tin'tt'm. Mot. uud..1 "ueft'i innelV"'to tht' .piR.d cord, IIIOr.
tottu' nuclei inMrY,le Muly ..11 tt"Bions of tht' br.ain.
Taken from : MontgOJDeJy, 1990 : 331-33
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1.4 Dietary Source of Serotonin
The synthesis of amine compounds such as serotonin, catecholamines, and choline is
regulated partly by the type of food one eats. For example, high dietary Tryptophan may
stimulate serotonin synthesis sufficiently to make one drowsy (Montgomery, 1990). Serotonin
is found in bananas, tropical fruits, and nuts (Table 1). These dietary sources may also
contribute to intestinal and blood 5-HT pools. One banana contains several milligrams of
serotonin, enough to elevate urinary levels of its metabolite, 5-HIAA and interfere with
diagnostic tests- for carcinoid (Meyers et aI, 1968). Children lacking the cofactor BH4,
essential for 5-HT synthesis, or with BH4 defect, are completely dependent upon being
supplied with exogenous neurotransmitters. Relatively low doses of 5-HT or dietary sources
of 5-HT appear to provide sufficient 5-HT for normal neurological functions in children with
ataxia and sleep disorders (Lipson et aI, 1991; Unpublished case history from The Children's
Hospital, Camperdown, NSW & The Adelaide Children's Hospital, SA.). The variability of
neurotransmitter release is regulated by a number of processes. One of these presynaptic
processes modulating neurotransmission is the change in neurotransmitter synthesis resulting
from the metabolic conseqp.ences ofeating and exercises (Meeusen et aI, 1995).
1.4.1 Dietary Restriction of Tryptophan
Preclinical studies demonstrate that Tryptophan-deficient diets decrease 5-HT
synthesis and diminish 5-HT pools in tissues. Studies, in which rats were fed a diet of corn
deficient in Tryptophan and lysine, had decreased brain Tryptophan and 5-HT concentrations
compared with controls. This neurotransmitter deficiency was reversed by a single injection
of Tryptophan. Similarly, in humans, clinical and preclinical studies suggest altered
serotonergic function in brain after dietary Tryptophan restriction. But confounding variables
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Table 1 - Concentration of amines in foods
4 4 0
0-2 6 0
2
5
0 23 4-5
0 1 0
0 1 0
0 0 0
0.1 10 0,
0.5-3.0 3' 0
Pawpaw
Pineapple (green)
Pineapple (ripe)
: Pineapple, canned juice
. Pineapple, fresh juice
1-2
50-60
19
23-25
J.tg/ml
12.
ug/ml'
3
4
4'
5
5
Taken from: Marley et ai, April 1970; 187-88
such as malnutrition cause a modest decreases in plasma Tryptophan levels. Dietary
restriction of Tryptophan has been used as a method to decrease 5-HT levels in these studies
(Miller et aI, 1992).
Serotonin plays a vital role in the regulation of human behaviours including
psychiatric disorders. Thus Tryptophan depletion has been used in studies of obsessive
compulsive disorder (QeD), eating disorder (bulimia), substance (cocaine and alcohol) abuse,
aggression and pain. The acute depletion of Tryptophan by dietaFy amino acid mixtures
provides a tool for studying the role of 5-HT in the pathophysiology and psychopharmacology
of psychiatric illness and provides a method to explore mechanisms of pharmacologic action.
Tryptophan depletion paradigms have been used to investigate the role of 5-HT in depression,
study of 5-HT function in drug free depressed patients and in antidepressant drug response.
These paradigms may also be helpful in the identification of subtypes of depression and for
predicting a treatment response (Miller et aI, 1992; Yogman et aI, 1985).
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1.5 Serotonin Deficiency
There are a number of possible mechanisms by which 5-HT deficiency within the
CNS might arise. These are impaired biosynthesis, Tryptophan deficiency, and reduced
transport (Montg.omery, 1990).
1.5.1 Impaired Biosynthesis
Defects in enzymes producing 5-HT or defects in synthesis or availability of cofactors
such as BH4 or pyridoxine which are involved in 5-HT synthesis results in impaired 5-HT
biosynthesis. Defective hydfoxylation of Tryptophan to 5-HTP occurs in BH4 deficiency.
Alternatively there may be problems with the peripheral production and transport of 5-HT
which may be a backup system at times when CNS de-novo synthesis of 5-HT is limited
(Montgomery, 1990}.
1.5.2 Tryptophan Deficiency
Tryptophan, the precursor of 5-HT is an essential amino acid obtained from dietary
sources. In addition to dietary deficiency, reduced CNS levels of Tryptophan could arise
from:
(i) defective transport of Tryptophan into the CNS involving defects, blocking or competitive
inhibition of the aromatic amino acid uptake system;
(ii) other processes within the CNS such as protein synthesis compete for the available
Tryptophan. Increases in these processes may reduce the availability of Tryptophan for 5-
HT biosynthesis; and
(iii) in severe CNS infections and inflammatory processes, CSF Tryptophan levels and CSF
5-HIAA are low indicating reduced 5-HT turnover (Montgomery, 1990).
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Tryptophan is the only amino acid, about -95% of which are -tightly bound to serum
proteins. However, it is the concentration of free Tryptophan that controls the concentration
of Tryptophan in the brain. The Tryptophan necessary for 5-HT synthesis enters the brain by
an active transport system, which also serves as a carrier for five other large neutral amino
acids (LNAA). Competition for the carrier site can lead to a deficiency of any of these amino
acids. This competitive transport system allows depletion of brain Tryptophan and
subsequently 5-HT, by administration of amino acid mixtures lacking Tryptophan. Dietary
manipulations that alter the ratio of Tryptophan to other amino acids can cause a relative
decrease in plasma Tryptophan. The validity of acute Tryptophan depletion by dietary amino
acid loading as a method to diminish brain 5-HT is supported by several studies-. Studies in
humans have d~termined that amino acid mixtures lacking in Tryptophan can lead to
substantial decreases in plasma free and protein oound Tryptophan (Miller et al, 1992).
/
1.5.3 Red'ueed Transport
If CNS 5-HT can oe supplied via platelet transport then the following transport
disorders may also contribute to 5-HT deficiency:
(i) reduced peripheral biosynthesis of 5-HT;
(ii) defects or altered regulation causing reduced uptake of 5-HT into platelets or increased
loss of 5-HT from platelets; and
(iii) reduced ability ofplatelets to release 5-HT into the CNS (Montgomery,1990).
1.6 Serotonin Reeeptors
Serotonin receptors were first described in 1957 and clinical research studies have
resulted in the development of new therapeutic agents useful for treating a number of
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psychiatric illnesses. The distribution of 5-HT receptors are widespread throughout the
cerebral cortex, the limbic system, the striatum, the brain stem, the choroid plexus, and almost
,
every other region ofthe eNS. It has been hypothesised that this widespread distribution of 5-
HT receptors may be the reason for the wideranging actions of therapeutic drugs which treat a
number of clinical disorders including anxiety, depression, OeD, eating disorders, panic
disorders, migraine, and chemotherapy related emesis. Understanding ofthe roles of serotonin
receptors in the function of the brain continues to grow from further studies especially with
recent cloning ofmany ofthe 5-HT receptor subtypes (Harrigton et aI, 1992).
New techniques in molecular biology in the 1990's have resulted in more detailed
study of serotonin and its properties in the brain. Serotonin alters mood and emotions and a
lack of serotonin has been implicated in the onset of different classes of headache (Leonard,
1994; RotlY, 1994). Recent advances in basic pharmacology have identified, defmed,
characterised and classified multiple receptor subtypes for 5-HT, contributing to emergence to
vast pharmacology of 5-HT. Highly selective agonists and antagonists at these receptor sites
are being developed as drugs for therapy and as pharmacological probes for assessing
functions of brain serotonin neurons in disease. Since its discovery, serotonin has become a
major player on the neurotransmitter "stage". (Fuller, 1992; Launay et aI, 1994).
1.6.1 Classes of Serotonin Receptors
Investigators, to date have acknowledged 14 separate 5-HT receptors, which are
divided into seven main families or classes (Figure 7).. Each class appears to mediate its own
set of biological responses, each showing therapeutic potential. The seven classes are 5-HT1,
5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 (Roth, 1994). Some of these receptor
classes also have different subclasses of receptors. The 5-HTl class is the largest and most
studied class of serotonin receptors and in the subclass, receptors are said to be 5-HT1-like
(Mills, 1995; Overmyer, 1990). The serotonin receptor system currently includes 14 subtypes
of serotonin receptors in the periphery and the CNS (Hartig, 1994; Leonard, 1994; Roth,
Figure 7 - The 5-HT~ family
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1994). There are also evidence implicating the role of specific 5-HT receptor subtypes in
thermoregulation, modulation of cardiovascular function, eating disorders, sleep, sexual
activity, anxiety states, aggression, schizophrenia, and depression (Leonard, 1994).
1.6.2 Location of Serotonin Receptors
(i) Both 5-HTl and 5-HT1-like receptors are located primarily in the· brain
(cortex,hippocampus, and raphe nueleus) and in some blood vessels. Their activation
prompts. inhibition of eNS neurons and induces some smooth muscle cells to relax and
others, primarily cranial, to contract. These receptors were thought to be involved in
migraine and other types of headache. Drugs acting on these receptors may also be
effective in treating generalised anxiety disorders, tardive dyskinesia, behavioural
dysfunction, and depression;
(ii) 5-HT2 receptors are found in the brain and smooth muscle cells through out the body,
mediate vasoconstriction, bronchoconstriction, and platelet aggregation. These receptors
also appear to be the site of action of hallucinogens. Drugs acting on these receptors are
effective as antipsychotics, anxiolytics and also act on the gastrointestinal system;
(Hi) 5-HT3 receptors are found in the lining and vagus nerve of the gut and in the
chemosensitive trigger zone that lies close to the emetic centre in the brain and function as
ion channels. These are the recepto17s that have been implicated in emesis. Drugs acting on
these receptors could be useful in treating emesis, schizophrenia, anxiety, and memory
difficulties;
(iv) 5-HT4 receptors are found in few brain areas (superior colliculus) as well as many
smooth muscles (oesophagus, intestine, and vascular tissue). Drugs having an affmity for
these receptors may have efficacy in stimulating colonic motility in patients with
constipation secondary to the side effects ofantipsychotic and antidepressant drugs;
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(v) 5-HT5 receptors are found in many important brain areas including the cortex,
hippocampus, and certain limbic and thalamic regions. Two distinct members ofthis
receptor family have been cloned though no function has yet been discovered for them;
(vi) 5-HT6 receptor is most highly emiched in basal ganglia while the 5-HT7 receptor is
concentrated in hypothalamus. Both these receptors are positively coupled to adenylase
cyclase and hl:j,ve a high affmity for a number of antipsychotic and tricyclic antidepressant
drugs while 5-HT7' agonists appear to regulate sleep-wake cycles. There is a possibility
that selective agents for these receptors could be useful for treating depression and
psychosis, unfortunately, no selective agents for these receptors currently exist
(Overmyer, 1990; Roth, 1994).
1.7 Relation to Physiological and Pathological Processes
1.7.1 Possible Chemical Mediation in CNS
It has been demonstrated that serotonin is found in the hypothalamus and a few other
areas of the brain. In addition to the tranquillising effect of reserpine there appears to be a
,
pronounced depletion of serotonin from body stores including the brain. It appears that
serotonin depletion blocks the tranquillising action of the drug. This fmding led to the
hypothesis that serotonin is a mediator of trans-synaptie conduction in the eNS or at least a
modulator of transmission (Figure 8 A&B). However, reserpine also depletes brain
norepinephrine and dopamine and it was difficult to decide which of its effects are due to
serotonin depletion and which to catecholamine depletion. Hence the evidence for and against
this hypothesis is indirect and incomplete (Ganong, 1969; Meyers et aI, 1968).
Figures 8 A&B - S-IIT neuron
A Diagram of a Serotonin :'Iieuron Showing the
~Iain Steps in the Life Cycle of Serotonin and the Sites at
Which Drugs Act*t
MAO
"t.!7""1f'='"~ydIo.~~
jo-methyl $-Kl"P=.,luc
s-HTP <Ieartlo.yl""
~~---~'T.....ylcypron"ne lotAO
, Pvsyline i inlobo.....
11lIilri+-----Is-Kn
/I~~':::;'~~~~-Hip >Ilinlly
"'I""l'IWt tnn.pon
IKhkwopMn~WllUM :UCS::;I.&W
Trypc"l'lWt h~od")lYIue
Postsynapt
"""'plor v- High >Ilinily~KT upuke~
IP-<:hIorophenYlaLln"j
r:enfluranunr: /
P:Iro.etine ll<upW:<
Fluo..etine inhibiion
·From reference 3. with pennission.
t Abbreviations: S-HIAA .. S-hydroxyindoleacelic acid. S-HT .. serotonin,
S-HTP .. S-hydroxytryptophan, MAO .. monoamine oxidaseo
Taken ftom :Risch et al, Oct 1992 : 4
Figure' 8 'B - 5-Hf neuron
Taken ftum :Ell Lilly and Co. (NZ) Ltd
23
Monoamine oxidase inhibitors, which are psychic energisers increases brain serotonin
but they also, increase brain norepinephrine and dopamine. Administration of 5-HTP, the
precursor of serotonin leads to excitement and signs of sympathomimetic activity. However
prior administration of monoamine oxidase (MAO) inhibitor intensifies this effect. MAO
inhibitors cause a rise in the intracellular contents of bound serotonin and also prevent the
destruction of free serotonin. MAO inhibitors by themselves have been shown to elevate brain
serotonin relatively more and rapidly than brain norepinephrine. Depletion by reserpine alters
norepinephrine and serotonin content equally. Reserpine causes electrophysiologic signs of
stimulation along with behavioural depression. But the behavioural effects of reserpine are
duplicated by other drugs such as chlorpromazine which do not alter the amine content
(Ganong, 1969; Meyers et aI, 1968).
It has also been possible to produce a selective depletion of brain serotonin by
administering p-chlorophenylalanine, which blocks the conversion of Tryptophan to 5- HTP.
This has been found to be the rate-limiting step in serotonin biosynthesis. This compound p-
chlorophenylalanine produces prolonged wakefulness in animals suggesting serotonin plays a
role in sleep but this effect has not been observed in man. There is also evidence that
serotonin is a mediator in descending fibre systems that inhibit the initiation of autonomic
impulses in the lateral gray columns of the spinal cord (Ganong, 1969).
Serotonin itself does not enter the eNS easily and the amount is limited by
cardiovascular effect. Systemic administration of serotonin does not demonstrate any action
on CNS because it does not reach the parenchymal cells of the CNS. Derivatives of
tryptamine that are less polar would be expected to enter CNS more easily. The results of
experiments applying serotonin directly to or into the brain are conflicting as are the
speculations concerning the role of serotonin in the aetiology of psychosis (Meyers et aI,
1968).
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1.7.2 Carcinoid Tumours
Neoplasms that arise from argentaffm cells are always "functional" which means they
synthesise and store serotonin. The serotonin liberated by the primary carcinoid tumour of the
GIT is small and is destroyed during its passage to the liver. Circulating serotonin from some
larger tumour masses and in some rare cases of bronchial adenoma causes a characteristic
syndrome consisting of diarrhoea, asthma (from bronchiolar constriction), and cutaneous
flushing. The signs occur paroxysmally and may be precipitated by eating, emotion, exertion
or pressure on a tumour mass. These effects can be duplicated by serotonin infusion. In
addition, extra serotonin can also cause subendocardial fibrosis leading to pulmonary stenosis
and tricuspid insufficiency. The diagnosis of this tumour is by detection of large amounts of
serotonin metabolite, 5-HIAA in the urine and no pharmacological treatment has yet been
realised (Meyers et aI, 1968).
1.7.3 Endomyocardial Fibrosis
In some areas of Africa, bananas and plantains, which are rich in serotonin, are
prominent in the diet and where diet is high in serotonin and dopamine produce endocardial
thickening. It is thought that the affected population does not metabolise serotonin as rapidly
as other populations because ofco-existing chronic diseases (Meyers et aI, 1968).
1.8 Pharmacological Effects
1.8.1 Mechanism of Action
Serotonin has multiple mechanism of action including augmentation of afferent
activity from chemoreceptors and direct actions on smooth muscle. Some reported underlying
actions are conflicting and are still presumed rather than established to be serotonin effects.
The peripheral effects of serotonin are more easily studied and have been better described
than CNS effects (Meyers et aI, 1968).
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1.8.2 ~ffects
1.8.2.1 Cardiovascular and Respiratory
Serotonin can cause immediate fall in blood pressure accompanied by bradycardia, a
rise in blood pressure accompanied by tachycardia, and a prolonged fall in blood pressure.
These effects depend upon the method of administration (rapid intravenous infusion or
injection), dosage, and other factors (Meyers et aI, 1968). Its direct effect on cardiovascular
tissue is more complex. Its constricts some arteries and dilates others. Serotonin has been
shown to dilate skeletal muscle and cutaneous arteries and to constrict renal, umbilical, and
splanchnic arteries. The cardiovasculaF effects of serotonin continue to confuse investigators.
Its cardiac action varies from species to species and between hypertensive and normotensive
subjects (Overmyer, 1990).
1.8.2.2 Non Vascular Smooth Muscle
Non vascular smooth muscle is stimulated by serotonin, which results in bronchiolar
constriction and increased intestinal motility. In infants, during the fIrst 3 months (except the
fIrst week) of life have peak serotonin concentrations in the evenings, which cause infantile
colics which is thought to be the result of increased intestinal smooth muscle contractions.
Melatonin decreases intestinal smooth muscle contractions, but trans-placental melatonin
derived from the mother is present in the infant's blood only during the fIrst week of life
(Weissbluth et aI, 1992). When serotonin is released from the gut, it can also trigger nausea,
tachycardia, and emesis. This is thought to be the reason why 30% of chemotherapy patients
still experience acute emesis despite a number of antiemetic therapies that have been
developed during the past decade (Overmyer, 1990).
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There is a large concentration of serotonin 5-HT3 receptors in the gut and the vagus
nerve, which connects the gut to the chemosensitive trigger zone in the brain. Researchers
suspect that serotonin released in the gut binds to receptors on the vagus nerve (Figure 9),
which sends signals to the trigger zone. Nerves in the trigger zone then send signal to a
nearby region of the brain to initiate contractions in respiratory and abdominal muscles - the
result is emesis. Figure 9 demonstrates one approach to prevent the emetic response by
blocking the 5-HT3 receptors on the vagus nerve with a serotonin antagonist, ondansetron,
which is now in phase III ofclinical trials (Meyers et aI, 1968; Ovennyer, 1990).
1.8'.2.3 Central Nervous System
Serotonin is a possible chemical mediator in eNS. Its actions on neurons in the brain
/
may. indirectly influence blood pressure, heart rate and respiration. Now we also know that in
the brain, serotonin alters mood and emotions and has been implicated in the onset of
different classes of headache (Ovennyer, 1990}. Discovery of drugs, which are serotonin
antagonist like the. psychotomimetic agents (Lysergic acid diethylamide, LSD and
antihypertensive, Reserpine) called attention to the correlation of behaviour and variations in
brain serotonin level. Despite these known effects the relationship of serotonin to mental
functioning remains uncertain (Ganong, 1969).
Figure 9-
Mediation and blocking of the emetic response
Gut·cell------------~_H--
Serotonin-- -II~-___j",...
Serotonin receptor (5-HT3)
on vagus nerve cell ------......M~1Ii
Emetic response
Ondansetron -----------:IF:
No response
The emetic response is mediated by serotonin (red) in the gut cell. When serotonin is released, it binds to the 5-HT
3receptors (green) on the vagus nerve cell (blue), provoking the response. But when a serotonin antagonist such as
ondansetron (yellow) is introduced, it binds to the receptor and blocks serotonin, thereby preventing the response.
Taken from : Overmyer, Nov 1990 : 121
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It is hoped the advances in serotonin pharmacology will expand our understanding of
the role of serotonin as a brain neurotransmitter in health and disease which will lead to
improved therapeutic agents. An example is that several advances in serotonin pharmacology
have implications for psychiatry with the introduction of selective serotonin reuptake
inhibitors (SSRIs) such as prozac in clinical use for depressive illness. The role of serotonin
in psychiatric disorders has been speculated almost as long as serotonin has been known to be
present in the brain (Fuller, 1992). However it is only recently that because alterations of 5-
HT receptor activity have been shown to occur in many psychiatric diseases, as a result, a
number of effective psychopharmacological agents have been developed. These agents range
in the treatment for diseases as diverse as schizophrenia and anxiety which either specifically
alter brain levels ofserotonin or bind to 5-HT receptor subtypes (Roth, 1994).
1.8~3 Serotonin Antagonist
An antagonist is a drug that binds to a cell receptor for a hormone, a neurotransmitter,
or another drug, and thus blocks the action of the other substance without producing any
physiological effect itself (Dorland's Pocket Medical Dictionary, 1982). An antagonist to
serotonin such as ondansetron is potentially an important analytical tool and therapeutic agent
as atropine. This fact generated enthusiasm for compounds and hypotheses, which are not yet
justified by the available data. Serotonin has multiple physiological and pharmacological
effects, hence the search should be for multiple types of serotonin antagonists (Launay et aI,
1994; Meyers et aI, 1968). The two classes of serotonin receptor antagonist compounds are
used as therapeutic candidates. These are 5-HT2 in anxiety, schizophrenia, depression, and 5-
HT3 in anxiety, schizophrenia, and substance abuse. In addition to their potential use in
psychiatric disorders 5-HT2 receptor antagonists are also of therapeutic interest in the
treatment of other diseases especially cardiovascular diseases. This is due to the important
role of 5-HT2 receptors on blood vessels and blood platelets and 5-HT3 as an anti-emetic
drug (Fuller, 1992).
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LSD was among the first compounds to be used in the laboratory as serotonin
antagonist. Its ability to cause toxic psychosis, lead to theories explaining the origin of the
psychoses. Other ergot derivatives are more potent serotonin antagonists but lack the
behavioural effects in human. Also methysergide (sansert) used in the treatment of migraine
is the most potent antiserotonin of all ergot derivative but is also potent enough to be a
vasoconstrictor to be effective (and dangerous) in the treatment of migraine. Other
antihistamines like cyprohepatidine (periactin) have antiserotonin effect in animals, which
was wrongly alleged to have special properties owing to its antiserotonin action (Meyers et aI,
1968).
There is no evidence that methoxylation OF N-methylation of serotonin occurs in the
body to generate a psychotogenic substance. However several related substances are
/
hallucinogenic or cause a toxic psychosis for example:
(i) tryptamine itself is generally similar to serotonin but is a convulsant;
(ii) DMT and DET (N,N-dimethyl and N,N-diehtyltryptamine are hallucinogenic if given by
injection. They are said in some circles to be suitable for a "businessman's trip";
(Hi) psilocybin (4-hydroxydimethyltrptamine) isolated from a mushroom, psilocybe mexicana,
used by Mexican Indians for its hallucinogenic effect; and
(iv) bufotenine or dimethylserotonin is isolated from the secretions of toad skin and from the
seeds of a plant, Piptadenia peregrina, used as snuff by some South American Indians. It
is hallucinogenic after injection (Meyers et aI, 1968).
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1.8.4 Serotonin Agonists
In phannacology, an agonist is a drug that has an affmity for the cellular receptors of
an another drug or natural substance which produces a physiological effect (Dorland's Pocket
Medical Dictionary, 1982) such as sumatriptan, a specific 5-HT agonist for acute treatment of
migraine (Launay et aI, 1994). Serotonin agonists compounds increase serotonin function by
decreasing serotonin turnover by acting on post-synaptic serotonin receptors independent of
tlle presence of functional serotonin nerve terminals. These compounds also decrease food
intake and REM sleep and are useful in depression and anxiety conditions (FulleF, 1992).
1.8.5 Selective Serotonin Reuptake Inhibitors (SSRIs)
Selective serotonin reuptake inhibitors are compounds that inhibit the uptake of 5-H'F
and decrease the whole blood 5-HT levels in man due to inhibition of platelet 5-HT uptake.
These compounds inhibit the serotonin transporter on serotonin neurons without inhibiting
catecholamine uptake or antagonising neurotransmitter receptors. They increase serotonin
function by decreasing serotonin turnover only where serotonin neurons are present and are
releasing serotonin and not where the serotonin neurons are totally non-functional as in some
diseases. SSRIs also decreases food intake and REM sleep, and have neuroendocrine effects
(Fuller, 1992; Mitchell, 1994).
Some of these compounds are now being used in clinical trials while some are being
marketed for the treatment ofmental depression. In addition to depression, the SSRIs are also
useful for treating many other psychiatric disorders (DeVane et aI, 1996; Roth, 1994). Some
of these SSRIs like fluoxetine, fluvoxamine, paroxetine, indalpine, citalopram, femoxetine,
zemeldine and sertraline are some of the newer antidepressants which showed antidepressant
efficacy in double-blind clinical studies and have been recently introduced in clinical practice
(Figure 10). But there are still some misconceptions about certain phannacological features of
SSRIs since their phannacological mechanism in depression is not yet fully understood.
Figure 10-
The new antidepressants: a guide for GPs
Two new classes of antidepressants have recently been introduced into clinical practice. A number of other novel anti-
depressants are likely to be marketed within the next few years. What is the role of these new antidepressants? How do
they compare in terms of efficacy. tolerability and toxicity?
Illustration for Modem Medicine by Wllliam B. Westwood.
Taken from :fv.fitchell, nee 1994 : 17
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There is no evidence that serotonin uptake inhibitors affect serotonin turnover by any
mechanism other than altering the amount of serotonin in the synaptic cleft (Fuller, 1992;
Mitchell, 1994).
1.8'.6 Serotonergic Drugs and Serotonin Syndrome
Serotonin syndrome is an iatrogenic disorder, which occurs most often by the
concurrent use of two or more serotonergic drugs (Table 2) that increase brain stem serotonin
activity by augmenting brain serotonin neurotransmission. It has also been reported with
single drug exposure in both therapeutic and overdoses settings. Serotonin syndrome is often
unrecognised because of the varied and non-specific nature of its symptomatology and signs
and symptoms similar to Neuroleptic Malignant Syndrome. It is an important drug related
complication of psychopharmacological therapy for depression, bipolar affective disorder,
QeD, and Parkinson's disease. It is characterised by variable alterations in cognition, and
behaviour, autonomic nervous system function and neuromuscular activity (Table 3). The
most common clinical features are changes in mental status, restlessness, myoclonus,
hypelTeflexia, diaphoresis (profuse perspiration), shivering, and tremor (Mills, 1995).
Primary care physicians commonly prescribe drugs as listed in Table 2 that can
produce serotonin syndrome, which has a potential mortality of eleven percent. In order to
decrease this potential mortality, serotonin syndrome must be both prevented by prudent drug
therapy and recognised when it is present. The majority of the patients with serotonin
syndrome can be effectively managed using four basic principles as follows:
(i) provide necessary supportive care;
(ii) discontinue all serotonergic drugs;
(iii) consider use ofantiserotonergic medications; and
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(iv) make necessary adjustments in the medication regimen before reinstituting serotonergic
medications (Mills, 1995).
Serotonin syndrome is associated with a good prognosis, although many patients are
severely ill on initial presentation. Symptoms rarely last longer than 72 to 96 hours. The fInal
management issue concerns restarting patients on appropriate pharmacological drug therapy
after their recovery from serotonin syndrome but very little information is available to guide
clinicians in this area. It seems appropriate to limit serotonergic medications in patients who
have recovered from serotonin syndrome since these patients are probably at higher risk for
recurrence on drug rechallenge. This can be achieved by discontinuing any combination drug
therapy, using lowe:r potency serotonergic agents, decreasing drug dosages, and closely
monitoring patients for sYmptom development (Mills, 1995).
Table 2
Serotonergic Drugs
Increase serotonin synthesis
L-tryptophan
, Decrease serotonin metabolism
Isocarboxacid (Marplan)
Phenelzine (Nardil)
Selegiline (Elderpryl)
, Tranylcypromine (parnate)
Increase serotonin release
Amphetamines
Cocaine
. Fenfluramine (pondimin)
Reserpine, initially (Serpalan, Serpasil)
, Inhibit serotonin uptake
. Tricyclie antidepressants
Amitriptyline (Elavil, Endep)
Clomipramine (Anafranil)
Desipramine (Norpramin, Pertofrane)
Doxepin (Sinequan, Adapin}
Imipramine (Tofranil, Janimine)
Nortriptyline (pamelor, Aventyl)
Protriptyline (Vivactil)
Selective serotonin reuptake inhibitors
Fluvoxamine (Luvox)
Fluoxetine (Prozac)
Paroxetine (Paxil)
Nefazodone (Serzone)
Sertraline (Zoloft)
Trazodone (Desyrel)
Other uptake inhibitors
Amphetamines
Cocaine
Dextromethorphan
Meperidine (Demerol)
Venlafaxine (Effexor)
Direct serotonin receptor agonists
Buspirone (Buspar)
Lysergic acid diethylamide (LSD)
Sumatriptan (Imitrex)
Non-specific increase in serotonin activity
, Electroconvulsive therapy
Lithium
Dopamine agonists
Amantadine (Symmetrel, Symadine)
Bromocriptine (parlodel)
Bupropion (Wellbutrin)
Levodopa
Taken from: Mills, Oct 1995: 1476-1477
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Table 3
Signs and Symptoms of Serononin Syndrome
(Review of 100 cases)*
Sign/symptom Frequency
(%)
Cognitive-behavioural symptoms
Confusion/disorientation 51
Agitation/irritability 34
Coma/unresponsiveness 29
Anxiety 15
Euphorialhypomania 14
Headache 13
Drowsiness 13
Seizures 12
Insomnia 11
Hallucinations (visual and auditory) 6
Dizziness 5
Autonomic nervous system
Hypertension 45
· Diaphoresis 45
Sinus tachycardia
. 36
Hypertension 35
Dilated pupils 28
Tachypnea 26
Nausea 23
· Unreactive pupils 20
· Flushing 16
Hypotension 15
Diarrhea 8
Ventricular tachycardia 6
, Cyanosis 5
Abdominal cramps 4
Salivation 2 I
Neuromuscular
Myoclonus 58
Hyperreflexia 52
, Muscle rigidity 51
Restlessness/hyperactivity 48
Tremor 43
Ataxia/incoordination 40
Clonus 23
, Babinski's sign (bilateral) 16
Nystagmus 15
Trismus 7
Teeth chattering 6
Opisthotonus 6
Paresthesias 6
* _The 100 cases are based on cases found by the
author in a Iitemture review
Taken from: Mills, Oct 1995: 1476-1477
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CHAPTER 2
PARTl
2. Methodology
2.1 Aim
This project specifically aims to produce an overview of serotonin research and
serotonergic disorders in humans. After preparing a general overview of serotonin and its
associated disease states, some specific disorders which appear to have good prospects for
rehabilitation will be selected and reviewed in detail. As part of this review biochemical data
/
related to serotonin will be analysed in order to establish if there is any causal relationship to
these disorders in children investigated at New Children's Hospital, Westmead,' NSW
between 1985-1995.
2.2 Epidemiological: Approach
An epidemiological research approach using literature reviews is used for this treatise.
An study designs involve some implicit (descriptive) and explicit (analytic) type (Table 4) of
comparison of exposure and disease status. An overview of serotonin research and studies in
humans involves descriptive studies using literature reviews and analytical epidemiological
approach to analyse data fOf· statistical association and a cause-effect relationship.
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Table 4 : Overview ofepidemiologic design strategies
Descriptive studies
Populations (correlational studies)
Individuals
Case reports
Case series
Cross-sectional surveys
Analytical studies
Observational studies
Case-control studies
Cohort studies - retrospective and prospective
Intervention studies (clinical trials)
Taken from: Hennekens et! ai, 1987: 18'
2.3 Literature Search
,/
The best way ofmanaging the vast amount of research information on serotonin is by
using computer technology as follows:
(i) literature search (MEDLINE and OVID) for collection of human studies (case studies to
analytical epidemiological studies) of serotonin;
(ii) create a data-base of serotonin studies using ENDNOTE and ENDLINK programs;
(iii) conduct a "meta-analysis" by summarising all collected data in a tabular form detailing
author, date, place, type of study, number of participants, confounders, selection bias,
measurement bias, conclusions and selecting specific areas with potential for
rehabilitation; and
(iv) investigate the relationship between previously collected biochemical data on serotonin
turnover with disease states and syndromes and analysing trends using EXCEL database
and SPSS statistical packages.
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An extensive Medline and Ovid literature searches were done from 1966-1996 as well
as hand searches from specific journals, texts and other sources such as pharmaceutical
company and an SBS TV programme. Since there are huge amount of information on
serotonin, a bibliographic database was set up by importing information from Medline and
Ovid into endnote and endlink library. These informations were classified into various
specific groups of serotonergic disorders, human studies of serotonergic disorders, annotation
of the bibliography, cross-indexing, referencing and linkage (Appendix A). The Medline
search was done at Cumberland College of Health Sciences Library, Lidcombe and Ovid
search was done at New Children's Hospital, Westmead and the database set up at New
Children's Hospital, Westmead, Biochemistry Research Section under the supervision of Dr
John Earl.
/
2.4' Outcome of the Project
2.4.1 Clinical and Therapeutic
Various drugs are already being used on a non-selective basis for treatment of
serotonin deficiency disease. A greater understanding of how serotonin and its precursors are
delivered to the central nervous system (eNS) will provide a basis for more selective and
long-term benefit for the treatment ofserotonin deficiency diseases.
2.4.2 Rehabilitation
An understanding of the serotonergic system is the first step towards implementing
prevention and rehabilitation of serotonin deficiency diseases. The result of meta-analysis of
case studies in the future may form the basis for selecting patients for further follow-up and
possibly treatment with serotonin pathway precursors or drugs, which will regulate serotonin
physiology.
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2.4.3 Research
The epidemiological information may help produce recommendations fOF future
human studies in serotonin deficiency diseases which will contribute to potential areas for
clinical application in treatment and rehabilitation of serotonin associated disorders. Currently
one of the major goals in serotonin research is the elucidation ofphysiologic functions of the
multiple serotonin receptor subtypes through the use of drugs that have high selectivity as
agonists Of antagonists at specific serotonin receptor subtypes. Such compounds have been
identified and are used in these studies and are being explored in clinical trials. Meanwhile
the search for more selective agents to activate OF antagonise specific receptor subtypes
continues (Fuller, 1992).
/
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PARTII
2.5 Epidemiological Research
2.5.1 Introduction
Human diseases have causal and preventive factors that can be identified through
systematic investigation using epidemiological approach. In order to formulate and test
hypotheses concerning possible causal or preventive factors Epidemiological studies are
conducted in human populations. Epidemiological principles and methods are thus applied to
design, conduct and analyse human studies. While basic reseaIch may add to our biological
understanding ofan exposure and disease, only epidemiology allows and offers the possibility
of altering the exposure and disease relationship and associated risk by intervention
(Hennekens et aI, 1987).
All study designs involve some implicit (descriptive) and explicit (analytic) types of
comparison of exposure and disease status. A recent development in modem epidemiology
has been the application ofepidemiological principles and methods to the design, conduct and
analysis ofclinical trial studies in which the investigators themselves allocate the exposures to
the participants who are being studied (Hennekens et aI, 1987). In the following section a
summary ofthe basic types ofepidemiological studies will be presented.
2.5.2 Descriptive Epidemiology
Descriptive studies are concerned with the general characteristics of the distribution of
a disease in relation to demographic factors and life style variables. These are the most
frequently encountered epidemiological design strategies in the medical literature since they
often provide the first important clues about possible determinants of a disease. Thus
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descriptive studies are primarily useful for the formulation of hypothesis that can be tested
using an analytic design. The main types of descriptive studies are: correlational studies
(populations), case reports and case series (individuals), and cross-sectional studies
(individuals) which are listed in Table 1 (Hennekens et aI, 1987}.
2.5.2.1 Correlational Studies
In correlational studies data is used from the entire population in order to compare
disease frequencies between different groups during the same period of time or in the same
population at different points in time. These studies often give important clues to causation
but are inhibited by the fact that there is no way of assessing the role of other factors
(confounders) in the proposed causal pathway (Hennekens et aI, 1987).
2.5.2.2 Case Reports and Case Series
The case report is the most common type of descriptive study of individuals found in
medical literature. They consist of a careful detailed report by one or more clinicians of the
clinical and diagnostic profile of a single patient. Case reports document unusual medical
occurrences and can often represent the first clues in the identification of new diseases or
adverse effects of exposures. The individual case report can be expanded to a case series,
which describes characteristics of a number of patients with a given disease. Case report and
case series studies represents an important interface between clinical medicine and
epidemiology but these studies have limitations as they have no comparision group. They are
very useful for hypothesis formulation, but cannot be used to test for the presence of a valid
statistical association (Hennekens et aI, 1987).
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2.5.2.3 Cross-Sectional Surveys
In cross-sectional surveys, the status of an individual with respect to the presence or
absence of both exposure and disease is assessed at the same point in time. These studies are
often useful for raising the question of the presence of an association but may lack the ability
to control for the effects of potential confounding factors. Also in this study design it is not
possible to determine whether the exposure preceded or resulted from the disease (Hennekens
et aI, 1987).
2.5.3 Analytical Epidemiology
/
In analytical study designs the comparison is explicit, since the investigator assembles
groups of individuals for the specific purpose of determining whether or not the risk of
disease is different for individual exposed or not exposed to a factor of interest. It is the use of
an appropriate comparison group that allows the testing of epidemiological hypothesis in
analytic study designs. There are two main analytic study design options: observational (case
control and cohort) and intervention (clinical trials) as listed out in Table 4. The major
difference between the two options is the role played by the investigator. In observational
studies the investigatOJ; simply observes the natural course of events in exposed and non-
exposed subjects and who has and has not developed the outcome of interest. In intervention
studies, the investigator allocates the exposure and then follow the subjects for the subsequent
development of disease Analytic studies can be used to generate additional research questions
but their chiefcontribution is to test epidemiological hypothesis (Hennekens et al, 1987).
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2.5.3.1 Observational Studies
There are two basic types: case control and cohort study.
2.5.3.1.1 Case Control Study
In a case control study, a case group or series of patients who have a disease of
interest and a control, or comparison, group of individuals without the disease are selected for
investigation and the proportions with the exposure of interest in each group are compared.
The potential problem in a case control study is that since both the exposure and disease have
already occurred at the time of the study, this design is susceptible to bias in, selecting,
reporting, and recording of cases and controls. This has led to scepticism in the past
concerning the value- of case control investigations. The potential for bias cannot be ignored
and it requires careful consideration of bias sources to minimise or avoid its occurrence.
Well-designed and conducted case control studies can provide valuable information on the
association between an exposure and disease (Hennekens et aI, 1987).
For a case control study to provide a sound evidence of whether there is a valid
statistical association between an exposure and disease, comparability of cases and controls is
essential. Hence, one of the ftrst tasks in any study is to establish strict diagnostic criteria for
the disease to ensure that the cases selected for the study represents a homogenous entity.
Cases can be selected from a number of sources: hospital based (common, easy, and
inexpensive) and population based case control or a random sample from a defmed
population, which will avoid selection bias. The selection of an appropriate comparison group
is the most difftcult and critical issue in the design of a case control study and there is no
control group that is optimal for all situations (Hennekens et aI, 1987).
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2.5.3.1.2 Cohort Study
In a cohort study subjects are classified on the basis of the presence or absence of an
exposure to a particular factor and then followed for a specified period of time, usually
several years to determine the development of the disease in each exposure group. Cohort
study can be a retrospective cohort or a prospective cohort. The feature that distinguishes a
retrospective cohort from a prospective cohort is whether the outcome of interest has occurred
at the time the investigator initiates the study (Hennekens et aI, 1987).
2.5.3.2 InteFVention Studies
Intervention studies are also referred to as experimental studies or clinical trials. The
/
distinguishing feature of the intervention design is that the investigator assigns the exposure
status of each participant. Intervention studies, which are well designed and conducted, can
provide the most direct epidemiological evidence to judge whether an exposure causes or
prevents a disease. It c~ also provide data of the highest quality, which can closely resemble
the controlled experiment done by basic science researchers. Intervention studies are often
considered as providing the most reliable evidence from epidemiological research because of
its randomisation as a means of determining exposure status in a trial. This unique strength of
randomisation in clinical trials where participants are allocated to a particular exposure group
at random, achieves control of all other known and unknown factors or variables
(confounders) that may affect the disease. The potential for bias in allocation to subgroups is
removed and investigators can be confident that the observed differences are not due to
selection bias, measurement bias or confounding. The larger the sample size, the more
successful the randomisation process will be in distributing these variables among the group
(Hennekens et aI, 1987).
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2.5.3.2.1 Types of Intervention Studies
Intervention can be either therapeutic (secondary prevention) or preventive (primary).
Therapeutic trials- are conducted among patients with a particular disease to determine the
ability of an agent to diminish symptoms, prevent recurrence or decrease of death from that
disease. A preventive trial involves the evaluation whether an agent reduces the risk of
developing disease among those free from that condition at the time of the study. Thus
preventive trial can be conducted among healthy individuals at usual risk. Therapeutic trials
are always conducted among individuals while preventive measures can be studied among
individuals or entire population (Hennekens et aI, 1987).
2.5.3.2.2 Problems with Intervention Studies
OtheF features of intervention studies are ethics and feasibility consideration,
including costs, which preclude the evaluation of many treatments or procedures in an
intervention study. An intervention study by defmition requires the active participation and
co-operation of the study subjects. Subjects may deviate from a medical therapy protocol for a
variety of reasons including developing side effects, forgetting to take their medication or
withdrawing their consent after randomisation. The problem of achieving and maintaining
high compliance is an issue in the design and conduction of all clinical trials. Compliance
levels must be measured which is not easy. The simplest measure is a self-report or pill count.
A more objective means of assessing compliance is by the use of biochemical parameters or
markers to validate self':'reports, which is expensive and logistically difficult. However
laboratory determination are also limited as it cannot be used as a reliable measure for long
term compliance (Hennekens et aI, 1987).
The potential for observation bias can also exist in an intervention study since the
knowledge of a participant's treatment status might influence the reporting of relevant events.
One approach to avoid observation bias is to keep the study participants and or the
investigators blinded until data collection has been completed. In a double-blind design,
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neither the participants nor the investigators responsible for assessment of outcomes know to
which treatment group an individual has been assigned. In a double-blind trial, the treatment
and comparison group has to be as nearly identical as possible. In many trials of drug
therapies, the comparison group is assigned to receiving a placebo. The use of placebo will
minimise bias in the ascertainment of both subjective disease outcomes and side effects. One
problem in the evaluation of a placebo control is the well-documented tendency for
individuals to report a favourable response to any therapy regardless of the physiologic
efficacy of what they received. This phenomenon is referred to as the placebo effect
(Hennekens et aI, 1987).
In a single-blind design, the investigator alone is aware of which intervention a
subject is receiving, while in an unblinded or open-label trial, both the subject and the
investigator know to which study group the individuals has been assigned. Again this types of
study design raises the potential for observation bias in the reporting of side effects or
assessment of outcomes. To reduce the potential for observation bias, the study groups
should be followed by independent examiners who are unaware of the subjects treatment
status (Hennekens et aI, 1987).
2.5.4 Statistical Association and an Cause-Effect Relationship
Since epidemiological research IS conducted among free-living humans,
epidemiologists can never achieve the degree of control that is possible in a laboratory. While
the results of any epidemiological study may reflect the true effect of an exposure on the
development of disease, it is also possible that the findings may have an alternative
explanation. The observed association could be due to chance or bias in the way the
individuals were selected into the study or the way in which the information was obtained or
reported or due to unmeasured or uncontrolled or confounding effects. All three (chance, bias
and confounding) alternate explanations must be considered before concluding the presence
of a valid statistical association. A test of statistical significance is the p value and in medical
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research if the p value is less than or equal to 0.05 then the association between the exposure
and disease is considered statistically significant (SS). Alternatively, if the p value is greater
than 0.05 then chance cannot be excluded as a likely explanation, and the fmdings are stated
to be not statistically significant (NS) at that level (Hennekens et aI, 1987).
Also an intervention study must have a sufficient sample size to have adequate
statistical poweF to detect reliably small to moderate but clinically important differences
between treatment groups. Studies of inadequate sample size are believed to have no
scientific value and have the potential for great scientific harm if the results are
misinterrupted. To prevent misinterruption of results, the confidence interval (Cl), or the
range within which the true magnitude of effect lies with a certain degree of assurance,
provides all the information of the p value to decide whether an association is statistically
/
significant at a specified level (Hennekens et aI, 1987).
Other measures of association, the Relative Risk (RR) and the Attributable Risk (AR)
are also frequently used in epidemiology. The relative risk estimates the magnitude of an
association between an exposure and disease and indicates the likelihood of developing the
disease in the exposed group relative to those who are not exposed. A relative risk of 1.0
indicates that the incidence of the disease in the exposed and nonexposed groups is identical
and thus there is no association observed between the exposure and the disease in the data. A
value of greater than 1.0 indicates a positive association or an increased risk among those
exposed to a factor. In a case control-study, the relative risk from a cohort study cannot be
applied but the RR can be calculated by calculating the Odds Ratio (OR) which is the ratio of
the odds of exposure among the eases to that among the control (Hennekens et aI, 1987}
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PARTllI
2.6 Overview of Serotonin Research: Case Studies and, Analytical Epidemiological
Studies: Meta-analysis ofHuman Studies (1985-1995)-Summaries (1-20)
Twenty studies in human on serotonin from the following eight countries: Australia
(1), Canada (4), Denmark (1), Finland (1), France (2), Italy (1), UK (5), USA (5) are
summarised below undeF studies with 5-HT reuptake inhibitoFs, 5-HT antagonists, 5-HT
agonists and biochemical studies, followed by a summary of these 20 studies in a tabular form
listing out the study type, participants, confounding, selection and measurement biases.
Seventeen ofthese studies are inteFYention studies such as clinical trials while three of
these studies are case control. Clinical trial studies used cases with placebo group as the
control group in the studies with drugs such as SSRIs, serotonin antagonist, and serotonin
agonist. Biochemical studies were mostly case control studies where matched normal
volunteers were used as the control group for the cases under study.
2.6.1 Serotonin Studies with SSRIs (Studies 1-8)
Study # 1 (Raptopoulas et ai, 1989)
It has been suggested that paroxetine have effects on whole blood 5-HT and
antidepressant properties with very low affmity for noradrenaline uptake sites but without the
side effects associated with noradrenaline uptake inhibition. Hence the aim of this study was
,
to investigate the effects of repeated oral administration of paroxetine on clinical parameters
(pulse, blood pressure, tremor, nystagmus) and to examine the relationship of whole blood 5-
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HT and plasma concentration ofparoxetine. Male volunteers (selection bias) (n=26) took part
in a parallel, double blind study to once daily dosage ofparoxetine with placebo after a 4-day
placebo washout period. Volunteers (n=8) received placebo while the remaining volunteers
(n=18) received paroxetine in different dosage on different days, through out 33-day study.
The result was a rapid prolonged depletion of whole blood 5-HT due to blockade of
platelet 5-HT uptake sites. There were no marked clinical effects, which were measured
manually for pulse and blood pressure, observer ratings (measurement bias) for tremor and .
nystagmus and pupil diameter gauge for pupil size. Statistical differences between placebo
and paroxetine treatment groups were evaluated by means of two-tailed student's t-test. This
study demonstrated that repeated dosing of paroxetine to healthy volunteers does not produce
the side effects commonly seen with tricyclic antidepressants. Paroxetine has a marked effect
on whole blood 5-HT, confIrming its powerful inhibitory effect on the uptake 5-HT. Although
this study is non-randomised and a small sample size, having a placebo group, a placebo
washout period, and a double-blind study, it minimised confounding and measurement bias.
Study # 2 (McClellard et ai, 1989)
Paroxetine, as stated in study #1, has antidepressant properties and it is more potent
and selective than tricyclic antidepressants such as imipramine and amitriptyline, in clinical
dosage of 30mg. This study examined the effects of 30mg of paroxetine in comparison to
amitriptylline (75mg) and placebo. Healthy volunteers (selection bias) (n=8) took paroxetine
(30mg), placebo, or amitriptyline (75mg) in a single blind (measurement bias), cross over
design. There were no statistically signifIcant differences between the drugs or placebo
treatment. The EEG profIle of paroxetine is different at different dosages, as is the case with
other 5-HT uptake inhibitors such as fluoxetine and fluvoxamine. This study was non-
randomised and small sample size, which leads to confounding.
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Study # 3 (Chouinard, 1992)
The involvement of serotonin in obsessive compulsive disorder (QCD) was postulated
several years ago based on the observation that serotonin reuptake inhibitor, clomipramine,
and SSRIs such as fluoxetine, sertraline, fluvoxamine and Zimelidine were found to be useful
in the pharmocotherapy of QCD. Sertraline is a nontricyclic, potent SSRI, which is currently
approved for the treatment of depression in several countries including the UK and the USA.
Two double blind, placebo-controlled studies (n=412) were undertaken to evaluate the
efficacy and safety of sertraline in QCD vs previous studies done with clomipramine.
The first study result was that sertraline given for 8 weeks in a daily dosage of 50-
200mg was a safe and effective treatment for QCD and superior to placebo. In second study, a
fixed dose design for 12 weeks duration confirmed the efficacy and safety of sertraline in
OCD at fixed dosages of 50, 100 and 200mg / day. This study also demonstrated that further
improvement in QCD symptoms could be achieved through continued treatment with
sertraline. Due to a large randomised sample size, double-blinded and placebo-controlled, it
minimised confounding, selection bias, and measurement bias.
Study # 4 (Gorelick et aI, 1992)
Clinical studies have shown that specific serotonin reuptake inhibitors may also be
useful in reducing alcohol intake in early stage problem drinkers. This study tested the effect
of serotonin uptake inhibitor, fluoxetine on voluntary alcohol consumption in male alcoholics
(selection bias). Alcohol dependent males (n=20) were housed in a hospital ward with 60ml
of 97.5 proof alcohol drink available in a fixed interval drinking decision paradigm. They
were also given a single-blind placebo (measurement bias) fOF 3 days, fluoxetine (up to 80mg
/ day) and placebo, double blind for 28 days. The fluoxetine group had lower alcohol intake
associated with lower requests for alcohol and less craving for alcohol as rated by research
staff (measurement bias) in the first week. There were no significant effects in later weeks.
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Study # 5 (Gordon et ai, 1993)
This study was done to determine whether clomipramine hydrochlodde, a serotonin
uptake blocker with anti-obsessional properties is effective for obsessive-compulsive and
stereotyped motor behaviours in autistic disorder compared with placebo and nonadrenergic
tricyclic antidepressant agent, desipramine hydrochloride. In this study (n=30), male and
female autistic patients from a referral sample were enrolled (selection bias and confounding
since no randomisation and small sample size). After 2 weeks of single blind (measurement
bias) placebo washout phase (n=24), autistic subjects completed a IO-week of double-blind
crossover comparison ofclomipramine, placebo and desipramine in outpatient clinics.
The study results showed clomipramine was superior to both placebo and desipramine
on ratings of autistic sYmptoms (p>O.05), with no difference between desipramine and
placebo. Both clomipramine and desipramine were superior to placebo for amelioration of
hyperactivity. Measurement biases were minimised by use of key outcome measures such as
the Autistic Relevant Subscale of the Children's Psychiatric Rating Scale, the Modified
Comprehensive Psychopathological Rating Scale-Obsessive-Compulsive Disorder Subscale,
and,the Clinical Global Impressions Scale. The conclusion from this study was that biological
links between compulsion and stereotyped, repetitive behaviours in autistic disorder should be
explored.
Study # 6 (Vassar et ai, 1994)
The effect of fluoxetine, a selective inhibitor of 5-HT uptake was compared with a
placebo in a randomised double blind longitudinal trial in (n=12) healthy volunteers (selection
bias and confounding due to small sample size). Sleep polygraph recordings were performed
at home twice before and once after 6 days of medication. After 6 days, fluoxetine
significantly decreased the amount of rapid eye movement (REM) sleep and there was no
"
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significant increase in the amount ofawakenings during night as well as ,no significant change
with regard to total amount of slow wave sleep (SWS). Subjective assessment (measurement
bias) revealed tendencies of improved sleep and well being in the fluoxetine group. This
study concluded that a comparatively small dose of fluoxetine (20mg I day) causes the same
type of changes in REM sleep which are characteristic ofmost antidepressive drugs.
Study # 7 (Fairweather et ai, 1995)
It is essential that antidepressants should be clinically effective and well tolerated as
. ..""
well as not cause sedation or impair psychomotor and cognitive function. Compounds which
induce these detrimental effects will increase the risk of drug related accidents in otherwise
ambulant patients. This study investigated the effects of a range of doses of litoxetine, a
serotonin. reuptake inhibitor, healthy young and middle aged, female volunteers (selection
bias and confounding). All healthy female volunteers (n=19), drug free (excluding oral
contraceptive), aged 18-35 and 40-65 years were admitted to a double-blind, randomised,
placebo controlled, 5-way crossover study where each subject acted as her own control.
Psychometric testing was carried out by test battery, which tested objective and subjective
tasks. Subjects' feeling of sleep and sedation was measured by the Leeds Sleep Evaluation
Questionnaire (LSEQ) (measurement bias). Pharmacokinetic profiles were determined from
blood sample analysis taken after the fmal dose on day 5.
In this study no subjective sedative effect were recorded (measurement bias). It is
important to obtain a subjective assessment of a patient's reaction as to how they feel. Results
from this study show that litoxetine did not appear to affect sleep significantly and
psychological effects of litoxetine were relatively small while drug effects were weak. This
result may be due to the small group size (confounding). Other evidence suggest that
litoxetine possess a similar profile to non sedative antidepressants or SSRIs like sertraline,
paroxetine, fluoxetine, and fluvoxamine and have no intrinsic sedative activity likely to
interfere with the performance of the activities of every day living for maintaining a maximal
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therapeutic response. These newer drugs which reduce depression without disrupting the
integrity of the patients cognitive processes, will have an important role to play in the
pharmacotherapy ofdepressive disorders.
Study # 8 (Norregaard et ai, 1995)
Generally antidepressants have shown an overall effect in the treatment of pain but
results are variable. The aim of this study was to examine the efficacy of antidepressant
dosages of the serotonin uptake inhibitoF, citalopram in fibromyalgia, a generalised pain
syndfome. In a double-blind placebo controlled study, (n=22) patients with fibromyalgia were
randomised to treatment with citalopram fOF 4 weeks with a dosage of 20mg / day while
(n=22) received a placebo. After 8 weeks of treatment no changes were observed in self-
"
assessment of symptoms (measurement bias); physicians' global assessment; tender points;
Becks depression score or volUntary muscle strength; and no difference were observed
between the groups. Patients were allowed to take concomitant medication like
acetaminophen, codeine or non-steroidal anti-inflammatory drugs (NSAID) which could
result in confounding. The very low placebo effect in this study might indicate that the
patients were not optimistic about the effect of the treatment especially when they were
informed that the test drug belonged to the group of antidepressants (measurement bias). Also
the long-standing symptoms were difficult to treat due to secondary physical, social and
psychological impairment (confounding). A better response may be obtained in patients with
shorter duration of symptoms.
Also from a population study in 1994, it was concluded that fibromyalgia does not
seem to have a distinct disease entity and the validity of American College of Rheumatology
classification criteria (ACR) was questionable (selection bias and confounding). Other studies
have also found the effect of a smaller pain modulating effect of noradrenaline reuptake
inhibitors and the presence of lower levels of different neurotransmitter metabolites
(confounding). In this study, citalopram showed no demonstrable effect on this group ofpain
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patients. The dosages used were in the lower/middle end. of the therapeutic range for
depression (measurement bias) and whether an increased dosage would increase success
should be examined. The strength of the study was sufficient to exclude an effect of
citalopram (95% confidence limit) which indicates the sample size was sufficiently large.
More placebo-controlled studies are needed in treatment of different pain syndromes with
different selective serotonin re-uptake inhibitors.
2.6.2 Serotonin Studies with 5-HT Antagonists (Studies 9-13)
Study # 9 (Leigb et aI', 1991)
A number of drugs at'e used alone or in combination to treat emesis associated with
cancer chemotherapy. This action is related to the antagonism of 5-HT3 receptors at
peripheral and possibly central sites. Granisetron (BRL 436 94) is a novel compound which
has been shown to be effective in controlling nausea and vomiting associated with various
emetogenic cytostatic regimens,. It is a potent selective 5-HT3 receptor antagonist.
Antiemetics are often pIescribed with benzodiazepine for the concomitant treatment of
psychological distress, sleep disorders, and adjuvant therapy for refractory nausea and
vomiting. Granisetron may be concomitantly used with lorazepam, a benzodiazepine, a
compound, which is known to affect central receptors. The impact of these compounds, alone
and in combination on psychometric performance needs to be investigated. This study
assessed the effects of granisetron and lorazepam on the psychometric performance and for
any interaction between the two compounds. This was a randomised, single blind
(measurement bias}, crossover, placebo controlled study of (n=12) healthy male volUnteers
(selection bias).
The results of this study showed strong evidence that lorazepam impaired
psychometric performance and suggest that granisetron does not impair psychometric
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performance and that it can be co-administered with lorazepam without producing unwanted
synergistic effects. There was no evidence of any interaction effect between granisetron and
lorazepam from subjective data (measurement bias) while lorazepam produced a marked
impairment of objective psychometric performance producing statistically significant
impairment in most of the variables measured. There was also room for confounding due to
small sample size, which may have, been minimised by randomisation.
Study # 10 (Silverstone, 1992)
In normal volunteers, amphetamine in moderate doses «20mg) decreases appetite and
improves performance in psychological tests. Larger doses may also cause increase alertness,
restlessness, elation, irritability, and a paranoid state. This well recognised actions of
amphetamine on mood, arousal, appetite, and psychological performance in humans has led to
its widespread use as a research tool in psychopharmacology. Preclinical studies suggest that
5-HT3 antagonists modulate dopamine-mediated response in the limbic system and may
therefore have a therapeutic role in psychiatry. This study examined the effect of ondansetron,
a specific 5-HT3 antagonist on psychological and psychomotor changes induced by
amphetamine in human volUnteers. Healthy male volunteers (selection bias) (n=9) took part in
this double blind, placebo-controlled, balanced-crossover study. Each subject received one of
the 3 treatment in a randomised manner as placebo / placebo; placebo / amphetamine (l5mg);
and ondansetron (4mg) I amphetamine (15mg). Subjects were assessed for self-ratings
(selection bias) of hunger, mood, energy, alertness, restlessness, irritability and the
abnormality of their overall subjective state.
The study results showed that amphetamine did not cause any significant changes in
self-ratings of mood, energy, alertness, restlessness, or irritability but induced a significant
increase in self-ratings for overall subjective state and a significant decrease in self-ratings of
hunger. Amphetamine also caused an increase in systolic blood pressure and a decrease in the
mean time taken to complete the psychomotor tests. Pre-treatment with ondansetron
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attenuated the effect of amphetamine on hunger and subjective state but not on blood pressure
or psychomotor perfonnance tests.
These fmdings suggest that in humans, 5-HT3 receptoF antagonists may partially
modify the subjective effects of amphetamine which is inc<:>nsistent with results from animal
studies that 5-HT3 receptor antagonists might affect neurotransmission in mesolimbic brain
regions. TheFe were some limitations of the methodology in this study such as no
placebo/ondansetron group, hence unable to compare the effects of ondansetron alone with
ondansetron and amphetamine. Amphetamine dosage of 15mg did not produce significant
changes in self-ratings ofmood, restlessness, alertness, energy, and irritability, as is seen with
higher doses of amphetamines in nonnal volunteers. Also it was not possible to assess
whether or not these individual psychological changes were attenuated by ondansetron. The
/
serum levels of amphetamine and ondansetron were not measured and since ondansetron
decreases gut motility, it is not possible to exclude pharmacokinetic interactions as the
explanation of the effects of ondansetron on amphetamine-induced psychological changes.
These methodological limitations may contribute to confounding and measurement biases in
this study. Repeating the study using a higher dose of amphetamine would help clarify some
ofthese situations.
Study # 11 (Sharpely et ai, 1994)
Studies indicate that 5-HT2 receptors are involved in the regulation of slow wave
sleep (SWS). The aim of this study was to further study the effects of 5-HT2 receptor
antagonists, ritanserin and kitanserin, on the sleep ofhealthy volunteers in order to clarify the
role of 5-HT2A and 5-HT2C receptors in the regulation of SWS. This study was carried on
healthy volunteers (n=8) (selection bias) with no history of psychiatric disorders, sleep
disturbance or drug abuse and not on any drugs. It was a double blind balanced over study.
Sleep recordings were made in the subjects' own homes (measurement bias). Subjects were
instructed to abstain from alcohol but nonnal caffeine intake was allowed (confounding).
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The results showed that ritanserin 5mg, produced a larger increase in SWS (51.4%)
than either ketanserin 20mg (17.2%) or ketanserin 40mg (24.4%) and has a higher affmity for
5-HT2C receptor binding sites in the human brain. It was concluded from this study that SWS
in humans is primarily regulated by 5-HT2C receptors. This hypothesis will need to be tested
further with more selective 5-HT2A and 5-HT2C receptor ligands as these become available
for clinical studies. It is also possible that pharmcokinetic difference between ritanserin and
ketanserin may account for their differential effect on SWS and also likely that other 5-HT
receptor subtypes may play a role in the regulation ofthe sleep wake cycle (confounding)~
Study # 12 (von der Ohe, 1994)
Since the turn of the century, there has been an interest in the colonic response to the
ingestion of a meal. Serotonin is known to stimulate proximal colonic function. This study
examined the hypothesis that 5-HT3 mechanisms mediate the post prandial gastrocolonic
response in humans. Fasting and postprandial colonic tone and motility were studied in
(n=12) healthy volunteers (selection bias) and the effects of a selective 5-HT3 antagonist,
ondansetron was assessed in a double blind, randomised, placebo controlled fashion.
Results of this study shows that tonic colonic responses after ingestion of a high fat
meal are inhibited by the 5-HT3 antagonist, ondansetron. Results also suggest that
ondansetron inhibited a component of the gastrocolonic response similar to that seen with
atropine. Measurement bias may be due to the different internal diameter of the manometry
barostat, which was used for measurement in this study, which caused discrepancy in the
results. Serotonin type 3 receptors have not been described on gastrointestinal smooth
muscles but are located in cholinergic interneurons (confounding). Data from this study
suggest the hypothesis, that the effects of ondanestron may be exerted through cholinergic
neurons. Further studies are needed to evaluate whether ondansetron acts through cholinergic
neurons or separately.
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Study # 13 (Sellers et aI, 1994)
Medication that act on the serotonergic system have been found to be ofbenefit in the
treatment of alcohol-dependent individuals. In this study, efficacy of ondasetron, a 5-HT3
antagonist in a dose of O.25-2mg twice / day (measurement bias) was tested in the treatment
of (n=71) non severely alcohol dependent males (selection bias) in a randomised, placebo
controlled study. The results showed significant group differences in both treatment and
follow-up with lower ondasetron dose producing the greatest reduction from baseline
(p<O.02-0.001). Within this group, there were an almost 4-fold greatel' number of patients
showing a clinically meaningful decrease in drinking. Lower baseline drinking and higher
level of education (confounding) were significant and strong predictors of drinking reduction
"dUring treatment. Ondasetron was very well tolerated, hence further long-term studies with 5-
HT3 antagonists alone or in combination with other treatment components may offel' promise
for treatment ofalcoholism.
2.6.3 Serotonin Studies with 5-HT Agonists (Studies 14-16)
Study # 14 (Bousser et aI, 1993)
Sumatriptan, a specific 5-HT agonist is a novel acute treatment ofmigraine. Studies of
efficacy and safety profiles of sumatriptan have been done in several short-term studies.
These studies are essential, if sumatriptan is to be of any value in clinical practice since
migraine is a recurrent disorder, which may persist throughout adult life. This study evaluates
the efficacy of self-administered subcutaneous sumatriptan in the acute treatment of early
morning migraine attack (measurement bias/selection bias). This was a double-blind,
randomised, placebo controlled, cross over, multicenter study in 13 neurology centres in
France of (n=101) patients, 18-65 years old of both sexes. The primary end point was
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headache relief such as reduction in headache severity, which was graded as moderate, mild
to none (measurement bias) after treatment. The results of the study demonstrated that
sumatriptan was superior to placebo for headache relief. Sumatriptan was preferred by 74%
of patients vs 17% for placebo (confounding) and 9% had no preference. This study
concluded that subcutaneous sumatriptan auto-injection is an effective and well tolerated
acute treatment ofearly-mommg migraine attacks allowing earlier return to normal activity.
Study # 15 (Lou et ai, 1995)
Cerebellar ataxia due to cerebellar dysfunction which may be disabling are caused by
a vaxiety ofhereditary or acquired diseases. Patients who are severely affected with cerebellar
disease often need assistance with activities of daily living. As the causes of many hereditary
and degenerative cerebellar diseases are unknown, there is no effective treatment, but patients
can be treated symptomatically to alleviate their disabilities. One approach to symptomatic
treatment is to modifY the neurotransmitter systems in the cerebellum, one of which is the
serotonergic system. The serotonin receptors in the human cerebellum are of the 5-HT1A
subtype. A precursor of serotonin, the levorotatory form of hydroxytryptophan has been
shown to have some beneficial effect on patients with cerebellar ataxia but it may cause a
scleroderma like illness. In addition it may also stimulate all receptor subtypes (confounding)
which may result in conflicting effects and unnecessary side effects. Hence serotonergic
agents, which bind with specific serotonin receptors in the cerebellum may be more effective
with fewer side effects, in treating patients with cerebellar ataxia. One such agent, buspirone
hydrochloride, a 5-HT1A agonist that has been used widely as an anxiolytic with few side
effects has been evaluated in this study in treating patients with cerebellar ataxia.
This was an open label study (confounding / measurement bias) of (n=20) patients
receiving buspirone hydrochloride up to 60mg / day for 8 weeks in a research hospital.
Clinical, physiological, and psychological assessments were the main outcome measures in
this study. Some of the improvement in clinical and self-assessment ratings (measurement
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bias) in performance seen in these patients may be due to a learning effect or due to an
antianxiety and antidepression effect of buspirone (confounding) and a placebo effect could
not be ruled out (confounding). Also all tests and the sequence of the tests were not done at
the same time of the day for each individual (measurement bias / confounding). The motor
performance is highly dependent on diurnal variation and circumstantial factors such as stress
and embarrassment as well as coffee intake which was alsonot controlled, can affect motor
performance (measurement bias / confounding). The sample size was small and subject to
subject variability was large (selection bias / confounding) and quantitative tests ofonly upper
extFemity function was done (measurement bias) but buspirone may have a more beneficial
effect on lower extremity function. Although the results demonstrated that buspirone may be
effective in treating mild to moderate cerebellar ataxia, a double blind, placebo controlled
study ofthe efficacy ofbuspirone in cerebellar ataxia is warranted.
/
Study # 16 (Lefebvre et aI, 1995)
The stimulatory effect of 5-HT on aldosterone secretion is now documented in various
animal species as well as evidence that 5-HT and/or serotonergic agonists also stimulate
glomerulosa cell activity in man by stimulating aldosterone secretion. Oral administration of
5-HT precu.rsors' increases plasma alclosterone levels and serotonergic antagonists decrease
aldosteronemia in patients with idiopathic aldosteronism. There is now strong evidence that
the action of 5-HT on adrenocotical cells is mediated through a 5-HT4 receptor subtype.
Recent studies have also shown that in humans, the 5-HT4 receptor agonist, zacopride, is a
potent stimulator ofcorticosteroid secretion.
The aim of this study was to investigate the effect of concomitant administration of
the 5-HT4 receptor agonist, cisapride and angiotensin-II (Ang II) in aldosterone secretion in
normal human subjects. Healthy male volunteers (n=8) (selection bias) were studied in a
randomised, placebo controlled trial in a simple blind fashion (measurement bias). The results
from this study provided further evidence that the action of 5-HT on glomerulosa cells is
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mediated through activation of 5-HT4 receptors. The data also indicates that in humans, 5-HT
does not potentiate the stimulatory effect of Ang II on aldosterone secretion and the
stimulative effects of cisapFide and Ang II on aldosteme secretion were only addictive. In
conclusion, this study demonstrated that 5-HT 4 receptor agonist, cisapFide, induces a marked
stimulation ofplasma aldosterone in healthy human subjects.
2.6.4 Biochemical Studies ofSerotonergic System (Studies 17-20)
Study # 17 (Marazziti et aI, 1991)
Specific biological markers have yet to be discovered in subtypes of mood disorders,
hence the growing interest in indices of serotonin function in view of its involvement in the
pathophysiology of these disorders. The recent discovery of peripheral markers of central
neurotransmitter system has broadened the scope of biological research in psychiatry. Human
platelets resemble presynaptic serotonergic neurons and permit us to investigate the
involvement ofthe serotonin system in the pathophysiology ofmood disorders. Platelets show
an active uptake of serotonin and the related [3H] imipramine [3H- IMI], similar to cerebral
binding sites. Various studies have shown a reduction in the number of uptake sites in
platelets of depressed patients as compared with healthy controls. A similar decrease has also
been observed in the number of 3H-IMI sites, which has been proposed as a biological
marker for depression. Some authors found a significant reduction between patients and
controls while other researches found no difference at all or a slight increase. These
differences might have been due to methodological factors such as possible existence of
seasonal rhythms; difference in platelet storage; preparation and assay; effects of varying
protein concentrations; previous pharmacotherapy and different washout periods. These
factors might have influenced the binding parameters, although no drug effect on IMI binding
has been reported. Also these factors may result in confounding and measurement bias in
these studies.
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This study evaluated the 3H-IMI binding in a clinically well characterised group of
(n=30) bipolar patients compared to (n=30) healthy control. In a subsample of (n=20) patients
and (n=20) controls, S-HT uptake parameter were measured as well to minimise confounding.
The results from this study showed no difference in IMI binding parameters between bipolax
patients and healthy controls. Also' other fmdings suggest that bipolarity influences one of the
main components ofthe S-HT transporter complex in platelets. In this case control study
seasonal and circadian rhythms (confounding) were avoided, compared to previous studies.
However the fmdings from this study suggest that the simultaneous measurement of different
serotonergic parameters, with a reliable diagnosis of the patients, might provide a capable tool
to distinguish different mood disorder subtypes. This conclusion needs to be evaluated in
further studies with a larger sample of affective patients.
Study # 18 (Abbott et ai, 1992)
In humans, serotonin has been manipulated by controlling the availability of its
precursor, Tryptophan. Tryptophan has been tested by itself as an analgesic in humans with
various types of experimentally induced pain and clinical pain. The result of role of serotonin:
in pain has been inconsistent which may have resulted from methodological differences. This
study investigated whether serotonin might play a role in morphine analgesia in
experimentally induced pain, in humans and evaluated its influence on pain threshold and
tolerance to cold-pressor pain. This study was carried out as a double blind, placebo-
controlled clinical trial of the effect of L-Tryptophan depletion on the analgesic effect of
morphine (lOmg intramuscularly) in the cold pressor in (n=10) healthy male volunteers
(selection bias). In addition, since morphine and Tryptophan depletion can alter mood
(confounding), affective responses to these treatments were also examined. Although the
study group was a non-addict population (selection bias), nicotine and alcohol was allowed
(confounding). Most of selection and measurement biases were avoided in this study
compared to previous studies, such as the nature of the subjects studied and the nature of the
amino acid mixture used for Tryptophan depletion.
/
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The level of Tryptophan in the brain does not depend only on the. plasma level of
Tryptophan but also on the plasma level of the other larger neutral amino acids (LNAA)
which compete for Tryptophan uptake into brain (confounding). This study also had selection
bias due to majority of the volunteers being science and engineering students since
psychosocial studies suggest that scientists tend to be oriented towards objects rather than
emotions and place high value on competence and control (measurement bias). The subjects
may therefore have been biased to attend to physiological aspects of the drug experience
ratheF than the subjective effects, also since the experiment emphasised the medical use of
morphine and the measurement of the pain response. However, the results of the study
showed that the depletion of plasma Tryptophan eliminates the analgesic effect of morphine
in tolerance to cold-pressor pain in humans. This fmding also suggests that opiate analgesic in
cold-pressor pain is dependent on serotonin because the synthesis of serotonin is controlled in
/
part by plasma Tryptophan.
Study # 19 (Iny et aI:, 1994)
Over the past few years there has been a considerable interest in the neurobiological
relationship between depression and anxiety. These studies followed from clinical
observation and reports of patients that symptoms of depression and anxiety co-exist and the
effective treatment of anxiety disorders with antidepressant drugs. A link between depression
and stress is suggested from the association of stressful life events with the onset of
depression.
Alteration in neurotransmittef systems, including brain norepinephrine (NE)
(confounding) and serotonin have been associated with the pathophysiology of both
depression and anxiety and may serve as common biochemical pathways for their expression.
Little human data is available concerning the effects of stressful events on 5-HT
neurotransmission, whereas the studies that have been conducted have produced inconsistent
results despite the implication of serotonergic mechanism in the pathophysiology of
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psychiatric disorders. Investigators have reported both increase and ,decrease in the synthesis
or metabolism of 5-HT in response to stress.
This case control study did 2 experiments with (n=48) psychiatric patients with
different subgroups (confounding) of anxiety, depression, and stress disorders, and was aged
matched with (n=13) healthy volUnteers (selection bias). In both experiments there was some
selection bias of controls such as interviews for personal history and medical students as
subjects, and measurement bias such as self':'Fating scores for depression and anxiety. The
fmdings from this study suggest that there is a neurochemical link between depression,
anxiety, and stress, and that disturbances in the neurochemical fmding may be associated with
specific symptomatology, independent of psychiatric diagnosis. This study also suggest
further studies on the nature of the [3H]: imipFamine binding sites and their relation to
/
serotonergic neurotransmission are needed to establish the usefulness of platelet [3Hl
imipramine as a reliable marker of 5-HT function.
Study # 20 (Lambert et ai, 1991)
Congestive cardiac failure is a debilitating disease characterised by impaired cardiac
function. In this study the aim was to investigate the relation between the central nervous
system, monoamine neural systems and sympathetic nervous stimulation (confounding)
accompanying severe congestive heart failUFe. Norepinephrine, epinephrine, and serotonin-
releasing neurons (confounding) in the brain stem and forebrain have an important regulatory
influence over sympathetic nervous outflow to the cardiovascular system.
Patients (n=22) with severe congestive heart failure who were being assessed for
cardiac transplantation (selection bias) and (n=29) healthy male volunteers (selection bias)
participated in this study. The fmdings in this study suggest that forms of sympathetic
suppressant therapy in heart failUre, specifically the use of centrally acting inhibitors of
sympathetic nervous outflow, such as clonidine, might be beneficial.
2.6.5 Summary Table of Serotonin Studies (1-20)
Abbreviations used in the summary table:
Study Topic:
AD - antidepressant
OeD - obsessive compulsive disorder
P - placebo
D - drug
Study Type:
DB - double blind
--SB - single blind
DB - unblinded
PC - placebo controlled
R - randomised
OL - open label
COS - cross over study,
Participants:
F - female
M-male
V - volunteers
HMV - healthy male volunteers
HFV - healthy female volunteers
RV - healthy volunteers
Confounder / Selection Bias / Measurement Bias
SS - sample size
UN - different neurotransmitters
SR - selfreporting
OR - observer rating
SA - subjective assessment
OMA - other medication allowed
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(paroxetine vs AD amitryptyline) (sertraline)
Study #
First Author
Date
Place
Study Topic
1
Raptopoules
1989
UK.
SSRII AD
(paroxetine)
2
McClelland
1989
UK
SSRII AD
3
Chouinard
1992
Canada
SSRI IOCD I
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Study Type clinical trial clinical trial clinical trial
D13/PC SB IPS I COS DB/PC/R
/
Participant n=26 (HMV) n=8(HV) n=412(C)
n=8 (P) n=4 (F)
n=18 (D) n=4(M)
Confoundel'
Selection
Bias
Measurement
Bias
Comments
DN
HMV
OR
paroxetine
(less side effects)
small SS
HV
SB
PvsD
(no difference)
fixed dose
D>P
Study # 4 5 6
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Author Gorelick Gordon Vasar
Date 1992 1993 1994
Place USA USA Finland
Study Topic SSRI SSRI SSRr
Alcohol Intake Autistic disorder Sleep
(fluoxetine) (c1omipramine) (fluoxetine)
Study Type clinical trial clinical trial clinical trial
SB/PCX31f DB/PC DB/R
DB/PC X 2817 COS
Participant
Confounder
Selection
Bias
n=20 (M)
alcohol dependent
locked hospital
ward
male cases only
n=30 (M/F)
outpatient
clinic
referral sample
n=12 (RV)
small SS
RV
Measurement OR/SB SB (placebo wash SA
Bias alcohol intake out)
Comments PvsD D>P fluoxetine
(no difference) (clomipramine) =
D=P antidepressant
(desipramine)
67
Study # 7 8 9
Author Fairweather Norregaard Leigh
Date 1995 1995 1991
Place UK Denmark USA
Study Topic SSRII AD SSRII AD 5-HT antagonist
(litoxetine) Fibromyalgia antiemetic
Study Type clinical trial clinical trial clinical trial
DB IPS I DB/PC/R SB/PC/R
5-COS COS
Participant n=19 (HFV) n=150 (C) n=12(HMV)
n=21 (D)
n=22 (P)
Confounder FV OMA small SS
DN Trigger factors
Selection HFV criteria HMV
Bias validity
Measurement SA SRISA/UB SA/SB
Bias drug-AD
(-) attitude (C)
Comments litoxetine results variable granisetron
(no sedative activity) further studies (no effect on-
performance)
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Study # 10 11 12
Author Silverstone Sharpley vonderOhe
Date 1992 1994 1994
Place UK UK USA
Study Topic 5-HT antagonist 5-HT antagonist 5-HT antagonist
psychiatry SWS GIT
(ondansetron I (ritanserin I (ondansetron I
amphetamine) ketanserin) placebo)
Study Type clinical trial clinical trial clinical trial
DB/PCI DB/PC DB/PC/R
COS "
Participant n=9 (RV) n=8 (RV) n=12 (RV)
n=5 (F)
m=3 (M)
Confounder small dose (D) (+) caffeine (+) variables
(+) variables DN
Selection HMV HV RV
Bias
Measurement SR equipment
Bias no DIP group
Comments further studies further studies further studies
with drugs more selective 5-HT ofvariables
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Study # 13 14 15
Author Sellers Bousser Lou
Date 1994 1993 1995
Place Canada France USA
Study Topic 5-HT antagonist 5-HT agonist 5-HT agonist
alcohol abuse mlgrame cerebellar ataxia
(ondansetron) (sumatriptan) (busiprone)
Study Type clinical trial clinical trial clinical trial
PC/R DB/PC/R OL
COS
/ Participant n=71 (M) n=101(C} n=20 (C)
alcohol dependent n=l1 (M)
n=9 (F)
Confounder education (+) variables (+) caffeine
male cases only (+) variables
dependency level
Selection male cases early morning
Bias dependency level attacks only
Measurement headache relief SA/UB
Bias grading
Comments further long D>P recommend
term studies double-blind
studies
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Study # 16 17 18
Author Lefebvre Marazziti Abbott
Date 1995 1991 1992
Place France Italy Canada
Study Topic 5-HT agonist Biochemical Biochemical
aldosterone platelet / mood tryptophan
(cisapride) (3H-IMI) morphine
Study Type clinical trial case control clinical triaL
Participant n=8 (HMV) n=30 (cases) n=60(HMV}
n=30 (control)
Confounder variables variables nicotine / alcohol
allowed/DN
Selection HMV non addicts /
Bias science students
Measurement single dose
Bias
Comments significant significant significant
fmdings fmdings fmdings
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Study # 19 20
Author Iny Lambert
Date 1994 1995
Place Canada Australia
Study Topic Biochemical Biochemical
platelet / depression heart failure
anxiety / stress neurotransmitters
[3H] Imipramine / (c1onidine)
[3H] Paroxetine
Study Type case control case control
Participant n=61 (M/F) n=51(HMV)
n=48 (cases) n=22 (cases)
n=13 (control) n=29 (control)
Confounder variables variables
Selection medical students cardiac transplant
Bias patients
Measurement SR / interviews
Bias
Comments recommend significant
further studies fmdings
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2.6.6 Discussion and Conclusion
Serotonin has become a major player on the neurotransmitter "stage" since its
discovery in 1948 in Clevland. Multiple receptor subtypes for 5-HT have been identified and
classified leading to the emergence of a vast pharmacology of 5-HT and the development of
iInportant ligands that mimic or block its action selectively. Also drugs that release 5-HT and
others that prevent its uptake, have been developed. In particular, 5-HT has been shown to
exert marked effects on the CVS (study # 20), eNS (study #1,2,3,5,7,11,15,17,18&19), GIT
(study # 9,10,12) as demonstrated in these studies. There has been a world-wide 5-HT related
research, due to its applicability in anxiety (study # 19), psychosis, hypertension, migraine
(study #14), obesity, nausea, depression (study # 1,2,7,17&19) and e10sely related disorders
such as aggression, panic disorder and QeD (study # 3&5) (Launay et aI, 1994).
/
The high content of 5-HT in human platelet has also stimulated much research and
some investigators consider platelet as a convenient model for serotonergic neurons, as it
might be useful for the prediction of the CNS activity of certain drugs as demonstrated in
study # 17&19. There is also considerable evidence in favour of 5-HT involvement in
migraine (study # 14) and other essential headaches; temperature regulation (study #18); food
intake (study # 10); neuroendocrine control (study # 16); extrapyramidal activity (study # 15);
and in more complex functions such as sleep (study # 6,11); mood (study # 17); perception
including pain (study # 8 &18); and sexual behaviour (Sicuteri et aI, 1976).
Interesting studies have also been carried out in many other areas too such as
myoclonus, alcoholism (study # 4), sleep disorders, mental disorders, in a worthwhile efforts
to continue research in order to contribute to the information on the role of serotonin in
human health and disease. Studies discussed in this chapter covers specific areas and may
contribute to improvements of therapy in these areas. The potential usefulness of drugs
intended to normalise such functions can only be established in man by using clinical (human)
pharmacological investigations as demonstrated by clinical trials in studies discussed in this
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chapter (Sicuteri et aI, 1976). These clinical trial fmdings are not always conclusive due to
obvious reasons of small sample size, lack of randomisation, biases, and confounding factors
as well as 'cost, feasibility and ethical issues of these studies. Adequate study design include
rigid diagnostic criteria; training of raters followed by assessment of inter-rater reliability; a
sample size estimation based on desirable statistical power; anticipated placebo and treatment
response rate; randomisation of subjects; uniform evaluation of adverse drug effects,
compliance checking, dummy medication; and appropriate statistical analysis including
multivariate analysis to identify predictors of response. Also study design should target
research with maximum outcome for paediatric labelling too (Wilson et aI, 1995).
However since these studies are done in humans these defects in these studies cannot
be fully avoided but can only be further minimised in future studies as recommended in some
of these studies discussed in this paper. Both biochemical and pharmacological approaches
are being used to study the relationship between serotonergic mechanisms and centrally
mediated functions in man. Biochemical approach attempts to correlate levels of 5-HT and its
principle metabolite, 5-HIAA in various body tissues and fluids for specific clinical signs of
eNS dysfunction. The pharmacological approach depends on the clinical observations during
the administration of drugs having selective effects on synaptic activity mediated by 5-HT.
Both approaches are indirect and not without methodological difficulties but when used
together, often provide important clues relevant to the functions of the 5-HT system (Chase et
aI, 1992).
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CHAPTER 3
3. Rehabilitation
3.1 Migraine
3.1.1 Definition and Statistics
Migraine is an episodic headache disorder characterised by various combinations of
neurologic, gastrointestinal, and autonomic changes. This disorder affects more than 17%
women and 6% men. More than 1t million people in the United States (US) suffer from
moderate to severe migraine resulting in much suffering and millions of lost work days
annually. Economic estimates show that the cost ofmigraine in the US ranges from $1 billion
to $17 billion per year (Silberstein, 1994; Smith, 1992; The Lancet, 1992). According to the
Australian Bureau of Statistics in 1991, a health survey conducted in Australia in 1989-1990,
reported that headache was the most frequent symptom reported, affecting 12.2% of the
population in the two weeks preceding the interview (Lance, 1995).
It had been that reported that 540,000 Australians suffer from chronic migraine
according to Professor James Lance and a team of neurologist at the Prince of Wales
Hospital, NSW, who are world leaders in migraine research (The Sun Herald, 1993). About
nine percent Australian boys and girls had suffered a migraine, and after puberty, girls were
twice as likely to have migraines than boys. Many children do not receive appropriate
treatment and if migraine is treated properly in teenagers, there is a 60% percent chance, it
will regress. It is important for children to have a healthy diet and avoid preservatives. Good
posture and being happy at school are also important preventive measures (Smith, 1992).
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3.1.2 Theories and Studies
The aetiology ofmigraine is unknown but there are three theories :
(i) areas of the brain normally supplied by capillaries are deprived ofoxygenated blood which
can produce ischaemic pain;
Cii) pain results from the pressure put on tissues by the distended anastomotic (shunt) vessels
that link arteries and veins in the head; and
(iii) vessels in the meninges become distended and inflamed (Overmyer, 1990).
There are other theories in which emphasis is placed on various chemical substances
like acetylcholine, histamine and neurokinin, enzymatic defects or unusual vasoactive
material as possible mediators of the migraine syndrome with the recent addition of serotonin
to this list (Anthony et aI, 1975; Lance, 1966; Sicuteri et aI, 1976). According to some
epidemiological studies such as study #14 discussed in chapter 2, about 20% of adults have
recurrent headaches, particularly migraine and tension headache. The main directions of these
studies is the role of neurotransmitters, the vascular system of the head, the mechanism of
autonomic regulation, the role of neurogenic inflammation in the generation of pain, and the
psychoemotional factors. Headache research has expanded in the past decade, mostly directed
at raising the standards oftreatment (Prusinski, 1994).
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3.1.3 The Role ofNeurotransmitter - 5-HT
Experiments and clinical fmdings strongly support the hypothesis that neurogenic
inflammation represents a pathogenic mechanism for migraine or cluster headache attacks.
Sensitisation of trigeminal nerve fibres from any kind of irritation or traumatic injury, leads to
release of neurotransmitters from the peripheral nerve endings. It results in plasma protein
exudation and oedema, vasodilatation, release of bradykinin, histamine, and serotonin that
further sensitise sensory fibres. Further evidence show that neurogenic inflammation is
actually a real mechanism in migraine pathogenesis (Anthony et aI, 1971; Buzzi et aI, 1993;
Lance, 1966; Szczudlik, 1992).
It has been suggested that 5-HT is somehow involved in migraine pathogenesis. It has
also been reported over 30 years ago that plasma 5-HT decreases and 5-HIAA increases in
urine of migraine patients during attacks compared to healthy controls. Platelets in migraine
patients in a headache free period appear rich in vesicles containing mainly 5-HT. Platelets
have been widely studied for their structure and functions since the largest reservoir of 5-HT
in the periphery is provided by platelets (Overmyer, 1990; Silberstein, 1994).
The disruption of serotonin levels may induce the vascular changes believed to cause
migraine. In a more recent study investigators found that blood vessels in the head contain
only one type ofreceptor, almost exclusively 5-HT1-like receptor. This reveals the possibility
of the development of agents that could bind selectively to this receptor. An effective drug for
stopping acute attacks of migraine is sumatriptan (imigrain) introduced in Australia in 1992.
Sydney researchers found the level of serotonin drops before a migraine attack and thus
sumatriptan acts like serotonin and helps stop the attack. This works for up to 75% of
sufferers (Overmyer, 1990; The Sun Herald, 1993).
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3.1.4 Trigger Factors
Foods such as cheese, red wine, chocolate and oranges are classic migraine triggers.
Migraines are also caused when bones in the neck or back are out of alignment for which can
be treated by massage, chiropractic treatment, stress management and exercise (Anthony et aI,
1975). It is quite possible that the ingestion of certain foods, emotional stress or hormonal
changes act as "trigger" factors for migraine by altering gut motility or liver metabolism, and
thereby altering serotonin levels in the blood (Lance, 1966). However, the results of a trial of
90 adult patients at the Prince Alfred and Prince Henry Hospitals conducted in 1989 showed
no relationship between diet and migraine. The investigators believe that trigger food only
affect a few migraine sufferers and they should avoid these foods (The Sun Herald, 1993}.
3'.1.5 Diagnosis,
The epidemiologic data suggest that interventions to improve the diagnosis and
treatment of migraine should be explored (Silberstein, 1994). The International Headache
Society (IHS) published a universally accepted classification and diagnostic criteria (Tables 5
A&B) for a broad range of headache disorders in 1988 in order to improve the classification
of headache disorders, both in clinical practice and in research. The IHS criteria is based on
expert consensus and have a major impact on clinical trials and on epidemiological research
but they have not been widely used in clinical practice (prusinski, 1994; Silberstein, 1994).
The formal criteria published by the IHS in 1988 have done much in facilitating the diagnosis
ofmigraine. Migraine headaches are now classified into two major types:
(i) migraine without aura, formerly known as common migraine; and
(ii) migraine with aura, formerly known as classic migraine.
The IHS system provides criteria for a total of seven subtypes ofmigraine (Silberstein, 1994).
Table 5 A & B - Diagnostic criteria for migraine
Table A : Mi2l'aine without aura*
Diagnostic criteria
A. At least five attacks fulfilling criteria B-D
B. Headache lasting 4 to 72 hours (untreated or unsuccessfully treated)
· C. Headache has at least two ofthe following characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe intensity (inhibits or prohibits daily activities)
4. Aggravation by walking stairs or similar routine physical activity
· D. During headache, at least one ofthe following occurs:
1. Nausea and/or vomiting
2. Photophobia and phonophobia
E. At least one of the following is present:
1. History and physical and neurologic examinations do not suggest and
organic disorder. I /
2. History and/or physical and/or neurologic examinations do suggest such
disorder, but is ruled out by appropriate investigations
3. Such disorder is present, by migraine attacks do not occur for the first time
in close temporal relation to the disorder.
· * Previously used terms include common migraine and hemicrania simplex
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· Table B : Mi raine with aura
Diagnostic criteria
•A. At least two attacks fulfilling criterion B
· B. At least three ofthe following four characteristics are present:
1. One or more fully reversible aura symptoms occur, indicating brain
dysfunction
2. At least Qne aura symptom develops gradually over more than 4 minutes, or
two or more symptoms occur in succession
3. No single aura symptom lasts more than 60 minutes
4. Headache follows aura with a free interval of less than 60 minutes (it may
begin before simultaneously with the aura).
· C. History, physical examination, and~ where appropriate, diagnostic tests exclude
asecon cause.
Taken from: Silberstein et ai, Oct 1994: S8
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3.1.5.1 Description ofMigraine Attack
Migraine attack is divided into five phases:
(i) Prodrome phase: occurs in 60% of migraine sufferers and often lasts from hours to days
before the onset ofheadache. These phenomena include psychological symptoms (depression,
euphoria, irritability, restlessness, mental slowness, hyperactivity, fatigue, and drowsiness);
neurologic symptoms (photophobia, phonophobia, and hyperosmia); and constitutionaL
symptoms (stiff neck, cold feeling, slugginess<, increased thirst, increased urination, anorexia,
diarrhoea, constipation, fluid retention, food craving, and autonomic features);
/
(ii) The aura phase, which comes immediately before the headache, which consists of focal
neurological symptoms, experienced by almost 20% of migraine sufferers. The aura is
characterised by visual, sensory, or motor phenomena and may also involve language or
brain stem disturbance;
(iii) Headache phase: the typical migraine headache is unilateral and throbbing with severity
ranging from moderate to marked and is aggravated by physical activity or simple head
movement. Pain may be bilateral, one side and become generalised with gradual onset,
peaks and then subsides, lasting between 4-72 hours in adults and 2-48 hours in children.
Other features as described in prodrome phase may accompany pain;
(iv) Termination phase when pain waves; and
(v) Postdrome phase: following the headache, the patient may feel tired, washed out, irritable,
listless, impaired concentration, scalp tenderness, mood changes, feel refreshed or
euphoric after an attack while others may feel depression and malaise (Silberstein, 1994).
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3.1.6 Pharmacologic Treatment
Effective migraine treatment depends on accurate diagnosis, identification, and
avoidance of headache triggers and a treatment plan that reduces the impact of a migraine
attack. The treatment should target those symptoms most disturbing to the individual patient.
Behavioural interventions are also useful but drugs are the mainstays of treatment for most
patients. Treatment of migraine may be acute (abortive, symptomatic) OF preventive
(prophylactic) but some patients with frequent severe headache often require both approaches
(Tables 6 A&B). Symptomatic treatment attempts to stop progression or reverse a headache
once it has started. Preventive therapy is given on a daily basis even in the absence of a
headache, to reduce the frequency and severity of anticipated attacks (Lance, 1995;
Silberstein, 1994).
Medication used in acute headache treatment include analgesics, antiemetics,
anxiolytics, non- steroidal anti-inflammatory drugs (NSAIDs), ergots, steroids, major
tranquilliseFs, narcotics, and more recently, selective 5-HT (serotonin) agonists such as
sumantriptan as described in study # 14. Sumantriptan selectively binds to 5-HT1-like
receptors and mimics the effects of serotonin by constricting vessels and it has few side
effects because its selective. One or more of these medications can be used in headaches of
differing severities. Preventive treatment includes a broad range ofmedications such as beta-
blockers, calcium channel blockers, antidepressants, serotonin antagonists, and
anticonvulsants. Many of these agents may interact with serotonergic neural systems by
binding to 5-HT2 or 5-HT2C receptor sites "down regulating" the 5-HT2 receptor or
modulating the discharge of serotonergic neurons (Lance, 1995; Overmyer, 1990; Silberstein,
1994).
---~---~~---------------------------------------..,
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Table 6 A& B - Acute and Pronhvlactic Mi2raine Therapy
Table A - Acute migraine therapy
Metoclopromide (Maxolon)
Sumatriptan (Imigran)
Ergotamine (Cafegot, Ergodryl, Migral)
Dihydroergotamine (Dihydergot Injection)
NSAIDs
Other analgesics
Table B - Prophylactic migraine therapy
· First line drugs
· Thin and wheezy
· Pizotifen (Sandomigran)
Cypropheptadine (Periactin Tablets)
· Plump and tense
Betablockers
Depressed and sleepless
Tricyclic antidepressants
Second-line drugs
· SeveJ!e headaches
Methysergide (Deseril)
· Prolonged aura
· Flunarizine (Sibelium)
Associated tension headache
· Sodium valproate (Epilim)
· NSAID
· Nocturnal attacks
Ergotamine (Cafergot, Ergodryl, Migral)
· Third line of defence
· Phenelzine (Nardil)
/
In desperation
Hospital admission for intravenous lignocaine and intramuscular
dihydroergotamine suspend other medications
Taken from: Lance, April 1995: 26-27
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The flow chart (Table 7) and practice points (Table 8) represents a simplistic approach
to a complex problem and helps to summarise the various steps in management of migraine
(Lance, 1995). The fact that so many medications are employed in the management ofchronic
headaches indicates that none is completely effective. Treatment is becoming more specific
with advances in knowledge of the pathophysiology of headache, but successful treatment
does demand the time and thought of the ph.ysician as well as the ongoing communication
with the patient (Lance, 1995; Silberstein, 1994).
/
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Table 7 - Treatment of Migraine: Flow Chart
Treatment of migraine
Patient with ICurring migraine
Avoidance oftrigger factors
Counselling
Relaxation therapy
Exercise programme
Treatment ofassociated conditions
1 1
Two per less attacks per month Three or more attacks per month
1
Acute therapy (see table 6A)
~
Constant frequenr ofattacks
Prophylactic therapy
cseetabler
Ifno improvement
~
InClaSing frequency ofattacks
Check for: Attack less
* trap situations than daily
* depression ----i
*oral contraceptives .,
*hypertension ,
* ergotamine or Attacks becoming
analgesic abuse daily
Consider:
*use ofamitriptylline (Tryptanol) or a MAO inhibitor
*psychiatric help
*withdrawal ofall medication except antidepressants
and hospitalisation for a lignocaine drip
Taken from: Lance, April 1995: 26-27
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Table 8 - Treatment of Migraine: Practice Points
Practice points
• The object of treatment for chronic headaches is to adjust the patient's
lifestyle to minimise the frequency and severity of attacks, provide
medication to abort or shorten each headache as it arises and, if necessary,
to suppress the tendency for headaches to recur.
• Acute migraine can often be settled by the administration of sumatriptan
(Imigran) or ergotamine tartrate' (Cafergot, Ergodryl, Migral).
• Sumatriptan should be taken only once the headache has started since it is
not effective if taken during an aura; on the other hand, ergotamine
preparations are best taken at the begining of an aura or at the fIrst sign of
a headache.
• If migraine recurs twice or more per month, and response to medication is
incomplete, daily medication is warranted (see table 6B)
• When both patient and doctor are driven to desperation by continuing
headache unresponsive to medication, admission to hospital for an
intravenous lignocaine drip should be considered
• Every effort should be made to help the patient with frequent tension-type
headache to overcome the causative factors because pharmacotherapy is
not always effective.
• If cluster headaches are recurring at a predictable time of the day or night,
oral ergotamine or an intramuscular injection og dihydroergotamine can be
given one hour beforehand to abort the attack. The inhalation of 100%
oxygen through a resuscitation mask (i.e. one without side vents) should
always be tried, as the response can be dramatic.
Taken from: Lance, April 1995: 30
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3.2 Alcoholism
3.2.1 Introduction
Alcohol abuse and dependence (alcoholism) remain a major public health problem in
the United States and the single most prevalent major psychiatric disorder among adults.
Psychosocial treatment of alcoholism can be highly effective, especially in patients with
stable and supportive social environments and good premorbid functioning. A general trend
in psychosocial treatment outcome studies is that about one-third of patients recover and
another one-third show improvement, while the remaining one-third do not respond well to
existing psychosocial treatment, hence a clinical need for effective pharmacological
treatment. Also with pharmacological treatment, there is a possibility that effective
medications might hasten the onset ofrecovery, and shorten the duration ofneeded treatment,
as well as lowering the economic cost of treatment and the burden of illness on the patient
and society (Gorelick, 1993).
The non-pharmacological treatment of alco~olism is just as important as
pharmacological treatment since most clinician would agree that medication alone is rarely, if
ever, a successful long term treatment approach, and that medication is best integrated into a
comprehensive psychosocial treatment program (Gorelick, 1993). However there are several
problems with the alcohol-sensitising drugs, such as disulfiram, currently used to decrease
alcohol consumption which was introduced in 1948. It became an established treatment
before it was rigorously tested for efficacy and safety and found to be associated with toxicity
and several contraindications for use. Their efficacy is unproven and many studies done had
serious methodological problems. All claims of efficacy and safety of any treatment must be
supported by several well-conducted, double blind, randomised controlled trials performed in
a sufficient number of patients. New therapies are needed because alcohol related problems
affect almost 20% of the adult population. A new strategy was developed that involves
attenuation ofalcohol intake via serotonin uptake inhibitors (Naranjo et aI, 1989).
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3.2.2 Theories and Studies
It has been postulated that acute and chronic alcohol administration is on a "biological
:
continuum" and that alcohol produces it immediate pharmacological effect by altering the
activity of biological systems. From fIrst administration and through chronic exposure, the
systems gradually adapt to alcohol. Thus, more alcohol is required to produce an equivalent
effect (tolerance), and the continued presence of alcohol is required to maintain the status quo
of the biological system (physical dependence). If alcohol is removed, a disruption of the
balance occurs (withdrawal). Hence the following conclusions:
(i) development of withdrawal behaviour in an organism after cessation of exposure to
alcohol indicates the presence ofphysical dependence;
(ii) the CNS mechanisms oftolerance, dependence, and withdrawal overlap;
(iii) altered neurotransmitter activity and hormone levels seen during alcohol withdrawal are
the result ofadaptations performed by the CNS during chronic alcohol exposure; and
(iv) the time required for hormone and neurotransmitter systems to return to pre-alcohol
baseline reflects the time required for the brain to "heal" from the insult ofalcohol.
Advances in biotechnology m measurements of CNS-regulated hormones
(neuroendocrinology) and neurotransmitters (neuropharmacology) now allow for
improvement and more highly refmed studies of alcohol withdrawal to be conducted (Wilkins
et aI, 1986).
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3.2.3 Serotonergic System
Serotonergic system has long been thought to play a role at several steps in the cycle
of alcohol abuse. Initial motivation may be triggered by anxiety, which may exhibit a
serotonergic component (5-HTIA receptor). Alcohol can potentiate the opening of 5-HT3
receptor ion channels, and agents which elevate the serotonergic tone, including serotonergic
agonists, uptake inhibitors and releasers, which have shown promise in assisting with
recovery from alcoholism (Hartig, 1994). The hypothesis that serotonin plays a role in the
modulation of alcohol intake and or considerable biochemistry, behavioural, and
pharmacological evidence from animal and human studies have verified alcohol dependence.
Central and peripheral levels of serotonin and its metabolite, 5-HIAA are modified by
alcoholisation. Also the use of pharmacological drugs modifying specifically serotonin
transmission decreases ethanol intake. Studies also suggest that a dysfunctioning of serotonin
uptake system could be implicated in the individual risk of alcohol dependence even if other
systems are involved in the regulation of alcohol behaviour (Doust et aI, 1992).
3.2.4 Pharmacological Treatment
3.2.4.1 Introduction
The development of new pharmacological treatment of alcoholism depend on our
understanding of the biological mechanisms regulating ethanol intake. Recent studies suggest
that a complex interaction of neurobiological and systemic factors regulate ethanol intake.
Several neurotransmitters (MAO, monoamines, and neuropeptides), hormones, and other
factors are possibly involved in mediating the initiation, maintenance, and cessation of
alcohol drinking. Due to the lack ofmedication specifically developed for modulating ethanol
intake, drugs that are being used for alcoholism studies are still under clinical investigation
for other indications such as antidepressants (Naranjo et aI, 1989).
/
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Manipulation of brain serotonin activity has become a major focus of interest in the
development ofnew pharmacological treatment ofalcoholism based on researches suggesting
that brain serotonin is inversely related to alcohol consumption. This evidence is based on
studies which showed differences in brain serotonin levels among rodents with different
spontaneous alcohol consumption and effects of drug induced changes in brain serotonin
activity on spontaneous alcohol consumption. The major class of drug used to change brain
serotonin activity in both animal and human studies are the serotonin uptake blockt:rs such as
citalopram, fluoxetine, and zimelidine as discussed in study # 4 in chapter 2. These agents
block the presynaptic uptake of serotonin which is the chief mechanism for inactivating the
neurotransmitter action of serotonin (Gorelick, 1989; Gorelick, 1993; Naranjo et aI, 1989).
Studies (Table 9) described by Gorelick (1989), looks at the effect of serotonin uptake
blockers on alcohol consumption in human subjects, each using a double blind and placebo-
controlled design.
A likely explanation for the effect of serotonin uptake blockers is a general inhibition
appetitive behaviour. Serotonin uptake blockers tend to decrease food intake especially
carbohydrates and since alcohol itself is a carbohydrate, it reduces body weight presumably
due to the role of serotonin in mediating food satiety. Another Likely explanation for the
effect of serotonin uptake blocker is the induction of a conditioned taste aversion to alcohol
since serotonin is a powerful mediator of taste aversions to a variety of fluids including
alcohol (Gorelick, 1989). There is also a reported decrease in interest or desire to drink in the
problem drinkers. Also the effects of serotonin uptake blockers on ethanol intake are not a
result of the antidepressant action of the drugs since subjects were not clinically depressed
and depression scores remain unchanged in these studies. All these fmdings support a general
role of serotonin in consummatory behaviours including addictive behaviours (Naranjo et aI,
1989).
Table 9 - f IUl11an Studies of Serotonin Uptake Blockers and Alcohol Consumption
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Taken from :Gorelick, (1989) 7 : 272
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3.2.4.2 Intoxication
The acute effects ofalcohol are those ofa sedative-hypnotic or CNS depressant. There
is now substantial evidence that alcohol effects are mediated by actions at a specific neuronal
membrane site, the y-aminobutyric acid (GABA)-benzodiazepine receptor complex. GABA is
considered an inhibitory neurotransmitter and GABA neurotransmission mediates typical
sedative-hypnotic medication effects such as raised seizure threshold, muscle relaxation, and
sedation. Benzodiazepines appear to exert their sedative-hypnotic effects by enhancing the
action of GABA on the chloride ion channel. Similarly alcohol exerts its effects by directly or
indirectly enhancing the action of GABA on the cWoride ion channel by influencing the
benzodiazepine receptor. These evidence stimulated research into the development of alcohol
antagonist, analogous to opiate antagonists such as naloxone and naltrexone as suggested by
/
the hypothesis that acute alcohol effects were mediated by endogenous opiate (endorphin) and
that opiate receptor antagonists might block or reverse alcohol intoxication. This hypothesis
has not been consistently established in animal or human studies. Also a variety of
compounds have been developed which interact with the benzodiazepine receptor in various
ways but human studies have been hindered by the potentially uncomfortable and dangerous
effects ofthese compounds themselves (Gorelick, 1993).
Another approach to the pharmacological treatment of alcohol intoxication has been
the development of amethystic or "sobering-up" medications, which would functionally
overcome the CNS depressant effects of alcohol. But no such medication has yet been shown
to be effective and safe in human studies since some of them pose the risk of producing
mixed CNS depressant / stimulant intoxications. CNS stimulants such as caffeine and
amphetamines are sometimes used for this purpose, often without medical supervision
(Gorelick; 1993).
A third approach to the treatment of alcohol intoxication is to enhance the clearance of
alcohol from the body. High doses of fructose will increase alcohol metabolism, but this is not
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a practical treatment because.of the gastrointestinal and other side effects produced by such
high doses of fructose. Several £imal studies have found that the mu opiate receptor
antagonists, naloxone and naltrexone increase the metabolism of alcohol but this fmdings has
not been explored in humans (Gorelick, 1993).
3.2.4.3 Withdrawal
Individuals undergoing withdraw~l from alcohol often experience anxiety, tremor, and
marked dysphoria (restlessness), and occasionally experience seizures and delirium tremens
(a form of alcohol psychosis), manifested by changes in eNS neurochemicals and eNS
regulated hormones (Wilkins et aI, 1986). Rational pharmacological treatment of the acute
alcohol withdrawal syndrome can now be guided by a greater understanding of its
/
neuropharmacological mechanisms. The most important mechanism is believed to be a
sudden relative deficiency in GABA neurotransmitter activity produced by the abrupt
discontinuation of alcohol intake, which previously had been substituting for, and suppressing
by negative feedback, endogenous GABA activity (Gorelick, 1993).
A second mechanism which contributes to acute manifestations of tachycardia,
hypertension, tremor, diaphoresis (profuse perspiration), and anxiety is due to increased
sympathetic autonomic activity mediated by increased neuronal firing in the locus coeruleus
area of the brain stem. The preferred approach to those patients who require pharmacological
treatment of their withdrawal symptoms is the administration of a cross-tolerant sedative-
hypnotic medication, many of which appear to increase GABA activity by acting at the
GABA-benzodiazepine receptor complex. The goal of pharmacological treatment is to
initially suppress the manifestations of acute withdrawal with sufficient doses of medication
and then progressively taper the medication doses to produce a controlled, milder withdrawal
syndrome which is safer and more comfortable for the patient (Gorelick, 1993).
A second approach to pharmacological treatment of alcohol withdrawal relies on
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reducing the increased sympathetic activity, either by administration of aB-adrenergic
antagonist such as atenolol, propanolol or by reducing neuronal ftring in the locus coeruleus
with administration of an x2-adrenergic agonist such as clonidine. These medications have
been found effective in controlled clinical trials in reducing alcohol withdrawal
manifestations but because they are not cross-tolerant sedative-hypnotics, these medications
are usually not used alone, but in conjunction with a sedative-hypnotic medication in order to
increase patient comfort and reduce the required dosage of sedative-hypnotic. Also despite the
proven clinical effectiveness of benzodiazepines when used appropriately, they have two
disadvantages:
(i) the potential for abuse, including physical dependence; and
/
(ii) the possible side effects such as sedation and cognitive impairment which could interfere
with the psychosocial component ofthe treatment.
Thus research continues on the development of even better pharmacological treatment for
alcohol withdrawal (Gorelick, 1993).
3.2.4.4 Kindling
Kindling is a new approach derived from the hypothesis that acute alcohol withdrawal
induces kindling. Kindling is the neurophysiological process by which intermittent, low
intensity brain stimulation, either electrical or chemical, results in an enhanced response to
later low-intensity stimulation. Alcohol or alcohol withdrawal-induced kindling has never
been directly demonstrated in humans but there is circumstantial evidence from retrospective
clinical studies, for example the positive association between seizure prevalence and past
history of severe acute withdrawal episodes. The kindling hypothesis has led to the use of
anticonvulsant medication such as carbamazepine, which blocks kindling in animal models, in
the treatment of alcohol withdrawal. Several controlled trials have found carbamazepine as
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effective as benzodia2;epines or barbiturates in relieving withdrawal symptoms and preventing
seizures during acute alcohol withdrawal. Also several other types of medication are under
study as possible treatments for alcohol withdrawal, such as other anticonvulsants (valproic
acid), nitrous oxide (laughing gas), and calcium channel blockers (Gorelick, 1993).
3'.2.5 Rehabilitation (Maintenance of Abstinence)
3.2.5.1 General Principles
There are at least four conceptual approaches to the pharmacological treatment of
alcohol dependence or to the use of medication to promote the long-term maintenance of
abstinence:
/
(i) suppression of withdrawal symptoms and alcohol craving by substitution with a cross-
tolerant sedative-hypnotic medication (analogous to methadone maintenance treatment of
opiate-dependent patients};
(ii) blockade of alcohol effects by administration of an antagonist at the neuronal receptor on
which alcohol acts (presumably the GABA-benzodiazepine receptor complex) so that
patients get no reinforcement from drinking (analogous to naltrexone treatment for opiate
dependence);
(iii) reduction in alcohol craving by manipulating the neurotransmitter system or systems that
mediate craving and reinforcement; and
(iv) alteration of alcohol metabolism to create an aversion contingency for drinking or
negative reinforcement for abstinence (Gorelick, 1993).
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In the US, only the fourth approach, by use of disulftram, is part of standard clinical
practice. The ftrst approach could be implemented with currently available medications, but
has never become part of standard clinical practice. The second and third approaches are
currently being researched, the second at animal level because of the current absence of
selective compounds with demonstrated safety in humans, and the third at clinical level as
well (Gorelick, 1993).
3.2.5.2 Substitution Approach
The substitution or maintenance agonist approach to treat alcohol dependence could
be implemented with benzodiazepines, which are used as self medication for this purpose by
some alcoholic patients, which might be effective for some of these patients. However, the
benzodizepine maintenance approach has never been subject to a prospective, random
assignment, placebo-controlled clinical trial and has never been accepted as standard clinical
practice. This is partly because clinical experience suggested that many alcoholic patients
would abuse benzodiazepines. Another approach to substitution treatment might be
administration of direct GABA agonists, such as acamprostate, a synthetic structural analogue
of GABA. Several controlled clinical trials in Europe have found this approach to be superior
to placebo in maintaining abstinence from alcohol over six-month treatment peFiod (Gorelick,
1993).
3.2.5.3 Antagonist Approach
It might be possible to develop antagonist medication of the benzodizepine-GABA
receptor complex in mediating the effects of alcohol that would chronically block the
reinforcing effects of alcohol, resulting in extinction of alcohol-seeking and -taking
behaviour. Clinical research along these lines awaits the development of a selective, potent,
and safe alcohol antagonist (Gorelick, 1993).
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3.2.5.4 Craving Reduction Approach
Expanded knowledge of the neurobiology of addiction suggest three-brain
neurotransmitter systems as likely targets for manipulation to reduce alcohol craving and
reinforcements, thereby reducing drinking behavioU1i:
(i) serotonin, because of its apparent role as a modulator of addictive and appetitive
behaviours;
(H) dopamine because of its role in the mesolimbic reward circuit; and
(Hi) endogenous opiates (endorphins) because of their apparent role ill mediating
/
reinforcement (Gorelick, 1993).
For therapeutic purposes, most research has focused on increasing brain serotonin
activity. There are three pharmacological manipulations, which will increase brain serotonin
activity and decrease alcohol intake:
(i) amino acid precursors Tryptophan or 5-hydroxytryptophan, which increase brain serotonin
synthesis;
(H) serotonin receptor agonists; or
(Hi) inhibitors of the presynaptic serotonin uptake pump, which result in more released
serotonin remaining in the synapse to act on serotonin receptors (Gorelick, 1993).
A series of studies done at the Addiction Research Foundation in Toronto found that
fluoxetine, sertraline, and several other serotonin uptake blockers given in antidepressant
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dosage for 2-4 weeks produced a 9-14% decrease in alcohol intake and doubling of the
number of abstinent days. The research subjects were "early problem drinkers" or "heavy
social drinkers" recruited by advertisement from the community (not diagnosed alcohol-
dependent patients seeking treatment for alcoholism). Similar fmdings were observed with
one study with fluoxetine in hospitalised male alcohol-dependent patients seeking treatment.
In both studies, no other psychosocial interventions to reduce alcohol intake were given.
These fmdings are pFomising but need to be confIrmed by long-term, realistic, controlled
clinical trials in abstinence-motivated alcohol-dependent patients enrolled in an integrated
psychosocial program before the actual usefufuess of serotonin uptake inhibitors can be
determined in the treatment ofalcoholism (Gorelick, 1993).
Two other approaches to manipulating brain serotonin activity that are currently
undergoing clinical study are direct stimulation of serotonin receptors and administration of
serotonin receptor antagonists. Several small-scale, open-label studies have found that the 5-
HTIA receptoF agonist, buspirone (anxiolytic), the 5-HT2 receptor antagonist, ritanserin (not
marketed in the US), and the 5-HT3 receptor antagonist, ondansetron (antiemetic), all reduce
alcohol intake and craving. The neuropharmacological mechanisms that account for the same
behavioural effects produced by both 5-HTIA receptor agonist and 5-HT2 or 5-HT3 receptor
antagonist, remain uncleaF. These receptors may involve different neuropharmacological
actions mediated by different receptor subtypes, for example, 5-HT3 receptors appear to
facilitate activity in the mesolimbic dopamine system (Gorelick, 1993).
Dopamine is the neurotransmitter ofa mesolimbic neural circuit with cell bodies in the
ventral tegmental area and axons extending to the nucleus accumbens and into the cortex.
This is referred to as the dopamine reward circuit because its stimulation either electrically or
chemically reinforces behaviour in animals, and destruction of the circuit abolishes reinforced
behaviour. Alcohol and other self-administered drugs acutely increase dopamine activity in
this neural circuit. This has focused attention on manipulation of brain dopamine activity as a
pharmacological approach to treatment of alcoholism. Several (but not all) controlled clinical
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trials have found the dopamine (02) agonist medication, bromocriptine is superior to placebo
in maintaining abstinence in alcohol dependent patients (Gorelick, 1993). The role of opiate
receptors in the nucleus accumbens in the reinforcing effects of alcohol has initiated interest
in the manipulation of brain opiate activity as a pharmacological treatment for alcoholism.
Two recent double-blind controlled clinical trials found that naltrexone (50 mg daily) was
better than placebo in reducing alcohol intake and increasing abstinent days among alcoholic
patients enrolled in out-patient treatment (Gorelick, 1993).
3.2.5.5 Aversive Contingency Approach
Disulf1ram is the only medication approved and the most widely used medication for
/
treatment of alcoholism in the US. Disulflram acts by inhibiting the enzyme, acetaldehyde
dehydrogenase, the second step in metabolism of alcohol. Inhibition of this enzyme when
alcohol is consumed results in alcohol metabolised to acetaldehyde and not further, resulting
in accumulation of acetaldehyde. It is the accumulation of acetaldehyde, which mediates the
toxic alcohol-disulfIram reaction. The mechanism of disulfIram's therapeutic effect is
considered to be creation of an aversive contingency for alcohol intake, which is, a person
who drinks while taking disulfIram experience punishment (the alcohol-disulfIram reaction)
rather than reinforcement, resulting in reduced alcohol intake. Clinical experience indicates
that disulfiram can be helpful in promoting abstinence from alcohol especially in many well
motivated patients with stable living situations (Gorelick, 1993).
3.2.5.6 Other Medications
Antidepressants like lithium and tricyclics have been used for the treatment of
alcoholism because of the frequent occurrence of affective (usually depressive) symptoms
among alcoholic patients entering treatment. But very few systematic clinical studies or
controlled clinical trials have been done to confrrm any clinical experience with these groups
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of drugs. Also manipulation of several peptide hormone systems are being studied in animals
in reducing alcohol intake or craving (Gorelick, 1993).
3.2.6 Conclusion
No new treatment for alcoholism has yet become standard clinical practice. However
over the next decade, benzodiazepine receptor antagonists and inverse agonists should
improve treatment of acute alcohol intoxication; adrenergic agents and anticonvulsants should
improve treatment of acute alcohol withdrawal; and serotonin uptake blockers and the mu
opiate receptor antagonists should improve long- term treatment of alcohol dependence. Also
neurobiological research over the past decade has greatly increased our knowledge of
alcohol's interaction with the nervous system with promising significant improvement in
/
pharmacological treatment for all phases of alcoholism. However there is a need for future
clinical research to reduce the current lack of knowledge or pharmacological treatment of
alcoholism in special populations such as women, the elderly, and those with concurrent
psychiatric diagnosis (Gorelick, 1993).
3.3 Eating Disorders
3.3.1 Introduction
Mood changes and affective states are frequently associated with changes in feeding
behaviour of food intake being anorexia nervosa and bulimia nervosa (Garattini et aI, 1989).
Appetite has been included into the field of 5-HT studies because ofthe weight gain produced
by certain drugs interacting with 5-HT as well as a number of appetite suppressants
modifying 5-HT metabolism. However the role of 5-HT in controlling food intake is not
understood and the more complex problem of appetite even less so (Sicuteri et aI, 1976).
However there is a good experimental evidence that one of the principal neurotransmitters
involved in the control of food intake and food selection is 5-HT (Leonard, 1994).
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These neurotransmitters participate in the control of a number ofbodily functions and
behaviours such as hunger, food choice, alertness, sensitivity to environmental stimuli and
disease states (Wurtman, 1979). Serotonin is known to be involved in eating disorders
(DeVane et aI, 1996) and is thought to be an important neurotransmitter involved in
hypothalamic control of food intake and metabolic economy. Enhancement of serotonergic
function by inhibiting serotonin uptake, releasing serotonin, loading with serotonin
precursors, or by direct activation of serotonin receptors has been shown to decrease food
intake in laboratory animals (Fuller et aI, 1991}.
3.3.2 Theories and Studies
Human and animal studies indicate that diet can alter plasma and brain concentrations
of neurotransmitter precursors, with possible implications for the synthesis and release of
brain neurotransmitters such as serotonin. Serotonin synthesis is limited by the availability of
its precursor, tryptophan in the brain. Consuming Tryptophan or carbohydrate-rich, protein-
poor meal increases brain levels of Tryptophan and serotonin. Although the carbohydrate
meal itself lacks Tryptophan, the meal causes insulin secretion which in turn decreases
plasma levels of large neutral amino acids that would ordinarily compete with Tryptophan for
transport across the blood-brain barrier. At this time it seems quiet correct to believe that the
brain is not oblivious to what the body eats (Spring, 1984).
The concentration of precursors in the circulation and in neurons change rapidly after
food consumption depending on what is eaten. Carbohydrate consumption, by altering plasma
amino acid levels, accelerates brain serotonin synthesis enhancing the release ofserotonin that
tends to diminish the animals desire to consume carbohydrate. Hence dietary manipulation or
consumption of individual nutrients can be used as tools for the experimental analysis of
functions mediated by monoaminoergic or cholinergic neurons and as adjuncts in the
treatment of some diseases of the neurons (Wurtman, 1979). Also consequences of acute and
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chronic dietary practices for psychological functioning and per formance warrant further
investigation (Spring, 1984).
3.3.3 Serotonin and Appetite
Neurochemical research on relationships between Tryptophan, 5-HT, and feeding has
centred on how feeding affect brain Tryptophan concentration, synthesis, and availability of
5-HT. Pharmacologists have been focusing on the use of serotonergic drugs such as
fenfluramine and ponderax (acts by releasing 5-HT) to control appetite. Research in this area
had lead to questions as to whether effects of feeding on Tryptophan and 5-HT function are
involved in the normal control of appetite and in eating disorders such as anorexia nervosa
and bulimia nervosa (Curzon, 1990).
Feeding or food withdrawal can affect the supply of Tryptophan to the brain and in
some circumstances 5-HT synthesis. Serotonergic drugs like fenfluramine (recently taken of
the market due to its possible side effect of heart valve disease) which releases 5-HT to post
synaptic receptors suppresses appetite and Tryptophan have a similar effect. Also feeding is
reported to release hypothalamic 5-HT. Therefore 5-HT can have a role in the normal
termination offeeding and perhaps also in disorders ofappetite. The recognition ofvarious 5-
HT receptor subtypes has stimulated research in this area. Most of the studies were done in
rats and study results suggest the existence of a 5-HT dependent hypophagic mechanism
which is more active in food deprived female rats than in males. This could conceivably have
a role in the greater incidence ofeating disorders in women (Curzon, 1990).
Serotonin acts in the CNS to modulate feeding behaviour in an inhibitory manner.
Serotonin does not cross the blood-brain barrier but drugs that alter its pharmacology in the
brain can modulate serotonergic effects. Fluoxetine is a highly specific inhibitor of active
serotonin reuptake into presynaptic nerve endings in the brain. It has been found to be
effective and safe in the treatment of depression and has shown a dose dependent weight-loss
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effect. Fluoxetine has, also been investigated in a number of studies in obese patients
including diabetics. It causes a dose-dependent decrease in food intake in rats and mice. The
reduction of body weight in obese patients treated' with fluoxetine is thought to relate
primarily from decreased food intake, although food intake data have not yet been reported in
humans. It is possible that mechanisms in addition to decreased food intake are involved in
the anti-obesity effects of fluoxetine. HoweveF further studies are needed to explore
fluoxetine as an adjunct to a strict regime of diet and exercise with possibly incorporating
behaviour-modification techniques (Fuller et aI, 1991; Wise, 1992).
The class of serotonergic agents that affect food intake is expanding and the
mechanisms involved are gradually becoming clearer, although the precise site or sites of
action are still to be elucidated. The favourable clinical results achieved with serotonergic
/
anorectic agents will certainly increase their use for therapeutic purposes as well as tools for
investigating serotonergic activity in man. This in turn will allow better understanding of the
links between 5-HT, other chemical mediators and hormones to help clarify the role of 5-HT
in eliciting physiological and pathological element ofbehaviour (Garattini et aI, 1989).
3.3.4 Anorexia Nervosa
3.3.4.1 Introduction
An article published in 1694 described, as "nervous consumption" is suggestive of
what we refer to as anorexia nervosa today. During the 18th and 19th centuries there were
frequent references in the medical literature to the condition of "chlorosis", which was
confined to young women. This disease was also known as "greene-sickness" or the "virgin's
disease" and was characterised by a curious greenish discoloration of the skin, amenorrhea,
pallor, weakness, loathing of food, accompanied at times by emaciation and "bulimia
emetica". The first cases clearly conformed to the modem concept of anorexia nervosa and to
the current diagnostic criteria in DSM-IV (Table 10). These were girls who deliberately
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decided not to eat, and stubbornly persisted in this pursuit despite increasingly ill health and
dramatic emaciation (Hartman, 1995).
The core symptoms of anorexia nervosa are deliberate weight loss, disturbed body
image and amenorrhea. OtheF common physical fmdings include emaciation, bradycardia,
hypertension, pallor, acrocyanosis, ankle oedema, breast atrophy with scanty pubic hair, and
stunting of growth due to premature epiphyseal fusion, which may be evident in the early
pubertal onset of anorexia nervosa. However, many patients conceal their weight reduction
strategies such as self-induced vomiting, laxative, diet pill abuse, compulsive exercise and
often give false account of their eating habits. Hence anorexia nervosa should be considered
in the differential diagnosis of any unexplained weight loss, and may be confused with
insulin-dependent diabetes mellitis, thyrotoxicosis, malignancy, malabsorption syndromes Of
/
infective conditions such as mv. Anorexia nervosa is a potentially life-threatening
psychiatric condition with a mortality ofup to 20% from a variety of causes. The most serious
complication is the risk of sudden death from a variety of causes as listed in Table 11
(Hartman, 1995).
3.3.4.2 Aetiology (Theories and Studies)
(i) Constitutional Contributions
The biology of anorexia nervosa has generated diverse theories, such as that pituitary
dysfunction, without a great deal of supporting evidence. Recently the studies ofbiochemistry
of appetite and eating behaviour in animals and humans have pointed towards the importance
of dopamine, noradrenaline, endogenous opiates, and other peptides. Serotonin has emerged
with more credentials than any other neurotransmitters. Serotonin has been shown in animal
experiments to be responsible for suppression of food intake and may be selectively involved
in satiation. It may also regulate body weight via thermogenesis and activity as well as
feeding, and may control nutrient selection, favouring carbohydrate intake. Appetite, stress
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response, mood, sexual and reproductive functions are all influenced by serotonin, making it a .
plausible element in the aetiology ofanorexia nervosa (Hartman, 1995).
In humans, serotonin function is different in men and women, which fits with the
epidemiology of the eating disorder, with young men accounting for only ten percent of
anorexia nervosa cases. Some authors suggest that abnormal brain serotonin function
represent a biological diathesis for anorexia nervosa. The causative relationship remains
unclear. Studies of anorectic patients have suggested attenuated serotonin function at low
weight and possibly elevated serotonin function following weight restoration. Disturbed
serotonin activity may be secondary to the state of starvation, or may be related to non-
specific elements of the disorder such as disorders ofmood or impulse control. There is also a
genetic element in the aetiology of anorexia nervosa. However this vulnerability may be
/
mediated by diverse factors such as growth rate in childhood, a predisposition to obesity,
personality types, or predisposition to psychiatric illness in general (Hartman, 1995).
(ii) Family and Psychodynamic Contributions
Anorexia nervosa has always been associated with psychological determinants, which
is the reaction of the patient and her family to the physical and social changes of puberty. It
requires psychological treatment with the involvement of the family, general practitioners,
and a multidisciplinary inpatient treatment programme as well as using self help resources
such as the Eating Disorders Associations (Hartman, 1995).
Table 10 - Anorexia Nervosa: Dia~nosticCriteria
DSM-IV dia2nostic criteria for 307.1 Anorexia nervosa
• Refusal to maintain body weight at or above a minimally normal
weight for age and height (eg, 85% ofthat expected)
• Intense fear of gaining weight or becoming fat, even though
underweight
• Disturbance in the way in which one's body weight or shape is
experienced, undue influence of body weight or shape on self-
evaluation, or denial of the seriousness of the current low body
weight
• In postmenarcheal females, amenorrhoea, ie, the absence of at
least three consecutive menstrual cycles
•
. Specify type:
• restricting type
,. binge-eating/purging type
Taken from: Hartman, 1995: 712-716
. Table 11 - Anorexia Nervosa: Medical Complications
• cardiovascular bradycardia, hypotension, ventricular
arrhythmias, congestive cardiac failure (terminal event)
• gastrointestinal: erosion of dental enamel, benign parotid
enlargement, oesophagitis and oesophageal ulcers, acute gastric
dilation, acute pancreatitis
• renal: electrolyte abnormalities, hypokalemia, hyponatremia,
hypochloremia, hypophosphatemia, hypokalemic nephropathy
• haematological: pancytopenia, bone marrow hypoplasia
• skeletal: osteoporosis, pathological fractures
• endocrine: hypothalamic hypogonadism, high cortisol with DST
non-suppression, neurogenic diabetes insipidus
• metabolic: impaired temperature regulation, impaired glucose
tolerance, hypercholesterolemia
• dermatological: lanugo, carotenodermia, thin, dry skin, purpura
Taken from: Hartman, 1995: 712 -716
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3.3.4.3 Treatment
Constitutional contributions require medical treatment while family and
psychodynamic contributions require psychological treatment (Tables 12 A&B). Individual
and/or family psychotherapy is seen as central to the treatment ofanorexia nervosa since there
is little support for the use ofpharmacological treatments. Arrest ofphysical deterioration and
reversal of weight loss has to be the fIrst step in any treatment programme. In 1995, as in
1874, there is little if any role for drugs in the treatment of anorexia nervosa. The loss of
appetite is essential for the diagnosis of anorexia nervosa, but while most anorectics deny
hunger, they are in fact in a starvation-driven state of extreme preoccupation with food.
Anorectics defend themselves against this craving with stubborn determination, hence the
little therapeutic use of appetite stimulating drugs. Drugs used to promote food intake and
/
weight gain such as cyprohepadine, amitriptyline, clonidine and opiate antagonists have
disappointing results. Paradoxically, one might expect drugs with appetite-suppressant effects
to be more useful as these might ameliorate the intense anxiety with which anorectics regard
meal times, and facilitate behavioural control ofeating (Hartman, 1995).
With the recently elucidated role of serotonin in appetite regulation, there has been
some tentative exploration of the use of SSRIs, such as fluoxetine, with appetite-suppressant
effects. A number of open trials using fluoxetine in weight-restored anorectics have had
promising results, but we should await the results of blind and controlled treatment studies
before using SSRIs in clinical practice (Hartman, 1995).
-------------------------------------------,
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Tables 12 A & B - Stepped Care for Anorexia Nervosa and the Role of GP
A. SEVERITY
excessive dieting
anorexia nervosa:
early onset or
short illness
1
anorexia nervosa:
long illness or
recurrences
TREATMENT
psycho-education,
counselling,
weight monitored
.1
parental
counsrg
out-patient family
therapy or
individual therapy
1
in-patient or day-
hospital treatment
1
section 3, MHA
CARE PROVIDER
general
practitioner
or self-help
1
general or child
PSYliatrist
specialist eating
disorder unit
B. The role of g~neralpractitioner
• pick up young people at risk of anorexia nervosa or showing early signs of the illness
(exaggerated concern about weight or shape, disturbed eating patterns, declining weight)
• in such cases provide advice about diet and about anorexia nervosa, and monitor weight
• provide the young person and her family with self-help information
• carry out physical examination, and special investigations (haematology, electrolytes,
serum protein, possibly radiology) if indicated
• make the diagnosis of overt anorexia nervosa based on standard diagnostic criteria, and
refer to general psychiatric or specialist services
• engage in a working relationship with the patient and her family and help them engage
with specialist services
• this is a chronic disorder. The general practitioner can be a line of continuity between
various medical and psychiatric services, perhaps over a period ofdecades
• with established chronic or recurring cases, monitor weight and be aware of possible
medical complications.
Taken from: Hartman, 1995: 712-716
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3.3.5 Bulimia Nervosa
Bulimia, an eating disorder most common among young women, is characterised by
binges of grossly excessive intake of food, followed by purges (induced vomiting) to prevent
absorption of excessive calories which would cause unwanted weight gain (Fuller et aI,
1991). Tryptophan depletion has been used to investigate the relationship between 5-HT and
eating behaviour in bulimic women (Miller et aI, 1992). However, the evidence for 5-HT
abnormalities in bulimia is not as striking in bulimia as it is in anorexia nervosa.
Fenfluramine, a serotonergic chug, which is both a reuptake inhibitor and releaser of 5-HT,
was found to suppress eating in bulimics, makes SSRIs logical candidates for trials in
bulimia. Also there has been reports of successful treatment with fluoxetine in adults who
were diagnosed as children or adolescents with bulimia. Fluoxetine is reported to decrease the
/
binges and purges in bulimic patients (Hartman, 1995).
3.4 Sleep Disorders
3.4.1 Introduction
5-HT has been implicated in the control of the sleep-wake cycle. Experiments were
done on cats earlier which indicated that depletion of 5-HT pharmacologically OF by
destruction of the raphe nuclei produced insomnia that could be reversed by administration of
5-HT or its metabolic precursor. This led to the "monoaminergic theory of sleep" which
postulated that sleep was triggered by the release of 5-HT. It was also discovered that
insomnia induced by depletion of 5-HT was temporary and with time, treated animals
reacquired the capacity to sleep. It has been demonstrated from single unit recordings in the
raphe nuclei that 5-HT containing cells decrease their fIring rate during the transition from the
waking state to sleep. It is clear now that control of sleep-wake cycle is more complicated
than originally proposed. It is controlled by several different groups of cells from several
brain regions in addition to raphe nuclei, including the locus coeruls and surrounding
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structures. These cells release a variety of neurotransmitters in addition to 5-HT, including
norepinephrine, acetylcholine, and histamine are known to be involved (Montegomery, 1990).
3.4'.2 Monoaminergic Theory of Sleep and Studies
A great number of experiments concerned with the various neurotransmitters involved
in the sleep regulation, have indicated that serotonergic transmission mechanisms play a role
as active factors or inducing processes in the organisation of sleep (Janssen, 1988; Yogman et
aI, 1985). Although there are evidence implicating the involvement of 5-HT in the sleep-wake
cycle, the- involvement of specific 5-HT receptor subtypes in sleep mechanisms is unclear.
Experimental evidence suggests that 5-HTIA agonists delay the onset of rapid eye movement
(REM) sleep while 5-HT2 antagonists suppress REM and have variable effects on non-REM
/
sleep (Leonard, 1994). Also studies in both humans and animals indicate that 5-HT2 receptors
are involved in the regulation of slow wave sleep (SWS) and in the regulation of circadian
rhythms and the sleep-wake cycle (Leonard, 1994; Sharpley et aI, 1994).
The identification of a large number of 5-HT receptor subtypes by means ofmolecular
neuropharmacology and the availability of specific 5-HT receptor ligands for clinical research
promises to further clarify the role of 5-HT in sleep physiology (Holsboer, 1992). Drugs
modifying 5-HT, and also noradrenaline, dopamine or acetylcholine, in appropriate areas of
the brain, are involved in the control of sleep. However many of these studies of the
relationship between the serotonergic system and sleep have been conducted in cats or rats
and since drug effects are species dependent, observations in these animals do not necessarily
apply to man. The relevance of such fmdings to humans remain unproven and the difference
may be of qualitative or quantitative nature (Leonard, 1994; Sicuteri et aI, 1976).
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3.5 Psychiatric and Neurological Disorders
3.5.1 Introduction
Although the function of serotonin in the CNS and brain is not well understood, there
is little doubt that it is important (Ovennyer, 1990). The fIrst indications that 5-HT was
potentially psychoactive came from observations made in the 1950's from studies with LSD,
DMT and others (Leonard, 1994). Biochemical studies in animals indicate that serotonin and
other biogenic amines including dopamine and norepinephrine act as neurotransmitters in the
eNS and are important in behaviour modulation. Phannacological studies in animals suggest
that alterations in these animals may be related to the aetiology of the affective and cognitive
disorders ofhuman psychiatric illness (Jimerson et aI, 1976).
Also the recent discovery of human platelets as the peripheral markers of central
neurotransmitter systems has broadened the scope of biological research in psychiatry.
Human platelets resemble presynaptic serotonergic neurons and permit us to investigate the
involvement ofthe serotonin system in the pathophysiology ofmood disorders. Platelets show
an active uptake of serotonin and the related 3H-imipramine similar to cerebral binding sites
as described in study # 17 in chapter 2 (Marazziti et aI, 1991). Many psychiatric investigators
have also used measurement of 5-HIAA in the CSF as an index of central serotonergic
function (Leonard, 1994).
The role of 5-HT in the control of the complex function called "mood" has been the
subject of many research reports (Sicuteri et aI, 1976). Investigators have also found 5-HT3
receptors in the limbic and cortical regions of the brain areas that are involved in emotion,
mood, and responsiveness to external stimuli. Antagonists that block 5-HT3 receptors in these
areas have therapeutic implications for a number of diseases including alcoholism and
schizophrenia (Ovennyer, 1990).
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However, the role of serotonin in schizophrenia is still unclear but research in this area
has promises ofbetter outcomes, patient advocacy and rehabilitation (Kahn et aI, 1993; Jones,
1993). Also the possible overlap between anxiety, depression, panic attack, aggression, and
QCD and the involvement of 5-HT in the symptoms of these disorders has recently led to the
investigation of various selective 5-HT uptake inhibitors and selective 5-HT receptor
agonists/antagonists in the treatment of these conditions. These disorders are treated with
serotonin agonists or compounds that increase serotonin reuptake such as paroxetine which
have fewer side effects and more effective rehabilitation (Chouinard, 1992; Leonard, 1994;
Murphy et aI, 1990; Roth, 1994; Sandyk, 1992). Serotonin is also implicated in a broad range
of psychiatric and neurological disorders in children and modulation of affective states
(Cohen et aI, 1977).
/
3.5.2 Depression
3.5.2.1 Introduction
For decades serotonin has been implicated in the pathophysiology of depression,
hence the extensive study of the 5-HT neurotransmitter system in relation to the biology of
depression and the mechanism of antidepressant action (Miller et aI, 1992). 5-HT is believed
to play a multifunctional role in depression which is anticipated from its involvement in the
physiological processes of sleep, mood, vigilance, feeding, learning, and possibly sexual
behaviour, all of which are deranged to varying extents in severe depression. However, the
involvement of precise 5-HT receptor subtypes in depression and in the action of
antidepressants is still unclear. It has been suggested that depression could arise from a
pathological enhancement of 5-HT2 receptor function from the observation that the functional
activity of 5-HT2 receptors on the platelet membrane is enhanced in depression (Leonard,
1994). A number of antidepressant agents possess a high affinity for 5-HT2A and 5-HT2C
receptors (Roth, 1994).
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3.5.2.2 Theories and Studies
Alterations in serotonergic neural activity had been proposed to be important in the
pathophysiology of depression for some time now. It has been proposed that noradrenergic
and serotonergic systems are "linked" and alterations in the activity of one system may
directly OF indirectly alter the activity of the other. Such a linkage could occur via a GABA-
ergic interneuron. Also recent studies demonstrating that 5-HT2A receptors may reside on
GABA-ergic interneurons supports this hypothesis. A number of studies have also suggested
alterations in serotonin metabolism and/or receptor function occur in depression (Roth, 1994).
There has also been increasing focus on the serotonergic system studies which suggest a
deficiency in the synthesis, release, or metabolism of 5-HT as well as alterations in the
serotonergic receptor systems in depressed patients (lny et aI, 1994). The original hypothesis
that a deficiency of 5-HT was a causal factor in the pathophysiology of depression was based
on a number of observations including the therapeutic efficacy of drugs such as SSRIs and
MAO inhibitors which enhance serotonergic neurotransmission and the initial fmdings of low
levels of5-HT in the CSF ofdepressed patients (Miller et aI, 1992).
Specifically, studies have revealed the following:
(i) decreases in the concentrations of serotonin in the brain and 5-HIAA in CSF ;
(ii) alterations in presynaptic and postsynaptic serotonergic receptors;
(iii) alterations in peripheral markers of CNS serotonergic function such as platelet serotonin
uptake, platelet (3H) imipramine or (3H) paroxetine binding, platelet 5-HT2 receptor density,
and whole blood serotonin content in depressed patients;
(iv) all known antidepressant agents have been shown to increase the efficacy ofCNS
serotonergic neurotransmission;
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(v) patients treated with antidepressants who exhibit a remission, rapid depletion of serotonin
results in a prompt clinical relapse; and
(vi) all known serotonin reuptake blockers so far studied have been demonstrated to be
clinically effective antidepressant medication (lny et aI, 1994; Risch et aI, 1992).
The identification and cloning of multiple serotonergic receptor subtype and the
identification and cloning of the serotonin transporter offer a further promise for elucidating
the role of eNS serotonergic neurons in the pathogenesis of depression and the development
of innovative treatment strategies for this disorder (Risch et aI, 1992). Many studies have
suggested that a subgroup of depressed patients have significantly decreased plasma
"
Tryptophan concentration, which may result in decreased brain serotonin concentrations. Also
a large number of studies have demonstrated that many depressed patients exhibit marked
reductions in the number of platelet (3H) imipramine binding sites. Hence the measurement
of platelet serotonin uptake or platelet serotonin transporter sites may provide a "window to
the brain" and potentially provide a useful, easily available laboratory "marker" to aid both in
the diagnosis of depression and in the monitoring of response to pharmacotherapy (Risch et
aI, 1992).
3.5.2.3 Treatment of Depression, Anxiety and Stress
A number ofnew serotonin reuptake inhibitors have been developed for the treatment
of depression which includes fluoxetine and sertraline, which are already marketed in the
United States of America (US) while other agents are being investigated in premarketing
studies. Pfizer, a world leading pharmaceutical company has serotonin research programmes
with worldwide research sites. Clinical comparison study of serotonin reuptake blockers has
indicated that these agents have equal efficacy with other known antidepressant medications
(Risch et aI, 1992).
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Drugs that affect serotonergic activity have also been reported to be effective in the
treatment of generalised anxiety disorder (GAD). Increasing evidence that serotonergic
reuptake inhibitors are effective in the treatment of patients with panic disorder provide
further support for a role of 5-HT in anxiety. There is also evidence that the relationship
between stress and psychiatric disorders is due in part to the effects of stressors on eNS
neurotransmitters, including 5-HT (lny et aI, 1994).
Animal studies have demonstrated that exposure to severe, uncontrolIabte stressors
results in the depression of active behaviour which appears to be mediated by neurochemical
changes. This evidence is suggested by drug treatment, which prevent the neurochemical
depletions associated with stresS', which can also prevent behavioural depression. Treatment
"
with antidepressant drugs can reverse the behavioural deficit once it has occurred. These
findings suggest that reduced amine concentration may hinder the organisms ability to deal
with further demands placed on them, thus increasing its vulnerability to psychological
disturbance (lny et aI, 1994).
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3.5.2.4 Pharmacotherapy of Depression in Children
Mental illness affects at least twelve percent (7-12 million) of American children and
adolescents (Table 13) with depression being increasingly reported in this age group.
Depression occurs in about 5% of children and adolescents in the general population.
Depression can impair normal cognitive and social development and interfere with the overall
functioning of children and adolescents. The economic burden is staggering at an annual cost
of $44 billion for lost of productivity and need for treatment. Effective treatment of
depression improves mood and enhances cognitive function. The use of antidepressant
medications in children and adolescents has increased in the past decade (Tables 14). The
SSRIs appear very promising but their safety and efficacy has not yet been established f011
children. Increased recognition of depression in children and availability of new
/
antidepressant drugs in adults warrants a review of both the disease and its treatment. If these
new drugs are to be used in children with depression they must be studied in children. The US
Food and Drug Administration (FDA) due to the absence of formal studies for labelling do
not approve the new antidepressant agents currently available for paediatric use. However,
increased recognition of depression in children and its impact on family well-being demand
paediatric use labelling for these antidepressant drugs (Wilson et at, 1995).
To- date the response of children and adolescents to antidepressant drug therapy has
been rather unimpressive. Most published studies in the use of medications for the treatment
of children and adolescents with major depressive disorder have used small samples of
patients with mild to moderate depression as well as including patients with secondary
depression as demonstrated in Table 14. Studies in children are limited and a considerable
amount of work remains to be done to optimise dose and efficacy and to defme the safety of
these agents in children. The safety and efficacy of SSRIs have not been established in
children (Wilson et aI, 1995).
'Table 13-
.Evidence for Involvement of Serotonin in Child/Adolescent Psychiatric Disorders*
Disorder> Evidence Reference
Bulimia
Anorexia
Autistic disorder
Obsessive-compulsive disorder
Asberg et aI, 197643
Arora and Meltzer, 198944
Zohar et aI, 198745
Leonard et aI, 198846
Insel et al. 198547
Wurtman and Wurtman, 197948
Halmi et ai, 198249
Weizman et al. 198650
Brewerton et ai, 19W5'
Robinson et ai, 198452
Anderson et ai, 198753
McBride et ai, 198954
Wender et aI, 197155
Hanna et ai, 199556
Selikowitz et ai, 199057
Nyhan etal,.19805B
Attention-deficitlhyperactivity
disorder
Depression Abnormal CSF 5-HIAA in suicides; abnormalities in
5-HT2 platelet binding and other 5-HT platelet measures
Superior response to serotonergic TCAs compared with
noradrenergic drugs; abnormal responses to m-CPP
challenge; higher CSF 5-HIAA in patients
5-HT inhibits food intake in animals; 5-HT <fgonists are
anorectic agents; cyproheptadine (5-HT antagonist)
possesses antianorectic properties; decreased
[3H)-imipramine binding
Abnormal response to m-CPP; suppressiO"n of eating by
feilfluramine
Hyperserotonemia compared with controls; blunted
response to fenfluramine compared with healthy controls
Diminished platelet 5-HT in 50% of children diagnosed
with minimal brain dysfunction; association of 5-HT with
aggression
Prader-WiIli syndrome Fenfluramine noted to be beneficial
Self-injury 5-Hydroxytryptophan beneficial in Lesch-Nyhlln syndrome.
• Abbreviations: 5-HIAA = 5-hydroxyindoleacetic acid; 5-HT = serotonin; m-CPP = m-chlorophenylpiperazine.
Taken from. : DeV&ne et at, 1996 : 59
·Table 14 ;.; RepOrts ofSSRIs in child I adolescent psyclDatric disorders
'" Reports of Serotonin Selective Reuptake Inhibitors in Child/Adolescent Psychiatric Disorders*t
Number9f 'Sh
dy
Du tion! Comparison Drug, Dose Rating
Subjccts Observation Treatment (mgld) Scale Result Reference
Depression
Controlled trial
40 Swk Placebo Fluoxetine, 60' HAM-D, Covi, 32 completers at follow-up; Simeon etal, 19904
cm, Raskin, improvement in both groups
SCL-5S by 3 weeks; no difference
between gro.u~in response
Open trials
15 6-7 wk PT: TCA, Fluoxetine, HAM-D,COI 11 completers; 64% response Boulos et ai, 19925
lithium 5-40 byHAM-D
6 Swk PT:TCA Fluvoxamine, BDI Significant decrease in Apter et ai, 19946
100-300 BDI scores
31 7-S9d None Fluoxetine, cm Retrospective chart review; Jain et ai, 19927
20-S0 74% showed some improve-
ment, although 43% showed
,Obsessive-compulsive
minimal or no change
disorder
Controlled trial
14 20wk Placebo Fluoxetine, 20. cm, Y-BOCS 44% improvement in Y-BOCS Riddle et ai, 1992&
score (nonsignificant);
significant change in cm
Open trials
4-20wk4 None Fluoxetine, cm, Y-BOCS Improvement in 50% of Riddle et ai, 19909
10-40 patients
14 S wk PT:TCA Fluvoxamine, Y-BOCS'" Significant improvement in Apter et al. 19946
100-300 Y-BOCS after Wk 6·
38 uptol9mo None Fluoxetine, cm Moderate-to-marked OeHer et al. 199510
mean =50 improvement in cm in 74%
Case reports
S <!:8wk None Fluoxetine, Cl 4 of 8 patients showed' <!: 50% Liebowitz et ai"
20-80 reduction in time spent on 199011
obsessive-compulsive
symptoms
Simeon et ai, 1990126 4-28 wk None Clomipramine + cm Some improvement in all;
fluoxetine, marked in 5
20-40
2mo None Fluoxetine, 30 Cl Remission with benefit on Bussin~ and Levin.
comorbid ADHD 1993 1
4wk Imipramine Fluoxetine, 60; Cl Improvement in depression Alessi and Bos,
buspirone, 30 and ritualistic practic~s 1991 14
5mo· None Fluoxetine, 80 Cl Elimination of compulsions Graae et al. 199215
but residual obsessions, and
little effect on trichotillomania
Tourette's disorder
Controlled trial·
11 4mo Placebo Fluoxetine, LO!. Y-BOCS Some improvement in tic Kurlan et al. 199316
20-40 severity, attentional abilities,
and social functioning
Open trials
13 (& 13 adults) 3-8mo None Fluoxetine, LOI Significant improvement in Como and Kurlan,
20'-40 LOI 1991 17
6 20wk None Fluoxetine, cm 50% response rate; all patients Riddle et al. 19909
10-40 were receiving concurrent
treatment for OCD
Case report
I 14d None Sertraline, 75 Cl Sertraline in combination With. Buckingham and
pimozide decreased motor! Gaffney. 1993 IS
vocal tics
Trichotillomania
Case reports
I S mo Imipramine Fluoxetine, ? Cl Patient became asymptomatic; Hamdan-AHen,
had comorbid autistic disorder 1991 19
4wk Imipramine Fluoxetine, 20 Cl Patient with comorbid Naylorand
depression experienced Grossman, 199120
transient improvement then
relapse
(Continued) ,
Reports ofSerotonin Selective Reuptake Inhibitors in Child/Adolescent Psychiatric Disorders*t (Cont'd.)
Study
Number of Duration! Comparison Drug. Dose Rating
. Subjects Observation Treatment (mgld) Scale Result Reference
I Smo Imipramine Fluoxetine. 10 Cl .Free of symptoms at S mo after Sheikha et al.
adding fluoxetine to imipramine 199321
therapy
6wk None Fluoxetine. 20 Cl Cessation of neurotic Gupta and Gupta,
excoriations within 6 wk 199322
6mo Imipramine Fluoxetine. 60 Cl Cessation of symptoms at 60 mg. Alexander. 199123
. \ and less response at 40 mg in a
39-year-old woman with onset at
age 13
Anorexia
Open trial
31 11 ±6 mo None Fluoxetine. Weight. Cl Good response in 10. partial in Kaye et ai, 199124
Io-SO 17. and POOf in 4
Case reports
I 6mo None Fluoxetine. 20 Weight. Cl lmprovemellt on most symptoms Lyles et al. 199025
ana weight gain
N/A None Fluoxetine. Cl Primary report of side effects of lancu et ai, 199226
4Q-6O galactorrhea, but remission noted
Bulimia
Open trials
I. 30 3-10 mo CBT Fluoxetine. 60 Cl Cessation of bingeing and purg- Trygstad. 199<J27ing in 15 patients. and 75%
I· 20 reduction in IS90d CBT Fluoxetine. 20 Cl 20% free of symptoms at 6 mo Wilcox, 199<98
Autistic disorder.
Open trial
23 11-426 d: None Fluoxetine, cm COl improved in IS of23 Cook et ai, 199229
20-S0 subjects; 13 patients on
other medications
Case reports
4 I-Smo None Fluoxetine, Cl Most improvement when Ghaziuddin et ai,
20-40 depressive illness present 1991 30
4 16 mo None Fluoxetine. Cl 3 of 4 patients improved Todd,1991 31
20-30
2mo PT: Imip- Fluoxetine, Cl Improvement in several domains MehIin¥er et ai,
ramine 20qod 19903 .
Swk None Fluvoxamine" Y-BOCS Dramatic improvement main- McDougle et ai,
ISO tained for S mo; coincident OCD 199033
Mental retardation
Open trial
16 7-467 d' None Fluoxetine, CGI COl i'mproved in 10 of 16 Cook et ai, 199229
Io-SO subjects; 12 subjects on other
medications
,Attention-deficit!
hyperactivity disorder.
Open trials
22 6wk None Fluoxetine, CGI, Cn: 19 completers; 58% of patients Barrickman et ai,
20-60 improved 1991 34
32 Swk Methyl- Fluoxetine, :s; 20; C-GAS,CDI, 94% of patients showed sub- Gammon and
phenidate methylphenidate Conners stantial improvement Brown, 199335
Overanxious disorderl
social phobia
Open trial
21 lOmo TCAs Fluoxetine, COl SI % showed moderate-to-marked Birmaher et ai,
10-60 improvement 199436
Case report
I 7mo Desipramine Fluoxetine, 20 Cl Patient with elective mutism Black and Uhde,
experienced complete recovery 199237
on fluoxetine and minimal benefits
on desipramine
Prader-Willi syndrome
Case reports
I 6mo PT: Chlor- Fluoxetine, Cl Fluoxetine better than Dech and Budow,
promazine 20-80 chlorpromazine 1991 38II N/A PT: Thio- Fluoxetine. 20; Cl Decreased weight, appetit,e, and Jerome, 1991 39
ridazine lithium compulsive behavior
,
(Continued)
I
• Reports of Serotonin Selective Reuptake Inhibitors in Child/Adolescent Psychiatric Disorders*t (Cont'd.) ,
'Number of
SUbjects
Study
DUI}\tionl Comparison
ObSelOvation Treatment
Drug, Dose
(mgld)
Rating
Scale Result Reference
70d PT: Thio- Fluoxetine,40 Cl SIB decreased with fluoxetine King, 1991<10ridazine but returned after 2 mo2y PT: Naltrex- Fluoxetine. 40 Cl SIB decreased 45%-55% with Bass and Beltis.one persistent benefJl. 199141
,Self-injury
, Case reports
1
,Enuresis
Case report
1 8mo PT: Imipra-
mine
Fluoxetine,40 Cl Fluoxetine equal to imipramine Mesaros. 199342
:*Only reports are listed whose primary purpose was to relate results of therapeutic trials; publications discussing only side effects are not presented.tAbbreviations: ADHD =attention-deficitlhyperactivity disorder; BDI =Beck Depression Inventory; CBT =cognitive behavioral.therapy;CDI =Children's Depression Inventory; C-GAS =Children's Global Assessment Scale; COl =Clinical Global Impressions scale; Cl =clinical im-'pression; Canners =Conners Parent Rating. Scale; Covi =Covi Anxiety Scale; CPT =continuous performance task; HAM-D =Hamilton RatingScale for Depression; LOI =Leyton Obsessional Inventory; OCD =obsessive-compulsive disorder; PT =previous therapy; Raskin =Raskin Dcpres-'sion Scale; SCL-58 =DSM-III 58-item Symptom Checklist; SIB =self-injurious behavior; TCA =tricyclic antidepressant; Y-BOCS =Yale-Brown,Obsessive Compulsive Scale.
.',"Case included because symptoms appear and treatment is usually initiated in childhood.
Taken from: DeVane et at, 199.6 : 57-59
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3.5.3 Obsessive-Compulsive Disorder (OCD), Panic Disorder and Anxiety
3.5.3.1 Introduction
QeD has an estimated prevalence of 0.5% in adolescents and a lifetime prevalence of
\
2-3% in the general population. QCD is a well recognised psychiatric illness characterised by
disturbing, unwanted, anxiety-provoking thoughts or ideas and repetitive impulses to perform
acts which may be considered abnormal, undesirable or distasteful to the patient. The
behavioural and social consequences of QCD are severe, adversely affecting education, work,
sexual, social and family functioning and in severe cases, precipitating complete social
withdrawal (Chouinard, 1992). Since 1980, QeD has been formally categorised in the
Diagnostic and Statistical Manual: of Mental Disorders of the American Psychiatric
Association as an anxiety disorder subtype, along with panic disorder (PD), phobias,
generalised anxiety disorder and post-traumatic stress disorder (Murphy et aI, 1990).
3.5.3.2 Serotonergic Hypothesis
Several clinical trials with SSRIs such as described in study # 3 leads to conclusion
that QCD is a serotonergic disorder in which drugs affecting serotonin reuptake have proven
therapeutic efficacy in QCD. Also the structural and functional abnormalities as well as
biochemical and physiological changes reported in QCD provide indirect support for the
serotonergic hypothesis (Chouinard, 1992; Murphy et aI, 1990; Roth, 1994). Clinical and
laboratory studies have also suggested that changes in brain serotonergic function may
contribute to anxiety symptoms and anxiety type behaviours as described in QCD. Serotonin
is one of several brain neurotransmitters and neuroendocrine systems implicated as having a
role in anxiety. However among all anxiety disorders, the most existing evidence implicates
5-HT to QCD. Most evidence from serotonergic system investigation indicate promising
contributions in understanding the psychobiology of QCD, PD, and other anxiety disorders
and their treatment (Miller et aI, 1992; Murphy et aI, 1990).
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3.5.4 Suicide
Serotonin research in suicidal behaviour has developed as an offshoot from 5-HT
depression research since suicidal behaviour has been mostly investigated as a core
characteristic of depression. Suicide is a phenomenon, which is the target of extensive
research now. Studies on suicide have always revolved around demographic, sociological and
psychological variables, which was lacking in biological dimension until a decade ago. Since
then, genetic aspects, neurochemical and neuroendocrine factors have been the major
biological research targets. The most extensively studied parameter in suicidal behaviour is
the concentration of 5-HIAA in the CSF and biochemical research related to dysfunction in
the 5-HT neuronal system in suicidal behavioUF (De Cuyper, 1987). Also studies show
reduction in brain serotonin content and in CNS (3H) imipramine binding in suicide victims
paralleled reports of marked reductions in platelet (3H) imipramine binding as possible
markers of suicidality (Risch et aI, 1992).
3.5.5 Schizophrenia
3.5.5.1 Introduction
The incidence of schizophrenia is without demographic bias and it occurs across all
cultures and socio-economic groups, affecting both genders with no evidence of clustering in
any specific population groups. The impact of schizophrenia on individuals and on society as
a whole is devastating. Majority of affected, individuals are unemployed, costing the family in
terms of loss ofwork time and expenditures incurred on behalf of the patient may range from
$10,000 to $15,000 annually with staggering national costs. For example in 1986-1987,
Canada spent $1.7 billion in direct health care costs, and another $1.2 billion in indirect health
care costs for patients suffering from schizophrenia. Also the course of illness varies with no
predictable markers of treatment response. Based on clinical observations, one-third of
patients respond well to therapy, one-third respond only partially, and the remainder tend to
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be classified as poor responders or treatment-resistant, requiring multiple or long term
hospitalisations (Jones, 1993).
In spite of the daunting nature and negative impact of schizophrenia on individual and
society as a whole, recent development in schizophrenia research from fmdings in the
neurobiology of schizophrenia have shown new insights into the pathophysiology of this
disorder. The introduction of novel antipsychotics is promising in improving the quality of
treatment for many schizophrenic patients with many clinical and psychosocial implications.
Hence improved clinical outcomes will promote greater autonomy in the patient which can
result in better social outcomes 1:l1rough increased patient advocacy and client-based
rehabilitation program (Jones, 1993).
/
In the past two decades, an increase in our understanding of the disease and the means'
to provide cafe fm individuals suffering from schizophrenia have resulted in a number of
fundamental changes in the field of schizophrenia, both medical and psychosocial. Issues
such as quality of life require current concepts and expectations as new therapeutic and
rehabilitative options emerge for caregivers to look beyond the goals ofrelapse prevention, to
possible rehabilitation and social reintegration. It is widely acknowledged that negative
symptoms are the greatest barrier to psychosocial rehabilitation, therefore treatments that
address this dimension of schizophrenia are bound to increase the prospects of the "3Rs":
reengagement, rehabilitation and reintegration (Jones, 1993).
3.5.5.2 Theories and Research
New doors have been opened by contemporary schizophrenia research with
developments in two research areas:
(i) recent fmdings in the neurobiology ofschizophrenia, and
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(ii) the emergence ofnew antipsycho~icswith novel mechanism ofaction.
These advances have broadened traditional concept of schizophrenia and have vast
implication in health care delivery to patients. In the past, research have focused almost
exclusively on the psychotic elements of the disorder since clinical models of schizophrenia
have traditionally been based on the theories ofpsychosis (Jones, 1993).
It is now clear that while the hyperdopaminergic theory of the mesolimbic system may
partially explain psychosis, it does not explain the complex and multidimensional nature of
schizophrenia. The clinical expression of this disorder varies greatly from one individual to
another with symptom complexes differing and changing between patients and at different
stages of the disease. It is currently hypothesised that in addition to dopamine D2, another
subtype of dopamine receptor, D4 may also be important in the aetiology of schizophrenia.
Also in addition to dopamine D4, the serotonin 5-HT2 receptor appears to play an important
role in the drug treatment of particularly negative symptoms of schizophrenia which was
previously resistant to treatment (Hovatta et aI, 1994; Jones, 1993; Joyce, 1993; Overmyer,
1990).
There is evidence in favour of the idea that specific alterations of serotonergic
function occur in schizophrenia. For some years now, specific alterations in 5-HT receptors
have been documented in schizophrenia, but the directions of these alterations have been
controversial (Ohuaha et aI, 1993; Roth, 1994). However, at present, there appears to be
consensus that 5-HT2A receptors are down-regulated in certain brain regions, while 5-HTIA
receptors are up-regulated in schizophrenics compared with normal controls (Roth, 1994).5-
HT system may play a major role in the pathophysiology and / or treatment of schizophrenia.
This is consistent with the fmding of altered serotonergic neurotransrnission and the unique
efficacy of antipsychotic drugs with 5-HT2A receptor antagonist activities in schizophrenia
(Hagan et aI, 1993; Roth, 1994).
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3.5.5.3 Rehabilitation (Client-Based)
The novel antipsychotics such as clozapine and risperidone are expected to bring
tangible improvements to the quality of life of patients suffering from schizophrenia by
greatly enhancing treatment compliance and facilitating better outcomes from psychosocial
interventions vital to patient rehabilitation. Improvement in negative symptoms, which drove
many patients into isolation, withdrawal and despair, begin to objectify their condition and
strive toward self-insight and autonomy. The introduction of better therapies for
schizophrenia in recent years has been paralleled towards client-based service delivery. As
patients gain more control over various aspects of thew illness, the drive and motivation to
advocate for better resources and for a better quality oflife also increases (Jones, 1993).
/
3.5~5.4 Conclusion
The movement towards patients' autonomy represents a very significant turning point
in the social history of schizophrenia. For centuries, people suffering from schizopnrenia have
been marginalized legally, socially, and economically and many faced bleak lives with little
hope of improvement and for some suicide have been the only escape. Hence the cost-benefit
of drug treatments and rehabilitation programs must be assessed according to their ability to
improve social outcomes (Jones, 1993).
3.5.6 Autism
3.5.6.1 Introduction
Autism is a developmental disorder affecting social, communicative, and intellectual
development in children (Cook, 1990). Autism became a popular term in child psychiatry
following report of children referred to as having early Infantile Autism. Initially Early
Infantile Autism was considered to be of probably psychological origin related to early
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rearing practices. The treatment approaches used were mainly psychotherapeutic with the idea
that inside the autistic shell one would fmd a potentially normal intact child. As time passed
there has been disillusionment with the psychotherapy approach and the recognition that the
term autism has been applied to a multiplicity of etiologically separate or unrelated
conditions. There is indication that some of the physiologic disturbances found in autistic
children are also present in children with other developmental disorders. The possibility is
that there is only one basic disturbance affecting many body systems in varying degrees and
manifests in a variety of overlapping syndromes. Objective markers are needed to allow the
demarcation of subgroups of autistic children for further studies in the field of developmental
disabilities which includes autism, schizophrenia, learning disabilities, language disturbances
in children as well as those children with mild developmental deviations (Piggott, 1979).
3.5.6.2 Theories and Studies
A number of studies have been carried out that focus on indoleamine, particularly
serotonin metabolism, as an area of possible disturbance in childhood psychosis. The
neurochemistry of autism has been studied extensively over the past three decades. Most
investigations of autism has been confmed to peripheral fluids and tissues because of lack of
sufficient animal and human model as relatively few diagnosed people with autism have died.
The most consistent fmding has been that over 25% of autistic children and adolescents are
hyperserotonemic but after 29 years of investigations, the mechanism of hyperserotonemia
has not been determined (piggott, 1979). However, from studies done, it is suggested that the
decline of the aminoacids in platelets from autistic children represents a biochemical marker
related to infantile autism (Gordon et aI, 1993; Rolf et aI, 1993).
The identification of the platelet alteration responsible for the hyperserotonemia of
autism should prove useful in several ways:
(i) provide a marker with less overlap with the normal population;
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(ii) lead to gene probes and chromosomal location which would be useful for neonatal
screening, subtyping, and more powerful genetic and family studies;
(iii) might allow early intervention and improved treatment;
(iv) provide a basis for focusing studies of brain neurochemistry and suggest modes of
neuropharmacological intervention; and
(v) basic fmdings and potential benefits derived from this exploration make further research
in this area ofgreat interest (Anderson et aI, 1990).
A case study with Tryptophan loading in 1958 indicated that autistic children might
have a diminished capacity to metabolise Tryptophan via the serotonin chain from the
fmdings of less urinary excretion of 5-HIAA. OtheF findings were that the autistic and
severely retarded children had higher blood serotonin levels than did the mildly retarded
group but no hyperserotonemia in the normal control children. In autistic they also found
significantly higher serotonin levels and significantly higher blood platelet counts than in the
normal children. But other studies concluded that elevated platelet serotonin levels do occur
in infantile autism but may not be specific to infantile autism. Other factors such as diet and
activity levels had not been systematically studied so that one cannot that their fmdings truly
represent a biologic difference in the autistic as compared to the non-autistic child (piggott,
1979).
Other studies clearly demonstrate the importance of genetic factors in early onset
autism in addition to indicating that autism is also associated with biological hazards in
infancy (Piggott, 1979). Further exploration of autism using molecular genetic techniques is
indicated especially in families in which familial aggregation of autism or related cognitive
disabilities is present (Cook, 1990). There are also accumulating evidence that organic
disturbances are related to and may be responsible for many ofthe symptoms seen in autistic
------------------------------------------.
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children. There is a need for continued research as to what degree these disturbances are
unique to autism or are also involved in a variety ofother developmental deviations which are
unclear (piggott, 1979).
3.5.6.3 Conclusion:
The aetiology of children called autistic probably are composed of a number of
subgroups with different basic pathologic process manifesting in similar clinical pictures.
There is increasing indication that at least some of these disturbances originate during
gestation, are present at birth, and become manifest when they interfere with the normal
course of development. Genetic vulnerability combined with environmental insult producing
autism, seems likely to account for some autistic children. The idea of an immunologic deficit
followed by a viral insult would fit this pattern (Piggott, 1979). We are also in need of
objective markers whereby various subgroups of children diagnosed as autistic or
schizophrenic can be clearly differentiated to facilitate thorough study toward a clarification
of underlying pathology. This could then lead toward specific effective therapy with
antipsychotic agents and selective serotonin receptor subtype agonists or antagonists
(Anderson et aI, 1990; Cook, 1990; Piggott, 1979).
3.6 Movement Disorders
3.6.1 Introduction
Functional abnormalities of monoamine neurotransmitters such as dopamine,
norepinephrine, and serotonin have been implicated in a broad range psychiatric and
neurologic disorders in children including seizures, movement disorders, forms of mental
retardation. A marked reduction ofboth dopamine metabolite, Homovanillic Acid (RVA) and
serotonin metabolite (5-1llAA) have been found in the CSF of children with epilepsy (Cohen
et aI, 1977).
--------------------------------------~
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3.6.2 Cerebellar Ataxia
Cerebellar ataxia may be caused by a variety of hereditary or acquired diseases, such
as cerebellar cortical atrophy, olivopontocerebellar atrophy, demyelinating diseases, vascular
diseases, infectious diseases, and trauma. Cerebellar dysfunction may be disabling causing
gait disorders such as staggering, unsteadiness, stumbling, and fear of walking, tremor, and
incordination of extremities, dysarthria (imperfect articulation of speech), nystagmus, and
difficulty with swallowing. Patients who are severely affected with cerebellar disease often
need assistance in activities of daily living. There is no effective treatment as the causes of
many hereditary and degenerative diseases are unknown. The patient may be treated
symptomatically to try to alleviate their disabilities (Lou et aI, 1995}.
One approach to symptomatic treatment is to modify the neurotransmitter systems in
the cerebellum, one of, which is the serotonergic system, which appears to play a role in
regulating motor output. Serotonin receptors in the human cerebellum are of the 5-HTIA
subtype. The levorotatory form of hydroxytryptophan, a precursor of serotonin, has been
shown to have some beneficial effect on patients with cerebellar ataxia. However the
levorotatory form ofhydroxytryptophan may cause a scleroderm-like illness and in addition, it
stimulates all receptor subtypes causing conflicting and unnecessary side effects. Serotonergic
agents which bind with specific serotonin receptors in the cerebellum, may be more effective
than the levorotatory form of hydroxytryptophan in treating patients with cerebellar ataxia
with fewer side effects as described in study # 15 in chapter 2 (Lou et aI, 1995).
3.6.3 Myoclonus
Myoclonus is a clinical term meaning a quick involuntary jerk seen in normal subjects
under certain circumstances including sleep and certain disease states indicating neurological
dysfunction. It was not until 1960's, when patients with myoclonus and major functional
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disability were reported, that attention was given to understanding its basis and
pharmacotherapy. Special attention was given to reports of myoclonus developing after
anoxic brain damage which responded to treatment with the serotonin precursor, 5-
hydroxytryptophan. However, further experience showed that only a few patients with
myoclonus benefited from this therapy (Snodgrass, 1990).
Myoclonus may originate in many CNS sites but the brainstem reticular formation is
especially relevant to myoclonus. Brainstem serotonin neurons have special influence on
spinal motor neurons, startle response, and myoclonus. Among 5-HT receptors, 5-HT1A
receptors are related to some forms of myoclonus although 5-HT2 receptoFs are also
implicated. GABA receptors are also related to some forms of myoclonus and stimulation of
GABA receptors may promote or antagonise myoclonus depending on which GABA
receptors are involved and the state of the system. Myoclonus is often associated with other
neurological symptoms which have greater impact on patient function, disability and respond
to pharmacotherapy (Snodgrass, 1990).
3.6.4 Gilles de la Tourette Syndrome
Tourette syndrome is a chronic, lifelong, hereditary neurological disorder
characterised by motor and vocal tics, obsessive compulsive behaviour and attention deficit
disorder which occurs in childhood. It is found in an ethnic and racial groups although the
exact prevalence is unknown due to misdiagnosis, under reporting, and few epidemiological
studies. Treatment includes medications such as serotonin receptor inhibitors and stimulants
to improve a child or adolescent's functioning, reassurance and support, guidance and
advocacy in relation to appropriate school placement as well as counselling and education of
the patient and family (Cohen et aI, 1992; Suchowersky, 1994).
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3.7 Discussion and conclusion
From various literature reviews in this treatise, it is evident that 5-HT is involved in a
variety ofphysiological processes and disturbances of these serotonergic functions may be of
importance in the aetiology of many GIT, CVS and CNS diseases. With the discovery of
subtypes of5-HT receptors, there has been the development ofdrugs with selective actions on
these receptor subtypes. The rapid expansion ofour knowledge ofserotonin receptor subtypes
should stimulate more research into the pathophysiological roles of these newly discovered
subtypes. These developments had and will lead to the development ofnew therapeutic agents
with increased efficacy and decreased side effects for treatment and rehabilitation of
serotonergic related disorders (Hartig, 1994; Leonard, 1994; Roth, 1994).
It is clear that a number of studies have indicated that serotonergic drugs are effective
in a number of psychiatric disorders. Evaluation of the functional status of 5-HT receptor
subtypes in psychiatric and neurological diseases may be of future importance in the
diagnosis and assessment of treatment response in such patients. Also further development of
selective ligands for all 5-HT receptor subtypes may ultimately lead to a better understanding
of the functional significance and clinical relevance of 5-HT receptors in health and disease
(Leonard, 1994; Roth, 1994).
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CHAPTER 4
4. Data Collection and Analysis of Clinical Diagnoses of Serotonergic Disorders
4.1 Introduction
In this cross - s~ctiop.a1 study of biochemical data and clinical diagnoses, the aim was
to investigate the CSF 5-IDAA (metabolite of serotonin) and HVA (metabolite of dopamine)
of cases in relation to their disease states. In a cross - sectional study, the exposure and the
disease status are assessed simultaneously as discussed in Chapter 2, hence it is not possible
to determine whether the exposure preceded or resulted from the disease. These data were
analysed for trends using an EXCEL database and the SPSS statistical package. The exposure
/
variables were the metabolites or 5-IllAA, HVA, and 5-IllAAIHVA ratio. The outcome were
the various clinical diagnoses while age, gender, multiple diagnoses, underlying pathology
and the role of other neurotransmitters were various confounding factors in this cross -
sectional study (Figure 11).
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Figure 11 - Interrelationship between an Exposure (El, Confounding Factor (CID and
Disease (D)
CONFOUNDER (CF)
Age/Gender
Multiple diagnoses
Underlying pathology
Other neurotransmitters
EXPOSURE (E)----------------------? CF ----------------------DISEASE (D)
(potential confounder)
5-HIAA
HVA
5-HIAAlHVA
Movement disorders
Epilepsy
Neurodegenerative
Psychiatric
Syndromes
Developmental delay
Others
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4.2 Methodology
The cases (n=226), ofwhich 50% were males (M) and 50% were females (F) was the
sampling frame in this cross - sectional study. These cases were accessed from the New
children's Hospital, Westmead, NSW, Biochemistry Unit from 1985 - 1995 who were
investigated for various neurological symptoms from the biochemical analysis of their CSF
concentration of 5-IllAA and RVA. Diagnoses were recorded for n=56 from microfilm kept
in the hospital medical records (MR = 1 for SPSS coding) and from clinical histories (CH = 2
for SPSS coding) on laboratory request forms for n=170. The only demographic
characteristics for these cases recorded in this cross - sectional study were gender and age.
The demographic data with diagnoses and biochemical results for 5-HIAA and RVA were
entered on EXCEL database for future reference and research (Appendix B). However,
"(n=24) cases were excluded from the study due to reasons such as no diagnoses / incomplete
data / oncology cases (n=20), adults and very high levels of 5-HIAA and RVA due to blood
brain barrier breakdown (n=4), as outlined in the flow chart (Figure 12).
The total study sample (n=202) ranged from 0-18 years (yrs) ofwhich 60% were aged
>2yrs. From this study sample 52% were admitted with single diagnosis and 48% were
admitted with multiple diagnosis which included underlying pathology such as developmental
disabilities (DD), cerebral palsy (CP), epilepsy, syndromes, or psychiatric disorders. On
EXCEL, these cases (n=202) were coded (1-7) for major diagnosis (DGC) (Table 15 A) and
in cases with multiple diagnoses, preference were given in order of specific serotonergic
disorders of interest (selection bias) such as movement disorders, neurodegenerative
disorders, and psychiatric disorders. Cases exposed to specific diseases in each group were
coded as yes (Y) and those not exposed to the specific disease in each group were coded as no
(N), which is the control group for specific diseases in each group.
Figure 12 - Flow Chart of Cases and Study Groups
Total cases
n=226
Oncology cases
Missing data
n=20
n=206
t---------. Adults/high 5-HIAA/HVA
n=4
n=202 ------~~>2yrs (n=122)
<2yrs (n=80)
I-- .Single diagnosis (n=106)
Multiple diagnosis (n=96)
1-- • Multiple diagnosis
in group 2 cases
n=9
n=193
<2 yrs age/outliers
n=l11
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Table 15 A - Coding for Major Diagnoses lDGC) with Subgroups
DGC Diagnosis Subgroups Number of cases (n=202)
1 Movement Ataxia 60
hypotonia
Dystonia
Myoclonus
Co-ordination
Posture
Cerebral palsy
Tourettes
Tics/tremors
GaitJhemiplegia
2 Epilepsy Temporal lobe 49
Intractable epilepsy
Infantile .spasms
Drop attacks /
Pseudoseisures
Fits/convulsions
Seizures/spasms
Febrile seizures
3 Neuro- Meningitis 52
degenerative Encephalitis
Cerebellitis
Meningoencephalopathy
inflammatory/febrile
TIA's (moya moya)
Optic neuritis
Guillian-Barre
4 Psychiatric Depression/anxiety 10
Psychosis/suicide
Conversion disorder
Behavioural problems
Autism
Dementia
Eating disorder
OCD/ADHD
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5 Syndrome Leigh's 23
Tourettes
Metabolic
Hypothalamic
Mitochondrial
Dismorphic
Myopathy
Guillian-Barre
Giangtism
GTD
COD
Sleep disorders
Migraine
Myasthenia
6 Developmental GlobaVsevere/mildlmod 5
Delay (DD) Mental regression
Intellectual regression
7 Others Spina bifida occulta 3
Osteogenesis imperfecta /
Scoliosis
Renal failure
Unknown aetiology
. "
,"
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The DOC were again recoded as individual groups (1-9) (Table 15 B) including some
specific movement and psychiatric disorders since the data analysed for statistical
significance showed a statistical significant association between these disorders with different
variables. It was also further noted that the group CP/dystonia had the highest cases of all
movement disorders. Some of these cases (n=9) from the group CP/dystonia with multiple
diagnoses were then excluded from the study set (n=193) since its inclusion resulted in a
bimodal distribution of5-HIAA in this data set.
The whole data set (n=206) was analysed for normality of distribution, mean, median,
and mode range for variables in relation to different diagnoses and groups. The whole study
set (n=202); study set (n=193) excluding cases with multiple diagnoses for group 2; study set
>2yrs age (n=122); and study set >2yrs age (n=111) excluding cases with multiple diagnoses
in group 2, as outlined in the flow chart (Figure 12) were all analysed on SPSS for various
trends and p values using t-test for statistical significance for different variables.
Table 15 B - Coding for Diagnoses by Subgroups as Groups
Groups Diagnosis (subgroups) Number of cases (n=202)
1 Epilepsy 81
2 Dystonia/cerebral palsy/ 23
Parkinsonism
3 TicsITourettes 4
4 Ataxia 19
5 Gait/other movement 19
6 Neurodegenerative 67
7 Psychosis 6
8 Autism 3
9 Other psychiatric 10
0 Others/Syndrome/DD 7
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(Recoding as groups includes multiple diagnoses, hence larger sample size in some groups)
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4.3 Biochemical Data Analysis and Results
In this cross - sectional study of (n=202) cases, the CSF 5-IllAA results ranged from
0.01-1.26 umol/L (N= 0.13-0.21 umol/L), HVA ranged from 0.09-0.79 umol/L (N= 0.22-
0.66umol/L) and 5-IDAAlHVA ratio ranged from 0.02-1.60.
The whole data set analysed for normality of distribution, mean, median, and mode
range for variables in relation to different diagnoses and groups are presented as scatter plots,
histogram and boxplots (Figures 13 A&B, 14 A&B and 15 A&B). It was noted that there
were various outHers which were investigated and excluded form the study set since mean is
sensitive to outHers (Figures 16 A&B, 17 A&B, and 18 A&B). The mean for different
variables in each study sets are presented in Table 16.
/
Also on analysis of regression of age with 5-HIAA and HVA (Figures 19 A&B, 20
A&B), there was a large cluster of cases (n=82) in less than 2 yrs age group which was also
excluded from the study set. It is known that children <2 yrs of age normally have a higher
serotonin levels and hence higher 5-IllAA compared to >2 yrs age. It was more valid to
compare 5-HIAA levels in only the >2 yrs age group since age is a confounder in this case
series and hence further analysis for P values, RR and 95% Cl were adjusted for age.
However, there was no significant gender difference in this cross - sectional study.
It was noted that the association between the movement disorders, neurodegenerative
disorders, and psychiatric disorders with different variables were significant when the study
set (n=202) were analysed for statistical significance (p values) (Table 17). In order to
investigate the data further, mean, p values for significance, crude RR with 95% Cl and RR
adjusted for age in some groups, were analysed using non parametric comparison, for study
sets n=193, and n=lll for each variables.
Figure 13 A
Box plot - Distribution ofS-lDAA by diagnoses
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Boxplot - Distribution of S-HJAA by groups
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Figure 14A
Boxplot - Distribution ofHVA by diagnoses
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.Boxplot - Distribution ofHVA by groups
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,Figure ISA ,
Boxplot - Distribution of5-HJAA/HVA ratio by diagnoses .
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Figure 16A
Histogram - Frequency distribution ofS-lDAA (with outliers)
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Histogram - Frequency distribution of S-HIAA (outliers excluded)
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Figure 17 A
Histogram - Frequency distribution ofHVA (with outJiers)
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Figure 17B
Histogram - Frequency distribution ofHVA >2yrs (outliers excluded)
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Histogram - Frequency distribution of5-HIAMiVA ratio (with outliers)
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Hist~ - Frequency distribution of5-HIAMiVA ratio (outliers excluded)
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Figure 19A
ScatteJ:plot - Distribution ofS-HIAA by age
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Figure 20 B
Boxplot - Distribution ofage >2yrs by groups
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Table 16 - Mean. Minimum and Maximum for S-HIAA. HVA. S-HIAAIHVA ratio
Variables Cases (n) Mean SD Min Max
S-HIAA
0-18yrs 193/202 0.15 +0.11 0.01 1.26
>2yrs 122/202 0.11 +0.06 0.03 1.26
>2yrs 111/193 0.10 +0.05 0.03 0.31
<2yrs 80/202 0.23 +0.12
HVA
0-18yrs 193/202 0.38 +0.17 0.09 0.79
>2yrs 122/202 0.31 +0.15 0.09 0.79
>2yrs 111/193 0.31 . + 0.15 0.09 0.79
<2yrs 80/202 0.46 +0.16
S-HIAAIHVA RATIO
0-18yrs 193/202 0.04 +0.20 0.02 1.6
>2yrs 122/202 0.39 0.07 6.0
>2yrs 111/193 0.33 +0.12 0.07 1.0
<2yrs 80/202 0.51 +0.24
(SD= Standard Deviation, Min= Minimum, Max= Maximum)
Table 17 - P values of 5-HIAA. HVA. 5-HIAAIHVA ratio for Groups
Groups (n=202) 5-HIAA HVA 5-HIAAlHVA
Epilepsy 81 0.10 0.53 0.07
Dystonia/CP 23 0.41 0.51 0.37
Tics/tourettes 4 0.26 0.18 0.78
Ataxia 19 0.04* 0.78 0.02*
Gait/other movement 19 0.52 0.40 0.08
Neurodegenerative 67 0.001* 0.001* 0.36
/
Psychosis 6 0.01* 0.20 0.01*
Autism 3 0.53 0.53 0.29
Other psychiatric 10 0.006* 0.03* 0.05*
Others (Syndrome/DD) 7 0.06 0.06 0.55
(p<0.05 = statistically significant = *)
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Data analy~is of study set (n=193). and >2yrs (n=111) of variables for p values,
showed a statistical significant association of5-mAA <0.11 with ataxia and psychosis groups
(p<0.05), neurodegenerative and psychiatric groups (p<0.005) in this cross - sectional study.
There was a significant increase in RR and 95% cr for dystonia and cerebral palsy >2yrs age
for 5-HIAA > 0.11 when RR and 95%Cr were adjusted for age for this group (Table 18).
The association of RVA <0.22 was statistically significant for other psychiatric group
and RVA > 0.22 for neurodegenerative group in this cross - sectional study. For ataxia and
other movement disorders, the association with RVA <0.22 and for RVA >0.22 was
statistically not significant. The RR and 95% cr for neurodegenerative group was also
statistically significant when adjusted for age while for other psychiatric group, RR and 95%
cr was not significant when adjusted for age (Table 19).
The 5-HIAAIHVA ratio < 0.44 was statistically significant for psychosis and other
psychiatric group and the 5-HIAAIHVA ratio> 0.44 was statistically significant for ataxia
and neurodegenerative groups in this cross sectional study (Table 20). This ratio of 5-
HIAAIHVA are useful in differenting whether the disorder is more likely to be associated to
low 5-HIAA or low RVA since they are an antagonist to each other. Hence, a ratio of <0.44
is more likely to be associated to low serotonin effect (low 5-HIAA) and a high ratio more
likely to be associated to low dopamine effect (low RVA).
The fmdings in this cross - sectional study show a statistical significant association of
the variables, 5-mAA, RVA, and 5-HIAAIHVA ratio to ataxia (as low RVA effect),
neurodegenerative (as low 5-HIAA or low RVA effect) and psychiatric disorders (as low 5-
HIAA effect). The non-significant association with p>0.05 means that the role of chance
cannot be excluded as an explanation. The fmdings are not statistically significant at this level
probably due to small sample size. However, the effect of other neurotransmitters and
multiple diagnoses as confounders and the possibility of selection and measurement biases
could not be excluded in this cross sectional study. It was also noted that for small sample
size the 95% cr was large and for larger sample size, the 95% cr were small and a marked
increase or decrease in RR and 95% cr in some groups when adjusted for age.
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Table 18 * Summary of Mean, :P values, and RR for Diagnoses with 5-IDAA < 0.11
Diagnosis Cases Mean SD *Sig RR 95%CI *Sig RR 95%CI
(Groups) n=193 p<0.05 (Age adjusted)
n=111 #p<0.005
(>2yrs) ns-not sig
Epilepsy 74 0.17 + 0.11 ns 0.6 (0.3-1.1) 1.5 (0.2-9.2)
>2yrs 30 0.09 + 0.05 1.3 (0.5-3.4) 1.5 (0.5-4.1)
Dystonia! 14 0.13 + 0.03 ns 1.3 (0.4-4.0) 0.7 (0.3-2.0)
cerebral palsy
>2yrs 11 0.13 + 0.04 1.7 (0.1-0.6) 5.5 (1.4-21)
5-IDAA> 0.11
Tics 5 0.09 + 0.03 ns 4.3 (0.5-39) 3.4 (0.3-38)
>2yrs 4 0.07+ 0.00 1.1 (0.1-11) 1.4 (0.1-14)
Ataxia 19 0.11 + 0.07 * 4.4 (1.4-14) * 2.5 (0.7-9.0)
>2yrs 18 0.14 + 0.07 2.0 (0.6-8.0) 2.1 (0.6-8.0)
Gait/other 16 0.19 + 0.13 ns 1.7 (0.6-5.0) 0.8 (0.3-2.3)
movement
>2yrs 11 0.10 + 0.03 0.4 (0.1-1.4) 2.2 (0.6-8.0)
Neuro- 64 0.13 + 0.10 # 3.0 (2.0-6.0) * 2.1 (1.0-4.4)
degenerative
>2yrs 46 0.09+ 0.05 2.4 (1.0-6.1) * 2.1 (0.8-5.0)
Psychosis 7 0.13 + 0.08 * 5.3 (0.6-47) 1.1 (0.1-11)
>2yrs 6 0.09 + 0.04 1.9 (0.2-17) 1.9 (0.2-17)
Autism 4 0.09 + 0.04 ns 2.0 (0.2-22) 0.6 (0.1-7.0)
>2yrs 3 0.09+ 0.04 0.2 (0.0-2.0) 4.1 (0.3-48)
Other
psychiatIy 11 0.18 + 0.12 # 4.4 (0.9-21) * 1.5 (0.2-9.0)
>2yrs 9 0.10 + 0.04 3.6 (0.4-30) 2.3 (0.3-20)
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Table 19 - Summary of Mean. P values. and RR for niagnoses with HVA < 0.22
Diagnosis Cases Mean SD *Sig RR 95%CI *Sig RR 95%CI
(Groups) n=193 *p<0~05 (Age adjusted)
n=111 #p<0.005
(>2yrs) ns-not sig
Epilepsy 74 0.39 + 0.02 ns 0.9 (0.5-1.9) 1.6 (0.7-4.0)
>2yrs 30 0.28 + 0.15 1.6 (0.7-3.8)
Dystonia! 14 0.35 + 0.14 ns 1.0 (0.3-3.6) 0.8 (0.2-3.4)
cerebral palsy
>2yrs 11 0.37 + 0.16 0.4 (0.1-2.1)
Tics 5 0.23 + 0.13 ns 2.4 (0.4-15) 2.6 (0.4-17)
>2yrs 4 0.14 + 0.00 2.2 (0.3-16)
Ataxia 19 0.37 + 0.19 ns 1.3 (0.4-3.7) 0.8 (0.3-2.5)
..
HVA>0.22
>2yrs 18 0.37 + 0.19 0.8 (0.3-2.4)
Gait/other 16 0.36 + 0.14 ns 1.2 (0.4-4.0) 1.4 (0.4-5.0)
movement
>2yrs 11 0.30 + 0.10 1.2 (0.3-4.5)
Neuro- 64 0.34 + 0.15 # 2.0 (1.0-4.0) * 2.2 (0.6-9.0)
degenerative HVA>0.22
>2yrs 46 0.28 + 0.11 1.7 (0.8-3.8)
Psychosis 7 0.28 + 0.18 ns 2.7 (0.6-13) 1.0 (0.2-5.0)
>2yrs 6 0.30 + 0.21 1.0 (0.2-6.0)
Autism 4 0.29 + 0.10 ns 3.6 (0.5-26) 3.9 (0.5-29)
>2yrs 3 0.29 + 0.10 1.0 (0.1-12)
Other
psychiatry 11 0.46 + 0.19 * 2.1 (0.6-7.5) 1.0 (0.3-4.0)
>2yrs 9 0.35 + 0.15 1.0 (0.3-4)
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Table 20 - Summary ofMean, P values, and RR for Diagnoses with 5-HIAAIHVA ratio
<0.44
Diagnosis Cases Mean SD *Sig RR 95%)CI
(Groups) n=193 *p<0.05
n=111 #p<0.005
(>2yrs) ns-not sig
Epilepsy 74 0.45 + 0.24 ns 1.3 (0.7-2.3)
>2yrs 30 0.33 + 0.10 1.5 (0.5-4.9)
Dystonia! 14 0.04+ 0.22 ns 1.1 (0.3-3.3)
cerebral palsy
>2yrs 11 0.41 + 0.25 2.0 (0.5-8.0)
Tics 5 0.42 + 0.11 ns 1.3 (0.2-8)
>2yrs 4 0.50 + 0.00 5.3 (0.7-40)
/
Ataxia 19 0.31 + 0.12 * 5.1 (1.1-23)
5-HIAAIHVA> 0.44
>2yrs 18 0.31 + 0.13 1.8 (0.4-9.0)
Gait/other 16 . 0.48 + 0.22 ns 1.1 (0.4-3.3)
movement
>2yrs 11 0.36 + 0.04 2.2 (0.3-18)
Neuro- 64 0.37 + 0.16 ns 1.3 (0.7-2.0)
degenerative .5-HIAAIHVA> 0.44
>2yrs 46 0.34+ 0.13 2.2 (0.8-6.0)
Psychosis 7 0.51 + 0.39 * 3.3 (0.4-28)
>2yrs 6 0.32 + 0.07 1.3 (0.1-11)
Autism 4 0.30 + 0.04 ns 1.6 (0.2-16)
>2yrs 3 0.30 + 0.04 1.7 (0.2-17)
Other
psychiatry 11 0.38 + 0.14 * 5.7 (0.7-45)
>2yrs 9 0.28 + 0.07 2.0 (0.2-16)
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4.4 Conclusion
An evaluation ofthe validity ofthe fmdings in this cross - sectional study, the roles of
chance, bias, and confounding as possible alternative explanation had to be considered in
further studies with randomisation, restriction, and matching of a sufficient sample size or
study groups. Continued researches with a sufficient sample size for different groups are
recommended for more consistent and statistically significant results. Some of the findings in
this cross - sectional study are consistent with literature reviews with the reported effects of
serotonergic disorders in children observed in CSF analysis for 5-IDAA and RVA for
movement and psychiatric disorders as discussed in Chapter 3 of this Treatise. However, a
number of studies have indicated that serotonergic drugs are effective in a number of
psychiatric disorders.
/
The Clinical Biochemistry Unit of New Children's Hospital, Westmead, NSW are in
the process of investigating neurochemicals of children with ADHD, Autism and Psychiatric
Disorders. It has been recommended that children with atypical symptoms who are intractable
to the usual therapy regimes for these neurological disorders should be investigated for
neurochemical defects by collecting CSF from these cases for neurotransmitter, platelet
serotonin and serotonin receptor studies (see draft protocol - Appendix B). However other
technical support will be essential to carry out these studies. Evaluation of the function of 5-
HT receptors in psychiatric and neurological diseases is important in the diagnosis and the
assessment of the response to treatment in these patients. Study of human platelet is also
important as the peripheral markers of central neurotransmitter systems in psychiatry
research. Other recommendations has been made to supplement these cases with serotonin
precursors (Tryptophan/5HTP) or drugs (SSRIs) in the hope of treating or rehabilitating these
cases (see draft protocol - Appendix B). Continuous case studies and clinical trials on such
cases would be most useful in recommending early intervention treatment, improved
treatment and rehabilitation ofdisorders associated with various neurotransmitters.
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Strategies used for Literature Search
Keywords Number of abstracts
Years 1992-96 1986-91 1980-85 1976-79 1966-75
Serotonin 7247 9341 6203 2754 2774
Human 2840 2932 1897 890 852
English 2541 2544 1626 689 459
Language
Abstract 2311 2360 1480 575 139
Age group
Kids
(6-12 yrs) 123 140 97 52 11
Adolescence
(13-18 yrs) 205 190 137 55 11
Adults 1075 1069 631 208 40
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Serotonin Project Database
The literature searches were imported into endnote and endlink library databases to create
databases on serotonergic disorders and studies under the following fJ.Ies:
File Names Database file names
Serotonin. Kids. all S.Kid.all
Serotonin. Adolescent. all S.Adol.all
Serotonin. Adult. all S.Adu.all
Total
Number of abstracts
423
598
3023
4044
/
A similar search was done on Medline from 1966-1996 using similar strategies and a total of
377 abstracts on serotonin studies were also imported into endnote and endlink library
databases.
This huge information was again classified into specific categories and files according to
specific disorders such as migraine, alcoholism, depression, and others and all duplicate
information were identified and discarded.
. g:\data\sarojm\group2.sav
ge @_h hva dgc ratio cp tic ata gai gro e n ps aut p s d 0 fi
1 M .03 .17 4.00 .180 .0 .0 .0 .0 .0 0 .0 .0 1 0 0 0 1
2 M .17 .36 3.00 .470 .0 .0 .0 .0 .0 0 1 .0 .0 0 0 0 0 0
3 M .25 .57 2.00 .440 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
4 M .32 .59 2.00 .540 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
5 F .49 .39 2.00 1.26 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
6 M .08 .23 2.00 .350 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 1
7 F .19 .48 2.00 .400 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
8 F .16 .61 2.00 .260 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 0
9 F .07 .20 2.00 .350 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 1
10 F .16 .54 2.00 .300 .0 .0 .0 .0 1. 1 .0 .0 0 1 0 0 0
11 F .03 .26 2.00 .120 .0 .0 .0 .0 1. 1 1. .0 0 0 1 0 1
12 M .20 .48 2.00 .420 .0 .0 .0 .0 1. 1 -.0 .0 0 0 0 0 0
13 M .22 .57 2.00 .390 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
14 F .05 .28 3.00 .180 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 0 0 1
15 M .10 .26 ·2.00 .380 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
16 F .08 .21 2.00 .380 .0 .0 .0 .0 1. 1 .0 .0 0 1 1 0 0
17 F .14 .39 2.00 .360 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 0
18 M .08 .14 3.00 .570 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 0 0 1
19 M .07 .26 2.00 .270 .0 .0 .0 .0 1. 1 .0 .0 1 1 1 0 1
20 M .08 .21 2.00 .380 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 0
21 F .08 .26 2.00 .310 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 0
22 M .09 .19 3.00 .470 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 1 0 1
23 M .05 .17 2.00 .300 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 1 0 1
24 M .14 .46 2.00 .300 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 1
25 F .29 .62 2.00 .470 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
26 F .21 .29 2.00 .720 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
27 F .37 .46 2.00 .800 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
28 F .15 .57 1.00 .260 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
29 M .15 .40 1.00 .380 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 0
30 M .32 .65 2.00 .490 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
31 F .21 .49 2.00 .430 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
1-1
g:\data\sarojm\group2.sav
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32 F .36 .44 2.00 .810 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
33 M .38 .90 2.00 .420 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
34 F .10 .26 2.00 .380 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
35 M .26 .44 2.00 .590 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
36 M .05 .16 3.00 .310 .0 .0 .0 .0 1. 1 1 .0 .0 0 1 1 0 1
37 M .13 .42 2.00 .310 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 1
38 F .20 .63 2.00 .320 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
39 M .04 .09 2.00 .450 .0 .0 .0 .0 1. 1 .0 .0 0 1 0 0 1
40 F ..07 .35 3.00 .200 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 0 0 0
41 M .26 .42 2.00 .620 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
:
42 F .50 .58 3.00 .860 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 0 0 0
43 M .08 .22 3.00 .360 .0 .0 .0 .0 1. 1 1 -.0 .0 0 0 0 0 1
44. M .38 .47 2.00 .810 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
45 M .14 .37 2.00 .380 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
46 F .15 .47 2.00 .320 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
47 F .09 .23 2.00 .390 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 1
48 F .09 .30 3.00 .300 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 1 0 1
49 M .32 .50 2.00 .640 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
50 F .13 .40 2.00 .330 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 1
51 F .08 .12 2.00 .670 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 0
52 F .23 .48 2.00 .480 .0 .0 .0 .0 1. 1 .0 .0 0 1 0 0 0
53 F .25 .77 2.00 .320 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 1
54 M .12 .40 2.00 .300 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
55 F .06 .12 1.00 .500 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 1
56 M .35 .50 2.00 .700 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 0 0 0
57 F .07 .19 3.00 .370 .0 .0 .0 .0 1. 1 1 .0 .0 0 1 0 0 1
58 M .06 .23 4.00 .260 .0 .0 .0 .0 1. 1 .0 .0 0 0 1 0 1 ,
59 M .27 .58 2.00 .470 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
60 M .16 .44 2.00 .360 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
61 M .09 .31 3.00 .290 .0 .0 .0 .0 1. 1 1 .0 .0 0 0 0 1 1
62 F .20 .49 2.00 .410 .0 .0 .0 .0 1. 1 .0 .0 0 0 0 0 0
2-1
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63 M .08 .32 2.00 .250 .0 .0 .0 .0 1. 1 1 1. .0 0 0 0 0 1
64 M .30 .19 2.00 1.58 .0 .0 .0 .0 1 . 1 .0 .0 0 0 0 0 0
65 M .11 .32 1.00 .340 .0 1. .0 .0 3. 0 .0 .0 0 0 0 0 0
66 M .07 .14 1.00 .500 .0 1. .0 .0 3. 0 .0 .0 0 1 0 1 1
67 F .20 .49 1.00 .410 .0 .0 .0 1. 5. 0 .0 .0 0 0 1 0 0
68 M .12 .39 1.00 .310 .0 .0 .0 1. 5 . 1 .0 .0 0 0 0 0 1
69 M .08 .21 1.00 .380 .0 .0 .0 1. 5 . 1 .0 .0 0 0 1 0 1
70 M .07 .19 1.00 .370 .0 .0 .0 1 . 5 . 0 .0 .0 0 0 0 1 1
71 M .12 .28 1.00 .430 .0 .0 .0 1. 5. 0 .0 .0 0 0 1 0 1
72 F .40 .63 1.00 .630 .0 .0 .0 1. 5 . 1 .0 .0 0 0 1 0 0
73 F .11 .38 1.00 .290 .0 .0 .0 1. 5. 0 .0 .0 0 1 0 0 1
74 F .13 .41 1.00 .320 .0 .0 .0 1. 5. 0 -.0 .0 0 0 1 0 1
75 M .07 .19 1.00 .370 .0 .0 .0 1. 5. 0 .0 .0 0 1 1 0 1
76 M .16 .44 1.00 .360 .0 .0 .0 1. 5. 0 .0 .0 0 1 0 0 1
77 M .08 .21 1.00 .380 .0 .0 .0 1. 5. 0 1 .0 .0 0 0 0 0 1
78 F .37 .38 1.00 .970 .0 .0 .0 1. 5. 1 .0 .0 0 0 0 0 0
79 F .48 .54 1.00 .890 .0 .0 .0 1. 5. 0 .0 .0 0 0 0 0 0
80 M .20 .31 1.00 .650 .0 .0 .0 1. 5 . 0 .0 .0 0 1 0 0 0
81 M .25 .41 3.00 .610 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
82 M .25 .43 3.00 .580 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 0
83 F .26 .39 3.00 .670 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 0
84 M .04 .10 3.00 .400 .0 .0 .0 .0 6 . 0 1 .0 .0 0 1 0 0 1
85 M .09 .15 3.00 .600 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
86 M .12 .30 3.00 .400 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 0
87 M .08 .28 3.00 .290 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
88 M .20 .61 3.00 .330 .0 .0 .0 .0 6. 0 1 .0 .0 0 1 0 0 1
89 F .20 .63 3.00 .320 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 0
90 M .46 .60 3.00 .770 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 0
91 M .07 .30 3.00 .230 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
92 M .10 .37 3.00 .270 .0 .0 .0 .0 6 . 1 1 .0 .0 0 0 0 0 0
93 F .07 .18 3.00 .390 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
3-1
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94 M .04 .36 3.00 .110 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
95 M .06 .23 3.00 .260 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
96 M .11 .24 3.00 .460 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
97 M .16 .47 3.00 .340 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 0
98 F .09 .26 3.00 .350 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
99 M .06 .27 3.00 .220 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 1 0 1
100 M .45 .66 3.00 .680 .0 .0 .0 .0 6. 0 1 .0 .0 0 1 0 0 0
101 F .09 .26 6.00 .350 .0 .0 .0 .0 6. 0 1 .0 .0 0 1 1 0 1
102 F .07 .15 3.00 .470 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
103 F .06 .23 3.00 .260 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
104 M .09 .26 3.00 .350 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
105 F .03 .19 3.00 .160 .0 .0 .0 .0 6. 0 1 ..0 .0 0 0 0 0 1
,
106 M .01 .46 3.00 .020 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 0
107 M .07 .27 3.00 .260 .0 .0 .0 .0 6. 0 1 .0 .0 0 1 1 0 1
108 F .15 .36 3.00 .420 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 1
109 F .18 .44 3.00 .410 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 0
110 M .06 .11 3.00 .550 .0 .0 .0 .0 6. 0 1 .0 .0 0 1 1 0 1
111 M .24 .69 3.00 .350 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 0
112 F .10 .26 3.00 .380 .0 .0 .0 .0 6 . 0 1 .0 .0 0 0 0 0 0
113 M .12 .36 3.00 .330 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
114 F .14 .41 3.00 .340 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
115 M .10 .38 3.00 .260 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
116 F .13 .41 3.00 .320 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
117 M .04 .26 3.00 .150 .0 .0 .0 .0 6. 0 1 1. .0 0 0 0 0 1
118 F .05 .20 3.00 .250 .0 .0 .0 .0 6. 0 1 .0 .0 0 1 1 0 0
119 M .09 .32 3.00 .280 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 1 1
120 M .05 .12 3.00 .420 .0 .0 .0 .0 6. 0 1 .0 .0 0 1 0 0 1
121 M .08 .34 3.00 .240 .0 .0 .0 .0 6. 0 1 .0 .0 0 0 0 0 1
122 F .23 .35 3.00 .660 .0 .0 .0 .0 6 . 0 1 .0 .0 0 1 0 0 0
123 F .05 .14 4.00 .360 .0 .0 .0 .0 7 . 0 1. .0 0 0 0 0 1
124 F .08 .22 4.00 .360 .0 .0 .0 .0 7 . 0 1. .0 0 0 1 0 1
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125 F .13 .54 4.00 .240 .0 .0 .0 .0 7. 0 1. .0 0 0 0 0 1
126 F .24 .22 5.00 1.09 .0 .0 .0 .0 7. 0 .0 .0 0 1 0 0 0
127 M .06 .22 4.00 .270 .0 .0 .0 .0 8. 0 .0 1. 0 0 0 0 1
128 F .12 .36 4.00 .330 .0 .0 .0 .0 8. e> .0 1. 0 0 1 0 1
129 M .08 .40 5.00 .200 .0 .0 .0 .0 9. 0 .0 .0 0 1 0 0 1
130 M .10 .57 5.00 .180 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 1
131 M .20 .39 5.00 .510 .0 '.0 .0 .0 9. 0 .0 .0 0 1 0 0 0
132 M .05 .17 5.00 .300 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 1
133 M .44 .77 5.00 .570 .0 .0 .0 .0 9. 0 .0 .0 0 1 0 0 0
134 M .10 .24 5.00 .420 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 1
135 M .30 .63 5.00 .480 .0 .0 .0 .0 9. 0 .0 .0 0 1 0 0 0
136 M .18 .63 5.00 .290 .0 .0 .0 .0 9. 0 ..0 .0 0 1 0 0 1
137 F .10 .34 5.00 .290 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 1
138 M .11 .40 5.00 .280 .0 .0 .0 .0 9. 0 .0 .0 0 1 0 0 1
139 M .42 .80 5.00 .530 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 0
140 F .12 .41 5.00 .290 .0 .0 .0 .0 9. 0 .0 .0 0 1 0 0 0
141 F .14 .55 5.00 .250 .0 .0 .0 .0 9. 0 .0 .0 0 1 0 0 1
142 F .13 .35 5.00 .370 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 0
143 M .26 .40 5.00 .650 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 0
144 M .11 .36 5.00 .310 .0 .0 .0 .0 9 . 0 .0 .0 0 1 0 0 1
145 M .06 .16 7.00 .380 .0 .0 .0 .0 9 . 0 .0 .0 0 0 0 1 1
146 M .06 .18 5.00 .330 .0 .0 .0 .0 9. 0 .0 .0 0 1 1 0 1
147 M .35 .63 5.00 .560 .0 .0 .0 .0 9. 0 .0 .0 0 1 1 0 0
148 F .22 .56 6.00 .400 .0 .0 .0 .0 9. 0 .0 .0 0 0 1 0 0
149 M .04 .29 2.00 .140 .0 .0 .0 .0 9. 0 .0 .0 0 0 1 0 1
150 F .12 .37 4.00 .320 .0 .0 .0 .0 2; 0 .0 1. 0 0 1 0 1
151 M .09 .29 4.00 .310 .0 .0 .0 .0 9. 0 .0 .0 1 0 1 0 1
152 M .23 .49 5.00 .470 .0 .0 .0 .0 9. 0 .0 .0 0 1 1 0 0
153 M .22 .56 4.00 .400 .0 .0 .0 .0 9. 0 .0 .0 1 0 1 0 0
154 F .28 .42 6.00 .670 .0 .0 .0 .0 9. 0 .0 .0 0 0 1 0 0
155 F .17 .51 7.00 .330 .0 .0 .0 .0 9. 0 .0 .0 0 0 0 1 1
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156 F .24 .53 6.00 .450 .0 .0 .0 .0 9 . 0 .0 .0 0 0 1 0 0
157 F .06 .21 7.00 .290 .0 .0 .0 .0 9 . 0 .0 .0 0 0 0 1 1
158 F .19 .57 5.00 .330 .0 .0 .0 .0 9 . 0 .0 .0 0 1 1 0 0
159 M .34 .82 6.00 .410 .0 .0 .0 .0 9 . 0 .0 .0 0 1 1 0 0
160 F .49 .77 5.00 .640 .0 .0 .0 .0 9. 0 .0 .0 0 1 1 0 0
161 M .05 .27 5.00 .190 .0 .0 .0 .0 9 . 0 .0 .0 1 1 1 0 1
162 F .08 .30 1.00 .270 .0 .0 1. .0 4 . 1 .0 .0 0 0 0 0 1
163 M .09 .38 1.00 .240 .0 1. 1. .0 4 . 0 .0 .0 0 0 0 0 1
164 F .08 .22 1.00 .360 .0 1. 1. .0 4 . 0 .0 .0 0 0 1 0 1
165 M .17 .43 1.00 .400 .0 .0 1. .0 4. 1 .0 .0 0 0 1 0 0
166 M .10 .23 1.00 .430 .0 .0 1. .0 4. 0 1 .0 .0 0 0 0 0 1
167 F .03 .43 1.00 .070 .0 .0 1. .0 4 . 0 '.0 .0 0 0 0 0 1
168 F .06 .58 1.00 .100 .0 .0 1. .0 4. 0 .0 .0 0 0 0 0 1
169 F .11 .40 1.00 .280 .0 .0 1. .0 4. 0 .0 .0 0 0 0 0 1
170 M .08 .31 1.00 .260 .0 .0 1. .0 4 . 0 .0 .0 0 0 0 0 1
171 M .08 .22 1.00 .360 .0 .0 1. .0 4 . 1 1 .0 .0 1 1 0 0 1
172 M .07 .28 1.00 .250 .0 .0 1. .0 4 . 0 .0 .0 1 0 1 0 1
173 F .23 .79 1.00 .290 .0 .0 1. 1. 4 . 1 1 .0 .0 0 0 0 0 1
174 M .19 .51 1.00 .370 .0 .0 1. .0 4 . 1 .0 .0 0 0 1 0 1
175 M .07 .27 1.00 .260 .0 .0 1. .0 4. 1 .0 .0 0 0 0 0 1
176 F .31 .77 1.00 .400 .0 .0 1. .0 4. 0 1 .0 .0 0 0 0 0 1
177 M .08 .12 1.00 .670 .0 .0 1. .0 4 . 0 1 .0 .0 0 0 0 0 1
178 F .06 .16 1.00 .380 .0 .0 1. .0 4. 1 1 .0 .0 1 0 0 0 1
179 F .06 .19 1.00 .320 .0 .0 1. .0 4 . 0 1 .0 .0 1 0 0 0 1
180 M .13 .51 1.00 . .250 1. .0 .0 .0 1. 0 .0 .0 0 0 1 0 1
181 M' .04 .54 1.00 .070 1. .0 .0 .0 2. 1 .0 .0 0 0 0 0 0
182 F .09 .27 1.00 .330 1. .0 .0 1. 2. 0 .0 .0 1 0 1 0 1
183 F .13 .22 1.00 .590 1. .0 .0 .0 2. 0 .0 .0 0 0 0 0 1
184 F .16 .54 1.00 '.300 1. .0 .0 .0 2. 1 1 .0 .0 0 0 0 0 1
185 F .12 .45 1.00 .270 1. .0 .0 .0 2. 0 .0 .0 0 1 0 0 1
186 F .07 .22 1.00 .320 1. .0 .0 1. 2 . 1 .0 .0 0 0 0 0 1
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187 F .11 .31 1.00 .350 1. .0 .0 .0 2 . 0 .0 .0 0 1 1 0 0
188 F .08 .30 1.00 .270 1. .0 .0 .0 2. 1 .0 .0 0 0 1 0 1
189 M .09 .11 1.00 .810 1. .0 .0 1. 2. 1 1 .0 .0 0 0 0 0 1
190 M .08 .37 1.00 .220 1. .0 .0 .0 2. 0 .0 .0 0 0 1 0 1
191 F .12 .33 1.00 .360 1. .0 .0 .0 2 . 0 .0 .0 0 0 0 0 1
192 F .18 .41 1.00 .440 1. .0 .0 .0 2 . 0 .0 .0 0 0 0 0 0
193 F .11 .45 1.00 .240 1. .0 .0 .0 2 . 0 .0 .0 0 0 0 0 1
194 F .13 .13 1.00 1.00 1. .0 .0 .0 2. 0 .0 .0 0 0 0 0 1
195 M .16 .38 1.00 .420 1. .0 .0 .0 2. 1 .0 .0 0 1 0 0 1
196 M .09 .16 1.00 .560 1. .0 .0 1. 2. 1 .0 .0 0 0 1 0 1
197 F .17 .66 1.00 .260 1. .0 .0 .0 2. 0 .0 .0 0 0 0 0 1
198 M .08 .22 1.00 .360 1. .0 .0 .0 2. 0 1 -.0 .0 0 0 1 0 1
199 M .20 .47 1.00 .430 1. .0 .0 .0 2. 0 .0 .0 0 0 0 0 1
200 F .08 .16 1.00 .500 1. .0 .0 .0 2. 0 .0 .0 0 0 0 0 0
201 M .08 .27 1.00 .300 1. .0 .0 .0 2. 0 1 .0 .0 0 0 0 0 1
202 M .09 .42 1.00 .210 1. .0 1. .0 4. 0 .0 .0 0 0 0 0 1
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DRAFT PROTOCOL FOR NEUROCHEMICAL INVESTIGATIONS OF
CHILDREN WITH ADHD, AUTISM, PSYCHIATRIC DISORDERS
Standard Protocol
URINE AND PLASMA INVESTIGATIONS
24 urine (on diet) and plasma samples are to be collected on three occasions for each
patient in the study, BASELINE, INDUCTION and MAINTENANCE. It would be
preferable for the study to be commenced when the child was free of infection and any
fever/infections which develop during the course of the study should be noted.
Baseline samples (1) will be collected before SSRI (serotonin selective reuptake
inhibitors) or NAG (noradrenalin agonists, dexamphetamine/ritalin) therapy
commences, (2) Induction samples will be collected on the day that therapy
commences and (3) Maintenance samples will be collected more than two weeks after
therapy has commenced, at a time to be noted, and provided there has been no change
in any drug regimens during this time..
24-HOUR URINE samples collected with the patient on diet restrictions will be
analysed for drug levels1, catecholamines, serotonin1, metabolites, MHPG1, pteridines
creatinine and PHPAA.
Blood samples (about 5m1 EDTA blood) will be collected, separated and analysed for
drug levels1,2, creatinine, neurotransmitters1and metabolite1levels, pteridines,
prolactin, MSH*, and platelet serotonin1,3 studies.
Notes:
1 These tests not yet fully developed.
2 Timing ofblood collection to be optimised for drug pharmacokinetics.
3 Performance of this test will depend upon availability oflab staff
Special Protocols
(a) SPINAL FLUID EXAMINATION
Children with very atypical symptoms or who are intractable to the usual therapy
regimens should be investigated for neurochemical defects by collection of
cerebrospinal fluid (on ice) for neurotransmitter studies and have platelet serotonin
studies performed.
(b) IMAGING
Quite a large group of children presenting with neurological abnormalities have low
CSF 5-HIAA and RVA. These children may either have neurodegenerative disease
(loss of brain stem neurones) or a metabolic or regulation defect affecting the synthesis
or storage of dopamine, serotonin and noradrenalin. At present there is no way of
clearly distinguishing between metabolic and neurodegenerative conditions.
Improved resolution in imaging techniques, new nuclear medicine technique~ ,
additional chemical and metabolite measurements in CSF (neurochemical imaging) or
loading tests with both (I-Dopa and 5-HTP) may help to categorise and develop
treatment methods for this group.
/
(c) SUPPLEMENTATION WITH SEROTONIN PRECURSORS
Children with a very low central serotonin levels (low CSF 5-HIAA) and a relatively
normal CSF RVA are quite rare. This group may either have specific degeneration
of the serotonergic system or a specific defect in serotonin synthesis, regulation, or
storage. Supplementation with tryptophan (TRY) or preferably 5-hydroxy-tryptophan
(5-HTP) should be-attempted to raise central serotonin levels. Patients undergoing this
therapy should be monitored by having baseline 24 hour urine sample (on diet)
collected before starting TRY or 5-HTP and a second 24-hour urine (on diet)
collected after 2 weeks on supplementation. Ifthe patients are taking SSRI's then their
regimen should be noted and remain unchanged during this protocol. Ifpossible a
second CSF sample should be collected and analysed for neurotransmitters 1-3 months
.after supplementation has commenced. Platelet serotonin levels, serotonin receptor
studies and platelet uptake of serotonin before and after supplementation may also be
ofvalue in investigating this group. Side effects of supplementation need to be closely
monitored including eosinophilia-myalgia for tryptophan, GIT problems with 5-HTP
and the serotonin syndrome when 5-HTP is used in conjunction with SSRI's.
Hospital
Royal Alexandra Hospital for Children
Institute of Pathology
Department of Clinical Biochemistry
Neurochemistry Laboratory
24 HOUR URINE COLLECTION FOR CATECHOLAMINES / HISTAMINE /5-HIAA
Plan to start collecting urine at a certain time ofday ego 12 noon.
Begin diet restrictions 24 hours before starting the urine collection.
At the starting time have the patient pass urine and discard the urine. From
/
this point onwards collect any urine in a clean plastic pot or container
such as a clean ice-cream container and pour it into the specially provided
plastic collection bottle which contains preservatives. Do not allow the
patient to pass urine directly into the collection bottle as the chemical
preservatives may cause irritation or burning. At the finishing time, 24 hours
after starting the collection, have the patient pass the final portion ofurine
and add this to the collecting bottle. Store the collecting bottle in a cool
area, not in direct ~unlight and when collection is finished return it to Sample Reception at
the Institute ofPathology, New Children's Hospital, Westmead.
Ifthe completed collection cannot be returned within 3 days after collection it
should be stored in a refrigerator to help preserve the sample until it can be
returned to the Children's Hospital. Ifthe patient is taking any medication during the
diet and collection period, make a note and give details to the Laboratory. Vasodilator
and salicylate drugs should be avoided ifpossible.
For further infomation contact the Department ofClinical Biochemistry, Telephone (02) 9845-3289
Cm Hawkesbury Rd & Hainsworth St,
WestmeadNSW
PO Box 3515 Parramatta NSW 2124
! \.
The New Hospital
Royal Alexandra Hospital for Chilren
PECIAL DIET FOR URINARY CATECHOLAMlNE / mSTAMINE / 5-mAA ESTIMATION
This special diet was designed by the Departments ofClinical Biochemistry and Nutrition and Dietetics and is
suitable for both adults and children having urine collected for catecholamines, histamine or serotonin studies.
he diet must be followed for 24 hours prior to and also during the course of urine collection.
VOID THE FOLLOWING:
FRUIT - bananas, canned and fresh pineapple, plums, grapes, kiwifiuit, cherries, blueberries,
raspberries, strawberries, blackcurrants, oranges & citms fruits, guava, mango, passionfruit, dried fruit
JAMS (except apricot)
VEGETABLES - tomatoes, mushrooms, avocado, spinach, broccoli, bmsse1 sprouts, cauliflower, eggplant,
broad beans, pickled vegetables ego sauerkraut
ALL NUTS & SEEDS including peanut butter and tahini
DAIRY - all cheese and cheese spreads, yoghurt flavoured with nuts, muesli containing nuts or above fruits,
chocolate yogo, banana, strawberry and chocolate flavoured milk, fruit smoothies
ALL FISH & SEAFOOD including canned, dried and salted fish and seafood
CHOCOLATE, COCOA & MILO
ALL PROCESSED MEATS ego devon, salami, sausages, ham, chicken loaf, turkey loaf
CHUTNEYS, malted or coloured vinegar, mayonnaise,. tartare sauce
FERMENTED FOODS: Yeast extracts ego Marmite,Vegemite, fish paste, fish sauce, soy sauce, meat gravy
ALCOHOL - all wine and beer (all fermented beverages)
FOLLOWING FOODS ARE ALLOWED:
BREAD & CEREALS All plain bread and breakfast cereals, whole meal and white
flour products except those containing nuts, seeds, fruit, flavourings or fillings listed above.
FRESH FRIDT - apples, pears, apricots, peaches, rockme10n, watermelon only.
VEGETABLES .. all fresh vegetables not listed above
COCONUT,COCONUTMILK
DAIRY - fresh milk, fresh cream, vanilla yoghurt, plain ice cream & custard,
strawberry yogo (contains artificial strawberry flavouring and no strawberries)
MEAT & CmCKEN (Freshly prepared)
SUGAR - Brown or white
SPREADS - Apricot jam and honey
CLEAR VINEGAR
VANILLA, NUTMEG
POWDERED STOCK (eg. for gravy) may be used only iffreshly prepared
DRINKS - milk, mi1kshakes (vanilla, coffee, plain or caramel flavoured), lemonade, tea, coffee
y queries on diet please contact Department ofNutrition & Dietetics. Telephone: (02) 9845-2225
alicylates and Bronchodilators should not be taken during collection. Ifunavoidable, record usage on request form. For further infomation on
edication or collection details contact the Department ofClinical Biochemistry, Telephone (02) 9845-3289
Cnr Hawkesbury Rd & Hainsworth St,
Westmead NSW
PO Box 3515 Parramatta NSW 2124
APPENDIXC
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OTHER RESOURCES
Dr John Earl, Biochemistry Research Unit, New Children's Hospital, West Mead.
Ph: (02) 98453289.
2FC Health Report, 7th April 1997. ABS Science Unit, Sydney (discussion: Dr William / Mr
Swan on cassette tape).
The Brain - Our Universe within (David Suzuki). Discovery Communication Production
Company, USA, (Fax: 0011 1301 986 4821). Series on Brain from 04-08-96 to 01-09-96.
SBS, Sydney (videotape). Ph: (02) 94302828.
The Role of Serotonin in Mood and Behaviour. Pfizer Pty Limited. Pfizer Video tape Library.
Fax: (02) 858137/ Ph: 008 226 655.
CNS - Discovery Video, October 1995. Pfizer Pty Limited. Pfizer Video tape Library.
Fax: (02) 858137/ Ph: 008226655.
Zoloft: Neurochemical Basis for Depression. Pfizer Pty Limited. Pfizer Video tape Library.
Fax: (02) 858137 / Ph: 008 226 655.
Zoloft: Predictable Antidepressant Response. Pfizer Pty Limited. Pfizer Video tape Library.
Fax: (02) 858137 /Ph: 008226655.
What you really need to know about: Obsessive Compulsive Disorder. (Videos for patients).
Roerig, Division ofPfizer Pty Limited, Sydney.
What you really need to know about: Depression. (Videos for patients).
Roerig, Division ofPfizer Pty Limited, Sydney.
What you really need to know about: Stress. (Videos for patients).
Roerig, Division ofPfizer Pty Limited, Sydney.
Eli -Lilly and Co. (NZ) Ltd - Depression. (Committed to improving the quality oflife of
people suffering from depression). Serotonin Neuron diagram.
